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Abstract 
 
Objectives: To determine predictors of disease progression in HIV-infected patients 
receiving treatment at the University of Malaya Medical Centre (UMMC). 
 
Methods: HIV-infected patients aged 20 years and above on treatment in the UMMC 
were followed up with a bidirectional cohort study starting in 2007. Patient records 
were investigated retrospectively to 1986 and prospectively until 2009. Kaplan Meier 
and Cox regression analysis were performed using SPSS. 
 
Results: A total of 1314 patients, 73.3 per cent were aged 20-39 years, 81.8 per cent 
male, 61.2 per cent Chinese, 45.2 per cent single, 73.5 per cent had only primary or 
secondary education, 43.2 per cent worked as professionals or non-manual workers, 
42.5 per cent had a monthly income of RM 1000-3000. The majority had baseline CD4 
less than 200 cells/µL (62.9 per cent), viral load more than 100,000 copies/ml (51.1 per 
cent), hemoglobin more than 12 g/dl (62.5 per cent) and normal liver function test (55.2 
per cent), were infected via the heterosexual route (65.8 per cent) and were in WHO 
clinical stage 4 (54.2 per cent). Most initiated HAART with 2 NRTI+ EFV (57.9 per 
cent), did not need second line HAART (88.5 per cent), and managed to achieve viral 
load less than 50 copies/ml (61.5 per cent). The median time to death in all AIDS 
patients was 65.7 months, and 15.0 months in AIDS patients who did not receive anti-
retroviral therapy. The median time to achieve viral load less than 50 copies/ml was 5.1 
months. At the end of the study, 63.6 per cent of patients survived. The predictors of 
death in all AIDS patients were unemployment (HR 1.59; 95% CI 1.26, 2.02), manual 
employment (HR 1.47; 95% CI 1.15, 1.87), those who have three or more opportunistic 
infections (HR 1.90; 95% CI 1.39, 2.58) and those who did not receive anti-retroviral 
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therapy (HR 2.89; 95% CI 2.37, 3.47). The predictors of death in AIDS patients on 
HAART were unemployment (HR 1.64; 95% CI 1.04, 2.57), CD4 which never 
recovered to more than 200 cells/µL (HR 4.03; 95% CI 2.21, 7.35), and inability to 
achieve viral load less than 50 copies/ml (HR 4.39; 95% CI 2.69, 7.16). Independent 
predictors of death for AIDS patients who did not receive anti-retroviral therapy were 
Chinese ethnicity (HR 1.57; 95% CI 1.15, 2.15), baseline viral load more than 100,000 
copies/ml (HR 1.35; 95% CI 1.02, 1.79) and being in WHO clinical stage 4 (HR 2.25; 
95% CI 1.65, 3.06). The predictors to achieve viral load less than 50 copies/ml were 
starting HAART with 2NRTI+EFV (HR 1.56; 95% CI 1.10, 2.20) and not needing a 
second line of HAART (HR 2.59; 95% CI 1.59, 4.21) and infection via injecting drug 
use (HR 0.54; 95% CI 0.35, 0.80) 
   
Conclusion: Every effort needs be made to ensure all HIV-infected patients in Malaysia 
are able to achieve a CD4 more than 200 cells/µL, viral load less than 50 copies/ml, and 
have access to triple drug anti-retroviral therapy as these are significant modifiable 
predictors of death in Malaysian HIV patients.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
Abstrak 
 
Objectif: Untuk menentukan peramal perkembangan penyakit dalam pesakit yang 
dijangkiti HIV dan menerima rawatan di Pusat Perubatan Universiti Malaya (PPUM).  
 
Kaedah: Pesakit yang dijangkiti HIV berumur 20 tahun atau lebih yang dirawat di 
PPUM telah diikuti dalam kajian kohort dua arah bermula pada tahun 2007. Rekod 
pesakit telah disiasat secara retrospektif hingga 1986 dan prospektif sehingga tahun 
2009. Analisa Kaplan Meier dan regresi Cox telah dijalankan menggunakan SPSS. 
  
Keputusan: Dari sejumlah 1314 pesakit, 73.3 peratus berumur 20-39 tahun, 81.8 
peratus lelaki, 61.2 peratus berbangsa Cina, 45.2 peratus bujang, 73.5 peratus ber 
pendidikan rendah dan menengah, 43.2 peratus pekerja profesional atau  bukan manual, 
42.5 peratus berpendapatan bulanan RM 1000-3000. Kebanyakan mempunyai CD4 
awal kurang daripada 200 sel/μL (62.9 peratus), HIV virus lebih daripada 100,000 
salinan/ml (51.1 peratus), hemoglobin lebih daripada 12 g/dl (62.5 peratus), ujian fungsi 
hati yang normal (55.2 peratus), jangkitan melalui hubungan heteroseksual (65.8 
peratus) dan dalam WHO peringkat klinikal 4 (54.2 peratus). Kebanyakan memulakan 
HAART dengan 2 NRTI + EFV (57.9 peratus), tidak bertukar kepada HAART baris 
kedua (88.5 peratus), dan berjaya mencapai HIV virus kurang dari 50 salinan/ml (61.5 
peratus). Tempoh purata hingga kematian untuk semua pesakit AIDS adalah 65.7 bulan, 
untuk pesakit AIDS yang tidak menerima rawatan anti-retroviral adalah 15.0 bulan dan 
tempoh purata untuk mencapai HIV virus kurang dari 50 salinan/ml adalah 5.1 bulan. 
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Pada akhir kajian, 63.6 peratus pesakit terselamat. Peramalan kematian dalam semua 
pesakit AIDS adalah pengangguran (HR 1.59; 95% CI 1.26, 2.02), pekerja manual (HR 
1.47; 95% CI 1.15, 1.87), yang mempunyai tiga atau lebih jangkitan oportunis (HR 
1.90; 95% CI 1.39, 2.58) dan tidak menerima terapi anti-retroviral (HR 2.89; 95% CI 
2.37, 3.47). Peramal kematian pesakit AIDS yang menerima HAART adalah 
pengangguran (HR 1,64; 95% CI 1,04, 2,57), CD4 yang tidak pernah pulih ke tahap 
lebih dari pada 200 sel/μL (HR 4,03; 95% CI 2.21, 7,35), dan ketidakupayaan untuk 
mencapai HIV virus kurang daripada 50 salinan/ml (HR 4.39; 95% CI 2.69, 7.16). 
Peramal kematian untuk pesakit AIDS tidak menerima anti-retroviral adalah bangsa 
Cina (HR 1.57; 95% CI 1.15, 2.15), mempunyai HIV virus lebih dari pada 100,000 
salinan/ml (HR 1.35; 95% CI 1.02, 1.79) dan WHO peringkat klinikal 4 (HR 2.25; 95% 
CI 1.65, 3.06). Peramal untuk mencapai HIV virus kurang dari 50 salinan/ml adalah 
yang memulakan HAART dengan 2NRTI + EFV (HR 1.56; 95% CI 1.10, 2.20) dan 
yang tidak perlu HAART baris kedua (HR 2.59; 95% CI 1.59, 4.21) dan jangkitan 
disebabkan suntikan dadah (HR 0,54; 95% CI 0,35, 0,80) 
 
Kesimpulan: Segala usaha perlu dilakukan untuk memastikan semua pesakit yang 
berjangkit HIV di Malaysia mampu untuk mencapai CD4 lebih daripada 200 sel/μL, 
HIV virus kurang dari 50 salinan/ml, mempunyai akses kepada HAART kerana ini 
adalah peramal kematian yang bermakna boleh diubah di kalangan pesakit HIV 
Malaysia. 
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CHAPTER 1 
 
INTRODUCTION 
 
This chapter introduces the whole thesis. Section 1.1 is on the global burden of HIV 
epidemic and describes the HIV infection worldwide, in the Asian region and in 
Malaysia. Section 1.2 introduces the anti-retroviral therapy for HIV-infected patients. 
Section 1.3 looks at the progression of HIV-infected patients. The rationale of this study 
is discussed in Section 1.4 the problem statement and research question are spelled out 
in Section 1.5 and 1.6 this is carried into Section 1.7 which looks at the objectives. 
General and specific objectives are documented in Section 1.7.1 and 1.7.2 while the 
contribution of the study is stated in Section 1.8. The conceptual framework of the 
research topic, which is the core issue of this research project is displayed in Section 1.9 
Section 1.10 describes the structure of the thesis followed by Section 1.12 which is a 
summary of this chapter 
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1.1  Global burden of HIV epidemic       
 
The global burden of HIV epidemic is influenced by many factors including the number 
of HIV patients, new HIV infection, the number of deaths with AIDS related disease, 
HIV transmission route and expansion of anti-retroviral therapy. More than 34.0 (95% 
CI 31.4 –35.9) million people of the world population were living with HIV by the end 
of 2012 (UNAIDS, 2012). The percentage of adults aged 15-49 years living with HIV 
was 0.8 per cent. New HIV cases in 2012 numbered 2.5 (95% CI 2.2-2.8) million, 
which is 20 per cent less than in 2001.  The number of deaths due to AIDS related 
diseases was 1.7 (95% CI 1.5–1.9) million,  which is 24 per cent lower than with AIDS-
related mortality rate in 2005 (UNAIDS, 2012). 
 
The epidemic burden of HIV infection varies considerably between countries and 
regions. The rate of infection in Sub-Sahara of Africa is the most severe with about 69 
per cent of all-HIV infected persons worldwide from in this region and where the ratio 
of people living with HIV and healthy people is 1 in 20. When compared to Asia, the 
prevalence of HIV infection in Sub-Sahara Africa is 25 times higher.  One point eight 
million newly HIV infections are reported in this region but this is a 25 per cent decline 
in comparison with 2001. Although the death rate from AIDS-related diseases declined 
by 32 per cent from 2005 to 2011, this region still has the highest death rate, accounting 
for about 70 per cent of  world deaths due to AIDS in 2011 (UNAIDS, 2012).   
 
The Caribbean, Eastern Europe and Central Asia were the regions most highly affected 
by the HIV epidemic after Sub-Saharan Africa. About 1.0 per cent of adults were living 
with HIV in all of the regions in 2011 but even in the Caribbean the rate of new HIV 
infection has declined by 42 per cent since 2001 and the number of AIDS-related deaths 
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has declined by 48 per cent. In Eastern Europe and Central Asia, the new HIV infection 
began increasing in the late 2000s with an accompanying 21 per cent increase in 
mortality from AIDS (UNAIDS, 2012) 
 
The HIV epidemic in Asia is variable and 60 per cent of the total world’s HIV 
epidemics are in Asia. Half of the HIV prevalence of Asia is in India. In Asia almost 5 
million people are living with HIV in different parts of South, South-East and East Asia 
(UNAIDS, 2012). 
 
The one peak of the Asia epidemic was in the mid-1990s and since 2000 the number of 
new HIV cases per year has declined more than half, but some regional epidemic 
remained stable. In South and South East Asia, there are 4.0 (95% CI 3.1-4.6) million 
people living with HIV and 280 000 (95% CI 170 000 - 370 000) new HIV cases in 
2011. In East Asia, 830 000 (95% CI590 000 - 1 200 000) people living with HIV and 
89 000 (95% CI 44 000 - 170 000) new HIV cases were reported in 2011 (UNAIDS, 
2012). In 2011, number of AIDS related deaths in South East Asia were 250 000 (95% 
CI 1900 000 – 330 000), which is 13.7 per cent less than the peak of mortality in 2005.  
In East Asia, the rate of HIV related mortality is still increasing; in 2011, total number 
of deaths due to HIV was 51 per cent higher than the mortality rate in 2005 (UNAIDS, 
2012).  
 
In many Asian countries, national epidemics are concentrated in a few provinces. For 
example, more than half (53 per cent) of people living with HIV of China are in five 
provinces. Indonesia’s HIV infection is in Papua and West Papua provinces (WHO, 
2011). In China, the number of people living with HIV decreased from 840 000 in 2003 
to 650 000 in 2005, then increased to 700 000 in 2007 and 740 000 in 2009 (Wang et 
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al., 2010). The number of AIDS cases decreased from 80 000 in 2003 to 75 000 in 
2005, then in 2007 it is increased to 85 000 and further increased to 105 000 in 2009 in 
China. The number of new HIV infections decreased from 70 000 in 2005 to 50 000 in 
2007 and again reduced to 48 000 in 2009 (Wang, et al., 2010).  
 
In China, the proportion of cases associated with sexual transmission was 43.6 per cent 
in 2005 and it is increased to 51.6 per cent and 59 per cent in 2007 and 2009 
respectively. The proportion of cases associated with injecting drug use transmission 
was 48.6 per cent in 2005 and which is decreased to 42.0 per cent in 2007 and further 
reduced to 24.3 per cent in 2009. Dramatic increases in HIV transmission among 
homosexual from 12.2 per cent in 2007 to 32.5 per cent in 2009 has been observed 
(Wang, et al., 2010). Total HIV surveillance sites increased by 20 per cent between 
2005 to 2007. Fifty-three point four per cent of prevalence come from the 5 highest 
prevalence provinces and less than 1 per cent of total infections from the 5 lowest 
prevalence provinces (Wang et al., 2009). The major route of exposure in China was 
heterosexual intercourse. There were a total of 37 million male commercial sex workers 
in China and 1 out of 3 of them were diagnosed with HIV (Wang, et al., 2009).  
 
In South East Asia, all countries except Thailand have an adult HIV prevalence lower 
than 1 per cent.  Thailand is showing increased HIV prevalence among male sex 
workers, which is almost double when compared to female sex workers (WHO, 2011). 
The prevalence among homosexual men increased from 17 per cent in 2003 to 31 per 
cent in 2007 and then reduced to 25 per cent in 2009 in Bangkok (WHO, 2011) 
 
The first HIV case detected in Malaysia was more than 25 years ago in 1986 (Goh, 
1987). In December 2012, the number of people living with HIV is estimated to be 
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more than 81,000. The cumulative figure showed the number of HIV, AIDS and death 
was  94,841, 17,686 and 14,986 respectively, thus 79,855 people living with HIV was 
reported in Malaysia in 2011 (MOH, 2012).  
 
The annual report of new HIV cases by the Ministry of Health has been on a steady 
decline from a peak of 6,978 in 2002. In 2011, there were only 3,479 new cases 
reported to the Ministry of Health, which is approximately halved of what was reported 
in 2002 and with an average of 9 new cases each day. The rate of HIV also shows a 
decrease from 28.4 in 2002 to 23.4 in 2005 and to 12.2 cases per 100,000 populations in 
2011 (MOH, 2012) . 
 
Overall, the country is showing a decrease in HIV rate among young people aged 13-29 
years while it is increasing among adults of 30-39 years. About 26 per cent of reported 
infections are amongst young people aged between 13-29 years old and around 1 per 
cent amongst people of less than 13 years old in 2011 (MOH, 2012). 
 
Males represent the majority (90 per cent) of cumulative HIV cases in Malaysia. Males 
have been showing a reduction in the rate of infection from 2003, but the rate of 
infection in females is increasing (MOH, 2012). The main reason for the Malaysian 
HIV epidemic is injecting drug use and new HIV case distribution reported that 
injecting drug user (IDU) increased from 60.4 per cent in 1990 to 74.7 per cent in 2000 
and decreased 55.2 per cent in 2009 (UNGASS, 2010). While heterosexual route 
reported from 4.8 per cent in 1990, 17.6 per cent in 2000 and increased 26.7 per cent in 
2009 (UNGASS, 2010). Homosexual route in Malaysia is still a stigma, reported to be 
0.4 per cent in 1990, 1.2 per cent in 2000 and 5.3 per cent in 2009 (Prime Minister's 
Department Malaysia & United Nations Country Team, 2010). Among males, 48 per 
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cent acquired HIV infection through IDU and 47 per cent by sexual mode. Most HIV 
infections among females occurred through heterosexual transmission (87 per cent). 
Females are increasingly getting infected with HIV, constituting around 21 percent of 
newly infected persons nationwide in 2011 compared to being barely 5 percent ten 
years ago (MOH, 2012) 
 
With respect to geographical distribution, there is quite a distinct trend in transmission 
mode over a period of 10 years in the states of Malaysia. It appears that HIV infections 
in eastern region states (Pahang, Terengganu and Kelantan) of Peninsular Malaysia are 
still driven by IDU whereas infections in the northern states (Perlis, Kedah, Penang and 
Perak) and southern region (Negeri Sembilan, Melaka and Johor) are mainly sexually 
driven (MOH, 2010). The infections in the central region (Selangor and Kuala Lumpur) 
are mainly IDU driven whereas East Malaysia (Sarawak, Sabah and Labuan) have 
always been predominantly sexually driven from the beginning of the epidemic (MOH, 
2012).  
 
There was a decrease in the number of AIDS-related deaths reported in 2011 
(UNGASS, 2012). The reduction in death rate has been achieved by the introduction of 
more affordable and accessible first and second line anti-retroviral therapy. As per 2011 
report, there were 14,002 people living with HIV on treatment, which is 37.5 per cent of 
the estimated number of people living with HIV eligible for anti-retroviral therapy 
(37,306). It has been estimated that by the end of 2015, Malaysia will have an estimated 
81,317 people living with HIV (Prime Minister's Department Malaysia & United 
Nations Country Team, 2010). 
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1.2  Anti-retroviral therapy   
 
Anti-retroviral therapy can help people living with HIV to live longer, increase quality 
of life and reduce AIDS-related deaths. Sixty six per cent of HIV-infected patients 
survived as a result of anti-retroviral therapy (Djauzi, 2007). According to the 2011 
world report, anti-retroviral therapy is enjoyed by 8 million people, which is 20 times 
the number in 2003. Since 1995, anti-retroviral therapy has added 14 million life-years 
in low and middle income countries, including 9 million in sub-Saharan Africa 
(UNAIDS, 2012). The guidelines of when to begin anti-retroviral therapy has been 
changed frequently (WHO, 2010a).  
 
Highly Active Anti-Retroviral Therapy (HAART) has been available world-wide since 
1996. It is a combination of 3 drugs which include 2 NRTI (Nucleoside Analogue 
Reverse Transcriptase Inhibitors) or NNRTI (Non-Nucleoside Analogue Reverse 
Transcriptase Inhibitor) and PI (Protease Inhibitor) and has substantially improved the 
prognosis of HIV-infected patients (WHO, 2010a). The clinical progression in HIV 
patients receiving treatment is estimated in different levels of viral load and CD4 count. 
The information about the prognosis of HIV infection is very important to monitor the 
progress of the HIV/AIDS epidemic, to develop treatment guidelines, to gain a better 
understanding of the prior treatment of HIV infection and to plan health services in the 
HAART period. These data are also important for the comparisons of treatment 
outcomes in resource poor settings once HAART becomes more widely available in less 
developed countries (Egger et al., 2002). Access to HIV care and anti-retroviral therapy 
still remain a challenge to control the HIV epidemic in developing countries due to the 
financial burdens for people living with HIV in accessing and receiving HIV care 
(Riyarto et al., 2010). 
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WHO guidelines currently recommend initiating HAART at CD4 counts less than 350 
cells/µL (WHO, 2010a). If CD4 measurement is unavailable, simple tools such as 
haemoglobin level and total lymphocyte count can be used as laboratory markers to 
initiate HAART in resource-poor settings (WHO, 2004). The question about when to 
initiate treatment should take into account that anti-retroviral therapy is a lifelong 
treatment, with significant adherence issues, potential side effects and high cost. To 
measure the HAART adherence, self-reported adherence (SRA) is an accurate 
instrument compared to therapeutic drug monitoring (TDM) and can be reliably used in 
practice in resource-poor settings (Bulgiba, Mohammed, Chik, Lee, & Peramalah, 
2013). 
 
There are six classes of anti-retroviral drugs available namely NRTI, NNRTI, PI 
(widely used worldwide), the Fusion inhibitor (FIs), Integration Inhibitor (IIs) and 
Maturation Inhibitors (still in limited used). Each class targets a different step in the 
HIV life cycle (Volberding & Deeks, 2010).   
 
The standard HAART Regimens (MOH, 2001a, 2001b; WHO, 2010a) comprise one of 
three possible regimens: 
- NRTI + NRTI + PI 
- NRTI + NRTI + NNRTI 
- NRTI + NRTI + PI + PI 
There are 3 classes of anti-retroviral agents in Malaysia: - NRTI: such as AZT 
(Zidovudine), d4T (Stavudine), 3TC (Lamivudine), ddI (Didanosine),   ddC 
(Zalcitabine)  
- NNRTI: Such as EFV (Efavirenz), NVP (Nevirapine) 
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- PI: Such as IDV (Indinavir), RTV (Ritonavir), SQV (Saquinavir), Kaletra (Lopinavir/ 
ritonavir)  
 
All the drugs except Saquinavir are available in the Ministry of Health’s formulary. 
Anti-retroviral therapy was introduced in stages in Malaysia. In 1989, AZT was 
available, in the early 1990’s ddI and ddC was also available and in mid-1990’s d4T 
and 3TC became available. In Malaysia, Highly Active Anti-Retroviral Therapy 
(HAART) was available from February 1997 with the entry of IDV but the cost of these 
drugs was high. In the late 1990’s, a standard regimen of AZT + 3TC + IDV, would 
cost close to RM 2000 per month. In 2003, the MOH took the initiative to access 
cheaper generic anti-retroviral drugs from India. This led to the introduction of generic 
d4T, RTV and NVP into Malaysia. Generic drugs such as AZT, ddI and the fixed drug 
combination of AZT + 3TC, followed subsequently in early 2004. This led to the 
second big jump in anti-retroviral therapy uptake locally (MOH, 2001a, 2001b).    
 
In Malaysia, anti-retroviral treatment is available at all general hospitals and some 
district hospitals where there are specialist physicians managing medical clinics. Anti-
retroviral treatment is also provided in some local university hospitals. All HIV clinics 
are run by physicians, who have had some training in HIV medicine. The infectious 
disease clinic at University of Malaya Medical Centre is the reference centre for 
patients with HIV and AIDS in Selangor state and is one of the major sites for anti-
retroviral treatment in Malaysia. 
 
One of the three targets of Malaysia millennium development goals (MDG) is to 
achieve treatment for all HIV/AIDS patients by 2010.  The Ministry of Health Malaysia 
reported that 9,962 people living with HIV had received anti-retroviral therapy by the 
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end of 2009 (Prime Minister's Department Malaysia & United Nations Country Team, 
2010). The Government of Malaysia provides first line anti-retroviral access for all 
HIV-infected patients without charging money at all government hospitals and clinics. 
From 2006, the Government of Malaysia provided anti-retroviral therapy to all HIV 
patients in prisons and drug rehabilitation centres. The second line anti-retroviral 
therapy is partly subsidized by the government (Prime Minister's Department Malaysia 
& United Nations Country Team, 2010). Malaysia will continue providing affordable 
access to clinical care for HIV patients through the public health system (MOH, 2012). 
1.3  Progression of HIV-infected patients 
 
There are many factors that may influence progression of HIV-infected patients to 
AIDS and death. This study is more concerned about AIDS progression to death. Based 
on the literature, the predictors of death in AIDS patients included socio-demographic 
characteristic, laboratory, clinical and anti-retroviral therapy. Predictors of disease 
progression in HIV-infected patients in developed and developing countries included low 
CD4, high viral load, opportunistic infection, older age and lifestyle such as injection drugs 
user (Bonnet et al., 2005; COHERE, 2012; Fregonese et al., 2012; Ghate et al., 2011; 
Osmand, 1998; Schwarcz, Hsu, Vittinghoff, & Katz, 2000). The predictors of death in 
AIDS patients are described in detail below.  
1.3.1  Socio-demographic characteristic  
 
a. Age  
 
Earlier studies showed that faster overall AIDS progression with increasing age in the 
absence of HAART (Langford, Ananworanich, & Cooper, 2007). A study with 4,252  
AIDS patients from the Asia Pacific region showed that people who are more than 50 
years old has an increased death rate (HR 4.29, 95% CI 2.10-8.79) (Falster et al., 2009). 
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The rate of disease progression among younger children, especially newborn HIV 
positive babies is also higher than adult patients. Between 1987 to 1996, a study 
involving persons diagnosed with AIDS showed higher mortality for participants aged 
40 years and above with a relative hazard of 1.43 (95% CI 1.30, 1.60) in San Francisco 
(Schwarcz, et al., 2000). Meanwhile, in another study using the Australian national 
surveillance for AIDS diagnosis, age of more than 45 years was independently 
associated with disease progression with HR of 1.54 (95% CI 1.29, 1.85) (Li, 
McDonald, Dore, & Kaldor, 2000). Similarly, in the Aquitaine Cohort, France, a study 
was conducted in 1996-2002 among patients with older age. This study revealed that 
participants aged 50 years or above has higher chance to develop AIDS or die, with HR 
of 2.4 (95% CI 1.4, 4.1) when compared to people with less than 50 years (Bonnet, et 
al., 2005)   
 
b. Gender  
 
The HIV disease progression rate was found to be influenced by gender. The study in 
AIDS males and females of 2,862 patients registered at the AIDS Surveillance System 
in Italy (1993 to 1998), showed different hazards of dying during the first and the 
second 6 month period of 1997 compared with 1993. In particular, the increase in 
survival appeared stronger in males than in females with HR of 0.51 (95% CI 0.39, 
0.66) in the first 6 month period of 1997 and HR of 0.22 (95% CI 0.16, 0.31) in the 
second 6 month period of 1997 for males, HR of 0.80 (95% CI 0.51, 1.27) and HR of 
0.32 (95% CI 0.18, 0.57) for females (Porta et al., 1999). A study in Malawi to 
investigate the effect of sex on mortality of HIV-infected patients receiving anti-
retroviral therapy from 2004 to 2006, has shown an increased mortality rate in males 
with HR of 1.70 (95% CI 1.35, 2.15) (Chen et al., 2008). Another study of the 
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Aquitaine cohort showed that gender was not associated with a significantly higher risk 
of progression to AIDS or death (Bonnet, et al., 2005). 
 
c. Socioeconomic Status  
 
A study in Canada showed that HIV-infected patients with low income (HR 1.29, 95% 
CI 1.17, 142) and unemployment status (HR 2.2, 95% 1.67, 2.89) are at increased risk 
of mortality (Druyts et al., 2009). A group of researchers carried out a study to estimate 
the AIDS survival by socioeconomic status neighbourhood, comparison between group 
before HAART (1993 to1995) and after HAART introduction (1996 to 1997) in Rome, 
Italy. In a retrospective cohort of persons with AIDS (diagnosed in 1993 to 1997) 
followed through July 31, 1998, socioeconomic status (SES) of the neighborhood was 
categorized into 4 levels (Level 4 is lowest SES). There was a small difference in the 
risk of death by SES for patients with AIDS diagnosed in 1993 to 1995. The death risk 
was higher in patients with lower SES, especially for levels III and IV with HR of 2.81 
(95% CI 1.38, 5.76) and HR of 2.55 (95% CI 1.27, 5.14) compared with the level I for 
1996 to 1997 (Rapiti et al., 2000). 
1.3.2  Laboratory results 
 
 
a. Lymphocyte T or CD4 cell count 
 
 
CD4 is the primary target of HIV. Their depletion severely limits the host response 
capacity. HIV infection can cause a great risk to T-cells directed immune response 
(Stebbing, Gazzard, & Douek, 2004). The CD4 count is a significant predictor of 
survival and disease progression. The study in Asia Pacific region showed that among 
patients with CD4 less than 100 cells/µL had HR of 34.97 (95% CI 18.01, 67.90) for 
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AIDS mortality risk and had HR of 8.59 (95% CI 5.66, 13.03) for non AIDS mortality 
risk (Falster, et al., 2009). An assessment of 1,188 AIDS patients from 19 clinical 
centres across the United States showed that CD4 less than 200 cells/ml is the strongest 
risk factor for mortality with HR of 2.7 (95% CI 1.9-3.9) (Puhan, Van Natta, Palella, 
Addessi, & Meinert, 2010). The Multicenter AIDS Cohort Study with 679 HIV infected 
males, on the clinical progression of disease following initiation of HAART found that 
CD4 cell count prior to HAART initiation in less than 200 cells/μL had a relative hazard 
of 2.25 (95% CI 1.13, 4.49) and 2.29 (95% CI 0.83, 6.33) for AIDS and death 
respectively (Jacobson et al., 2002). Similarly, the study conducted in the Aquitaine 
Cohort, France in 1996-2002 showed that patients with CD4 counts less than 50 
cells/μL had an increased risk of progression with HR of 13.0 (95% CI 3.8, 44.3) while 
patients with CD4 count 50-199 cells/μL with HR of 5.1 (95% CI 1.6, 16.3) had 
increased risk of disease progression compared patients with CD4 count more than 350 
cells/μL (Bonnet, et al., 2005). The Women’s Interagency HIV Study showed that after 
HAART initiation, those with CD4 counts less than 200 cells/µL had an increased risk 
of death compared to those with more than 350 cells/µL (HR 2.66; 95% CI 1.42, 4.99), 
from AIDS with HR 47.61 (95% CI 5.69, 398.40) (Anastos et al., 2004). 
 
b. Viral load 
 
The importance of laboratory marker as CD4 count and in the peripheral blood is based 
on the quantity of viral load (Anastos, et al., 2004; Osmond, 1998). The association of 
quantity viral load and risk of HIV has been studied by many researches. From a study 
of 1,578 adult patients who received HAART for more than 6 months in Thailand 
showed that, the predictor of AIDS was viral load more than 1,000 copies/ml with HR 
of 2.8 (95% CI 1.3, 6.1) (Fregonese, et al., 2012). A study cohort of 165 hemophiliac 
patients revealed that the CD4 count  and viral load level were independently associated 
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with developing AIDS with an HR of 6.4 for viral load more than 10,000 copies/ml 
(Osmand, 1998). Additionally, in a study involving 679 HIV infected men, one of the 
significant determinants of developing AIDS was viral load more than 100,000 
copies/ml at HAART initiation with HR of 1.63 (95% CI 0.79, 3.36) (Jacobson, et al., 
2002) while, the study among 1,132 women patients has shown all cause deaths were 
higher (HR 3.44; 95% CI 1.67, 7.09) in patients with viral load more than 10,000 
compared to those with viral load of less than 80 copies/ml (Anastos, et al., 2004). The 
strongest prognostic markers in PLWH were viral load and CD4 count and where there 
is widespread HAART use, the effect of demographic factors is not clear (Anastos, et 
al., 2004). The effectiveness of anti-retroviral therapy is measured by the ability to 
achieve viral load less than 50 copies/ml. When an individual first starts HAART, it is 
desirable that virologic suppression is achieved as quickly as possible (as demonstrated 
by a reduction in the viral load to 50 copies/ml), preferably within the first  6 months of 
HAART (Smith et al., 2004). 
1.3.3  Clinical condition 
 
 
a. Exposure Risk  
 
The Concerted Action on Sero Conversion to AIDS and Death in Europe (CASCADE) 
collaboration study showed strong evidence that the effect of transmission category on 
AIDS prognosis has changed over time (Porter et al., 2003). Before 1997, IDU had less 
risk of AIDS progression than men who have sex with men (MSM) with HR of 0.74 
(95% CI 0.64, 0.86). However, this trend was reversed in 1999-2001 with HR of 2.76 
(95% CI 1.87, 406). Similarly, in the Spanish multicenter study of seroconverters 
(GEMES) cohort study, IDU had a faster AIDS progression than MSM with HR of 2.28 
(95% CI 1.47, 3.54). IDU also had a faster progression to death with HR of 2.17 (95% 
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CI 1.22, 3.87) (Pérez-Hoyos et al., 2006). After the introduction of HAART, there was 
continued reduction in AIDS and death. The differences detected in IDU patients could 
be explained by poorer access to anti-retroviral therapy, undesirable delays in initiating 
HAART, poorer adherence, and non AIDS related competing mortality such as drug 
related deaths and hepatitis C virus co-infection (Pérez-Hoyos, et al., 2006).  
 
b. Opportunistic infection  
 
The presence of opportunistic infections (OI) affects  the quality of life in HIV-infected 
patients with OR of 5.29 (95% CI 1.97,14.21) (Astoro, Djauzi, Djoerban, & 
Prodjosudjadi, 2007). An opportunistic infection that occurs in the course of increasing 
HIV immune suppression are mainly caused by infectious agents like PCP 
(Pneumocystis carinii pneumonia),  CMV (Cytomegalovirus) and Varicella zoster virus. 
HIV mediated immune suppression changes host control of the infectious agent 
resulting in disease and the disease process in turn activates HIV, hastening the rate of 
immune suppression (Osmand, 1998). However, in Western industrialized countries, 
many opportunistic infections are now rare (Hoffmann, Rockstroh, & Kamps, 2007). 
This is particularly true for those infections that are associated with severe 
immunodeficiency, such as CMV and MAC (Mycobacterium Avium Intracellulare 
Complex). Now, the opportunistic infection incidence has been reduced to less than one 
tenth of their frequency in the pre HAART era. Moreover, survival times after initial 
diagnosis of opportunistic infections has also improved. A study with 150 participants 
with Toxoplasmosis demonstrated 5-year survival of 8 percent after the diagnosis from 
1990 to 1993. It  increased to 30 per cent in 1994 to 1996 and it rose to approximately 
80 per cent in 1997 (Hoffman, 2006).  
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In developing countries such as in China and India, there are many cases of tuberculosis 
infection in HIV-infected patients. A study in Indonesia aimed to establish HIV 
prevalence and uptake of unlinked anonymous testing and voluntary counselling and 
testing (VCT) among tuberculosis patients in Jogjakarta (Mahendradhata et al., 2008). 
A total of 1,269 tuberculosis patients, 77.9 per cent agreed to be tested and the study 
demonstrated HIV prevalence of 1.9 per cent. Unlinked anonymous HIV testing is well 
accepted and can be implemented with modest additional efforts (Mahendradhata, et al., 
2008). Tuberculosis was the primary cause of death in 9.0 per cent of all AIDS-related 
deaths, while PCP accounted for 4.7 per cent in Brazil (Saraceni et al., 2008). In 
Malaysia, unsuccessful treatment in TB/HIV patients was associated with intravenous 
drug use with OR of 2.72 (95% CI 1.44, 5.16) (Ismail & Bulgiba, 2013) 
1.5  Problem Statement 
 
 
Advances in anti-retroviral therapy have changed a fatal disease into a chronic disease 
and influenced the survival of HIV-infected patients. (Volberding & Deeks, 2010). The 
evidence from literature review in developed and developing countries suggests that 
many factors can influence the mortality of HIV-infected patients and the effectiveness 
of anti-retroviral therapy. However, the picture is not very clear in Malaysia as there are 
few studies to fall back on. Therefore, the researcher would like to explore the 
predictors of death and predictors to achieve viral load less than 50 copies/ml in AIDS 
patients because different patients from different regions may respond differently to 
HIV infection. The time of death may vary among the patients with some patients 
taking longer to die while others do so quickly. The progression of disease among 
Malaysian HIV-infected patients is not well studied and the researcher do not know 
very much what influences this progression 
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1.4  Rationale of Study  
 
 
Anti-retroviral therapy has been helping to increase the survival of HIV patients. Most 
of the studies have been conducted in developed countries and only a few articles have 
been published regarding AIDS progression to death in other countries (Wong, Chan, & 
Lee, 2004). In Malaysia there is a lack of scientific research focusing on AIDS 
progression and anti-retroviral therapy (Kamarulzaman, 2005). There are few articles on 
AIDS progression to death in Malaysia. A study was been conducted in Sungai Buloh 
Hospital, Malaysia on the effect of HAART on AIDS mortality and AIDS defining 
events among AIDS patients based on a retrospective cohort from 1997 until 2008 (Mat 
Shah, Bulgiba, Lee, Haniff, & Mohamad Ali, 2012). This study started in 2007, 
following patients retrospectively to 1986 (20 years) and prospectively until 2009 (3 
years). The previous study in Sungai Buloh was on AIDS patients with HAART while 
our study included all AIDS patients whether they were on HAART or not.  The 
purpose of the Sungai Buloh Hospital study was to determine associated factors in 
AIDS mortality while this study is to determine the predictors of AIDS death and the 
predictors of the ability to achieve viral load less than 50 copies/ml.  
 
Based on the research problem statement, there is a need to do a study focused on  
determining factors associated with progression from AIDS to death and to achieving 
viral load less than 50 copies/ml. Predictors of death and predictors of ability to achieve 
viral load less than 50 copies/ml are unknown in Malaysian HIV-infected patients. This 
is the first study on AIDS progression conducted at the University of Malaya Medical 
Centre (UMMC). The University of Malaya Medical Centre was chosen because it is a 
major referral centre in Malaysia and the HIV patients from other government hospitals, 
private hospitals, and general practitioners are referred to University of Malaya Medical 
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Centre. The factors that influence progression of the disease and to achieve viral load 
less than 50 copies among HIV-infected patients attending at the Infectious Disease 
clinic at University of Malaya Medical Centre not unravel clearly.  
 
1.6  Research Question  
 
What are the determinants of progression to death and to achieve viral load less than 50 
copies/ml in HIV-infected patients in the University of Malaya Medical Centre? 
 
1.7  Objectives  
 
1.7.1  General Objective 
 
To determine predictors of progression and survival of HIV-infected patients being 
followed up in the University of Malaya Medical Centre  
 
1.7.2  Specific Objectives 
 
 
a. To describe the characteristics of HIV-infected patients in the UMMC  
b. To determine the survival time of HIV-infected patients in the UMMC  
c. To determine the 5 and 10-year survival of HIV-infected patients in the UMMC 
d. To determine the predictors of death in all AIDS patients, AIDS patients on HAART 
and AIDS patients not on anti-retroviral therapy 
e. To determine predictors to achieve viral load less than 50 copies/ml in AIDS patients 
on HAART  
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1.8  Contribution of study 
 
1.8.1  Public health significance  
 
The outcome of this study provides meaningful information that can be used to create a 
better treatment setting in the University of Malaya Medical Centre, which is potentially 
useful to nurses and clinicians. It will also help to guide health care providers in 
Malaysia by providing awareness for routine examination of CD4, viral load and anti-
retroviral adherence which may help to achieve better survival for AIDS patients. It will 
also help to determine the predictors of progression in AIDS patients and its 
accompanying complications which could have an impact on Malaysian Clinical 
Practice Guidelines (CPG) in AIDS treatment. 
 
1.8.2  Building the knowledge 
 
 
The major findings of this study are the predictors of death in AIDS patients and time of 
death in Malaysia. It also has helped to measure time to achieve the effectiveness of 
anti-retroviral therapy and the predictors to achieve viral load less than 50 copies/ml in 
Malaysia. This study could help with progression of death in HIV-infected patients 
mainly in Malaysia and other developing countries. 
  
 
 
 
 
 
 
1 Introduction 
 
20 
 
1.9   Conceptual Framework 
 
 
This study AIDS progression to death has been conducted based on four components 
such as socio-demographic characteristic, laboratory, clinical and anti-retroviral 
therapy. Each component consists of different variables, and twenty two variables and 
eight outcomes were included in this study. The conceptual framework of the 
determinants in AIDS progression to death is summarized in Figure 1.1  
 
 
 
Figure 1.1 Conceptual framework of determinants AIDS progression to death1 
 
 
 
 
 
HAART: 
1. Initial combination   
2. Need second line 
3. Combination at the end of study 
4. Achieve VL ≤ 50 copies/ml 
 Sociodemographic 
characteristics: 
1.  Age 
2.  Gender 
3.  Ethnicity  
4.  Marital status  
5.  Education  level 
6.  Occupational type 
7.  Monthly income  
 
 
 
 
Laboratory tests: 
1. CD4 count 
2. Viral Load (VL) 
3. Hemoglobin  (Hb) 
4. Total lymphocyte count TLC) 
5. Liver Function Test (LFT) 
 
AIDS patients 
Progression to 
Death 
 
Clinical Condition: 
1. Exposure risk 
2. WHO clinical stage 
3. Body Mass Index (BMI) 
4. Opportunistic infections (OI) 
5. Number of OI 
 
 
 
Outcome: 
1. Time to death in all AIDS patients 
2. Time to death in AIDS patients on HAART 
3. Time to death in AIDS patients not on ART  
4. Time to achieve viral load less than 50 copies/ml 
5. Predictors of death in all AIDS patients 
6. Predictors of death in AIDS patients on HAART 
7. Predictors of AIDS patients not on ART 
8. Predictors to achieve viral load less than 50 copies/ml 
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1.10  Structure of the thesis 
 
This thesis is divided into 6 chapters. Chapter 1 is the introduction of the thesis i.e. the 
background of study, problem statement, rationale of this study, research questions, 
objectives and contribution of the study  
 
Chapter 2 discusses the systematic review of the literature. This begins with the biology 
of HIV, continues with the natural history of HIV infection and pathogenesis of AIDS, 
detection of HIV antibody and clinical stages of HIV/AIDS and covers the 
epidemiology, treatment and factors associated with disease progression  
 
Chapter 3 details the materials and methods used for this study, including study design, 
study area, duration of study, study population, study setting, ethical approval, sampling 
and sample size calculation, data collection, data management and statistical analysis.  
 
Chapter 4 shows the results of a comprehensive statistical analysis and is divided into 
the descriptive analysis, survival analysis and Cox regression analysis.  
 
Chapter 5 discusses the findings of this study. This starts with the profile of study 
subjects continues with a discussion about time to death in all AIDS patients, AIDS 
patients on HAART and AIDS patients not on anti-retroviral therapy. This includes the 
required time and major predictors to achieve viral load less than 50 copies/ml in AIDS 
patients on HAART and a comparison with other studies in developed and developing 
countries.  
 
Chapter 6 is the concluding chapter with recommendations and further studies.  
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Figure 1.2 Structure of the thesis 2 
Chapter 1 
Introduction 
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Literature reviews 
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Methods 
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Results 
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Discussion 
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Conclusion and recommendations 
Introduction, global burden and HIV epidemic, anti-
retroviral therapy, HIV progression, rationale of study, 
problem statement, research question, objectives, 
public health significance, conceptual framework and 
structure of thesis   
Introduction, systematic review of search strategy, 
biology of HIV, epidemiology, transmission, HIV 
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variables, data collection, data management, data 
analysis 
Introduction, distribution of characteristic of HIV-
infected patients and AIDS patients on HAART, time 
to death, the 5 and 10-year survival, time to achieve 
viral load less than 50 copies/ml, predictors of death in 
all AIDS patients, in AIDS patients on HAART, in 
AIDS patients not on anti-retroviral therapy and 
predictors achieving viral load less than 50 copies/ml 
in AIDS patients on HAART 
Introduction, discuss the profile of study subject based 
on socio-demographic, laboratory, clinical and anti-
retroviral therapy, discuss the median survival time and 
the 5 and 10-year survival, predictors of death, 
predictors to achieve viral load less than 50 copies/ml 
and compared to other studies and make critical 
appraisal, the strength and limitation of study 
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1.11  Summary 
 
In this chapter, the global burden of HIV infection in the world, Asia region and 
Malaysia were reviewed including the transmission mode of HIV-infected patients. 
From the literature review, it is well documented that the anti-retroviral therapy can 
reduce the morbidity and mortality of HIV-infected patients, prolong the survival and 
quality of life. There are many studies regarding progression of HIV-infected patients 
conducted in developed countries and only a few studies in developing countries 
including Malaysia. It is still unclear what the predictors of death and predictors to 
achieve viral load less than 50 copies are in Malaysian HIV-infected patients. This 
study represents the first known attempt by a researcher to determine the predictors of 
disease progression in AIDS patients receiving treatment in the University Malaya 
Medical Centre Kuala Lumpur.     
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CHAPTER 2   
 
 
LITERATURE REVIEW 
 
2.1  Introduction 
 
The detailed literature search on a full topic of research is presented in this chapter. 
Section 2.1 introduction. Section 2.2 systematic review search strategy. Section 2.3 
biology of HIV, discussion on structure of HIV, viral genome, HIV types, blood 
differentiation and CD4, HIV co-receptors, life cycle of HIV, natural history of HIV 
infection and pathogenesis of AIDS, detection of HIV antibody and clinical stages of 
HIV/AIDS. Section 2.4 epidemiology of HIV/AIDS, this is continued in section 2.5 
with the transmission of HIV. Section 2.6 progression of HIV infection, this is carried 
into section 2.7 which looked at the survival time of HIV-infected patients. Section 2.8 
explained about anti-retroviral treatment for HIV/AIDS, included classes of drugs, anti-
retroviral initiation, switch second line of anti-retroviral therapy, pre HAART era and 
HAART era and section 2.9 discussed about time and other factors to reach viral load  
less than 50 copies/ml and section 2.10 summary of the chapter 
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2.2  Systematic review search strategy  
 
The search strategy techniques applied in this study include extensive querying 
database, index searches of scientific proceeding, journal supplements and review 
material, cross referencing of bibliographies and backtracking of references from 
articles. The following searched were done using full terminology and Boolean 
keywords. They were entered into electronic bibliography databases, such as Pub Med 
Central, Science Direct and Scopus. The search as of 25
th
 October 2012 at Pub Med data 
base, were run through a etiology study filter, limiting the items in human, adult, 
English language and full text. A total of 5,345 articles containing keyword “HIV 
progression” were identified. The next search was conducted with a narrow filter and 
total numbers of articles were shortlisted in 2,107. An advanced search using AND 
determinants terms managed to generate 514 articles. Finally 66 articles were chosen as 
potential studies. While the search in Science Direct database in 20
th
 November 2012 
using “HIV progression” term resulted in a total of 7,490 articles. The second search 
which was limited to selected journals and 15 years of publication, showed a total hit of 
2,370 articles. This was continued with advance search using AND determinants which 
resulted in 882 articles and 88 articles were identified as potential studies. In Scopus 
database, search in 6
th
 December 2012 with “HIV progression” term and limited to 15 
years of publication extracted 5,300 articles were obtained after excluding non-medical 
journals, which is a total of 3,834 articles. Advanced search with AND determinants 
terms achieved a total of hit of 323 articles of which and 61 articles were shortlisted. 
Flow chart of search strategy is as shown in Figure 1.1  
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Figure 2.1 Flow chart of search strategy 3 
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2.3  Biology of HIV 
 
Human immunodeficiency virus (HIV) is classified as retrovirus, which contains double 
strands of ribonucleic acid (RNA) as it is a genetic material. It is associated with 
immune suppression diseases where patients observe symptoms of diseases much later 
after infection due to long viral incubation. HIV causes Acquired Immune Deficiency 
Syndrome (AIDS) (Barre-Sinoussi et al., 1983) 
 
2.3.1  Structure of HIV 
 
 
HIV has a cylindrical eccentric nucleoid or core. The nucleoid surrounds two identical 
single strands of ribonucleic acids (RNA) which encode the virus genes (Figure 2.2). 
This genetic code for structural proteins and the regulatory protein control the viral 
activity. The viral protein p24 is found within the viral envelope in capsid shape. 
Antigen p17 lies between the virus envelope and the core. External knob-like structure 
is formed by the envelope glycoprotein gp120 which can be noticed on the surface of 
HIV. The transmembrane protein, gp41 anchors gp120 to the viral envelope, creating 
both external and internal domains. The membrane lipid layer is originated from the 
host cell (Ratner et al., 1985) 
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Figure 2.2 Structure of HIV 4 
Source: (http://www.sexuallytransmitteddisease.info/aids/aids-pictures) 
 
2.3.2  Viral genome 
 
 
Transcription prepares sites for the formation of viral deoxyribonucleic acid (DNA). 
The viral genome as a transactivator is tat (encodes transactivator protein), rev (encodes 
a regulator of expression of viral protein) and vpr (encode viral protein R). The viral 
genome as a protein regulator is vif (associated with viral infectivity), nef (encodes a 'so-
call' negative regulator protein) and vpu (encodes viral protein U) to manage the rate of 
viral replication and termination. For example, tat protein p16 and p14 activate the viral 
transcription. The p14 rev protein is responsible for the transport and stability of viral 
RNA. The p27/p25 nef protein is active in the down regulation of CD4 cells (Watts et 
al., 2009). The viral genome consists of three structural genes termed as env, gag  and 
pol  (Watts, et al., 2009):  
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a. env gene (envelope gene): envelope precursor gp160 (glycosylated polypeptide 
precursor) which is processed to form gp120 (the exterior glycoprotein) and gp41 
(the trans membrane glycoprotein), protein is embedded in the viral envelope 
which sustains the virus to join the target cells.  
b. gag gene (specific antigen group): gag precursor (p53), coding of viral core, 
cleaved into  smaller products : p18, p24 (nucleocapsid protein) and p15  
c. pol gene: (polymerase gene), encodes the viral enzyme: protease (p10). reverse 
transcriptase (p66/p55) and integrase (p32) 
 
The function of protease is particularly to split pol and gag precursor polypeptides into 
functionally active proteins. The replicating of RNA genome is proceeding through 
reverse transcriptase in the presence of DNA polymerase. Endonuclease is important in 
proviral integration, tev is present in some HIV-1 isolates with the partial incorporation 
of env and with no or little rev properties (Watts, et al., 2009) 
 
 
 
Figure 2.3 HIV genome 5 
Source: (Huckaby, 1998) 
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2.3.3  HIV types   
  
 
There are 2 types of HIV infections, HIV-1 and HIV-2. Generally HIV-1 infections are 
more virulent than HIV-2 (Reeves & Doms, 2002). The type of HIV is defined by the 
genomic organization, vpu is a unique gene found in HIV-1 while vpx is found in HIV-
2. The HIV-2 crossed reacted with the gag core protein p24 of HIV-1. The percentage 
of amino acid homology between env and pol is low (Watts, et al., 2009). Genetically, 
HIV-1 can be classified into four groups, specifically M group (major), O group 
(outlier) and N and P the two new groups (Figure 2.4). Genetic changes in HIV 
recombinant viruses could result in altered biologic properties that affect the pathologic 
features and consequences of HIV infection. Recombinant strains of HIV spread in new 
regions and new host are identified throughout the world as different subtypes 
(Hemelaar, Gouws, Ghys, & Osmanov, 2006). The HIV-1 group P is a new strain 
discovered in August 2009 closely related to the gorilla simian immunodeficiency virus 
(Plantier et al., 2009). The majority of HIV-1 infection belongs to group M, which have 
been divided into nine genetically different subtypes; A, B, C, D, F, G, H, J and K 
(Hemelaar, et al., 2006). The distribution of HIV-1 subtypes in various countries can be 
seen in Table 2.1. Different subtypes of two viruses can join into a cell of infected 
human and assimilate with its genetic material. Most of the new strain can be 
transmitted to more than one person but they cannot remain in the same form for long. 
This form is called circulating recombinant form (CRFs), the combination of subtypes 
A and B were called CRF A/B (Hemelaar, et al., 2006). 
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Figure 2.4 HIV type and subtypes 6 
Source: (http://www.Avert.org/hiv-types.htm) 
 
Table 2.1 The relationship between HIV-1 subtype and distribution location 1 
Subtype Country 
A West Africa 
B Europe, America, Japan, Thailand, Australia 
C Southern Africa, India, Nepal 
D Eastern and Central Asia 
F Central Africa, South America, Eastern Europe 
G Central Europe  and Africa  
H Limited to central Africa 
J Central, North Africa, West Africa, Caribbean 
K Limited to Cameroon  and Congo  
 
Source: (Hemelaar, et al., 2006) 
 
A study in 1997 showed that group O was formed out of 2 per cent of HIV positive 
samples where it is usually spotted in Cameroon and not common outside of west 
central Africa (Peeters et al., 1997). From early versions of HIV-1 test kits, group O 
could not be detected. Now more advanced HIV test have evolved to detect group O and 
N. In 1998, group N was discovered in Cameroon. In 2006, only 10 N groups were 
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identified while group M and group O were not detected at all (Yamaguchi et al., 2006). 
A new report on analyzed HIV sequence similar to a simian immunodeficiency virus 
found in gorillas (SIVgor) was released in 2009. This virus was isolated from a 
Cameroonian woman and believed to belong to group P (Plantier, et al., 2009).  
 
2.3.4  Blood differentiation and CD4  
 
 
Blood volume consists of 45 per cent blood cells and 55 per cent of blood plasma. 
Blood plasma is the liquid component of blood with yellow colour as the medium of 
blood cells. The volume of blood plasma consists of 90 per cent water and 10 per cent in 
the form of a solution in the form of protein, glucose, coagulation factors, mineral ions, 
hormones and carbon dioxide emissions. Blood plasma is also as the medium in the 
process of excretion (Anthea et al., 1993).  
 
All blood cells are generated at the site where haematopoietic stem cells (HSCs) reside, 
during the foetal period, HSCs resides in the liver and in the bone marrow after birth, 
except for T-cells, which are formed in the thymus from progenitors derived from these 
hematopoietic sites. Haematopoietic stem cells have the ability to give rise to all of the 
different mature blood cell types and have an average lifetime about 3 to 4 days in the 
human body. A blood cell (a haematocyte) is a cell produced by haematopoiesis and 
normally found in blood. In children, haematopoiesis occurs in the marrow of the long 
bones such as the femur and tibia. In adults, it occurs mainly in the pelvis, cranium, 
vertebrae, and sternum (Kawamoto, Wada, & Katsura, 2010). The process of 
hematopoiesis in human displayed in Figure 2.5 
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Figure 2.5 The process of hematopoiesis in humans 7  
Source: (Anthea, et al., 1993)  
 
Blood cells are divided into three categories, namely erythrocytes, leukocytes and 
platelets. Firstly, platelet or thrombocyte is a very small cell with diameter 2–3 µm, 
irregularly shaped, do not have a nucleus containing DNA and have average lifespan 
just 5 to 9 days.  They circulate in the blood are involved in haemostasis, leading to the 
formation of blood clots. Platelets form the clots by releasing thread-like fibres. 
Secondly, red blood cells (RBC) have the main component called hemoglobin. 
Hemoglobin is an iron-containing protein that facilitates the transportation of oxygen 
and other respiratory gases to tissues (carries oxygen and collect carbon dioxide) and 
has a lifetime of about 120 days. Thirdly, white blood cells (WBC) or leukocytes have 
an average lifespan about 3 to 4 days in the human body and is used for defending the 
body against both infectious diseases and foreign materials. The WBC divided into five 
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differentiation are basophils, neutrophils, eosinophils, monocytes and lymphocyte 
(Anthea, et al., 1993).  
 
The Lymphocytes divided into large lymphocytes and small lymphocytes. Large 
granular lymphocytes include natural killer (NK) cells. Small lymphocytes consist of T- 
cells and B-cells. The T-lymphocyte cell or called cluster of differentiation 4 (CD4) is a 
primary cellular receptor for HIV entry. The CD4 cell or helper T-cells are special cells 
in the immune system which react when the HIV enters and infects the human body. 
The CD4 cell count plays an important role in the human immune system as it helps the 
body to attack the infection and diseases. When the CD4 cell count does not work 
properly, then the person will easily fall sick. A healthy individual usually has CD4 cell 
counts in the range of 500-1,800 cells/µL. The schematic of blood differentiation and 
CD4 are displayed in Figure 2.6. 
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Figure 2.6 Blood differentiation and CD4 8 
 
 
2.3.5  HIV co-receptors 
 
The CD4 is a primary cellular receptor for HIV entry. The HIV attaches CD4 cell by the 
interplay among viral envelope, gp120 and a specific part of the CD4 molecule and it is 
present in abundance on CD4 cell count, both mature and immature T-lymphocytes. The 
chemokine receptors function as cofactors and allow HIV entry here: 
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a. C-X-C chemokine receptor CXCR-4 (fusin) 
 
CXCR4 was expressed by T-lymphocytes (Doranz, Berson, Rucker, & Doms, 1997). 
CD4 and CXCR4 were co-expresses on cell allowing T-tropic HIV isolates to fuse and 
infect cells. The gp120 of HIV interacts with CXCR4 and CD4 to the cell and to cause 
conformational changes in gp120/gp41 complex allowing membrane fusion with gp41. 
CXCR4 is normally expressed on T cells and not on macrophages and cannot be united 
with M tropical HIV isolates (Doranz, et al., 1997). Stimulation with bacterial cell wall 
products can promote CXCR4 expression on macrophages and allow infection by HIV 
T tropic strain, mediating entry of SI (syncytium inducing). CXCR4 infect 
lymphocytes and cause a rapid progression of disease (Moriuchi, Moriuchi, Turner, & 
Fauci, 1998).  
 
b. C-C Chemokine receptor CCR-5 
 
Co-receptor CCR5 was found after the identification of CXCR4. CCR5 is expressed by 
monocytes, CCR5 with the presence of CD4 to allow fusion to HIV membrane (Deng et 
al., 1996). HIV gp120 depends on CD4 to bind to CCR5. As antibody inhibition, CD4 
can decrease 87 per cent of CCR5 binding (Trkola et al., 1996). M tropic HIV isolates 
using co-receptor CCR5 for infection of macrophages and T-cells. Individuals with 
specific mutations in CCR5 co-receptor appear to be resistant to HIV infection. CCR5 
strains are transmitted and usually predominate early in infection (Liu et al., 1996). 
 
c. Additional chemokine receptors (CCR-2 and CCR-3) 
 
Can also serve as a co-receptor for HIV under certain circumstances in vitro but are not 
believed to function as co-receptors in primary isolates. A chemokine CCR3 is 
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expressed on eosinophils and microglia. It is used for some HIV infection at microglia 
and resulting CNS pathology (He et al., 1997). It is likely that other chemokine 
receptors may also bind gp120 and allow HIV entry (Trkola, et al., 1996). 
2.3.6  Life cycle of HIV 
 
 
There are 10 steps of replication in the HIV life cycle (AIDSinfonet.org, 2012): 
 
 
Step 1: HIV-1 surface glycoprotein gp120 interacts with the high affinity receptor, CD4 
leads to a conformational change in gp120, permitting interaction with cellular 
receptors, CXCR4 or CCR5 
Step 2: Interaction of gp120 with CD4 and receptor, the virus then fuses with the host 
cell allowing RNA release into host cells. 
Step 3: Reverse transcription of genomic RNA into DNA 
Step 4: Viral DNA enters the host cell’s nucleus 
Step 5: The integration of DNA is called provirus 
Step 6: Transcription 
Step 7: RNA processing and nuclear export of processed viral RNA 
- HIV-1 rev protein controls the expression of different types of viral mRNA 
- Once a sufficient level of rev accumulates, the single spliced and un-spliced 
HIV-1 RNA meet up in the cytoplasm and fuse with viral structural proteins  
Step 8:  Translation of viral mRNA into proteins 
Step 9:  Assembly of viral proteins and genomic RNA  
Step 10: Budding of immature viral particles, viral env proteins are utilized to bud 
through the host cell membrane. The viral gag and gag poly-proteins are 
cleaved by the viral protease during or shortly after budding, generating 
mature infectious virions.   
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Primary HIV infection is related to extensive virus replication and widespread 
dissemination of the virus  (AIDSinfonet.org, 2012) 
 
 
Figure 2.7. Life cycle of HIV 9 
 
Source: (AIDSinfonet.org, 2012)  
2.3.7  Natural History of HIV infection and pathogenesis of AIDS  
 
HIV infection may occur by sexual contact or parenteral exposure to blood and blood 
products. HIV virus in the blood will appear and the viral can be detected within 7 to 10 
days but majority of HIV infection in the initial stage will be silent. HIV-infected 
patients may not realize any symptoms till about 7-21 days later where HIV antibodies 
may appear in the blood (Barker et al., 1998). Patients in the early stage of infection 
often develop a seroconversion illness or acute HIV infection syndrome such as flu-like 
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symptoms, fever, lymphadenopathy, rash, loss of weight due to low appetite, diarrhoea 
and general lethargy and malaise. During the acute stage (after infection for 2-4 weeks), 
levels of virus in the bloodstream may be high (viral load can achieve 10,000.000 
copies/ml in the blood) (Barker, et al., 1998). This happens because virus duplicate 
quickly as the immune system has yet to increase an effective repressive response, 
including the production of antibodies that can stop the virus particles (at this time as 
impact the total of CD4 count drops to very low levels and this person is very 
infectious). Subsequently as immune response recovers, appearance of antibody was 
directed against the virus. At this point, stabilized viral set point for 3 to 4 months and 
the level of virus in the blood declined (Figure 2.8). In the blood stream the value of 
virus become much lower, the patient feels well and less infectious. An infected person 
in this condition may feel well for 9.4 years (Morgan et al., 2002). 
 
When the virus copies its genetic code many mistakes appear. The body’s immune 
system has limited ability to control HIV. Genome with an average of 9,000 bases in 
total, might display an error in almost every genome copied. These genetic errors cause 
changes of appearance in the virus, thus making it more difficult for the immune system 
to identify it. Consequently, through a progressive shift, the virus takes the form that the 
immune system cannot respond to the infection, the rate of infection begins to 
accelerate. The total number of CD4 cell count starts dropping. When the CD4 cell 
count falls lower than 400 cell/µL (critical threshold), the body can no longer support 
itself (Barker, et al., 1998). At this point of time HIV infected person starts experiencing 
AIDS conditions and common opportunistic infections start to occur. Various possible 
infections that can occur are mycobacterium tuberculosis infections, pneumocystis 
carinii pneumonia (PCP), oral/pharyngeal candidiasis, cytomegalovirus (CMV), chronic 
diarrhoea, meningitis, toxoplasmosis cerebri, etc. Generally doctors will prescribe 
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prophylactic drug such as cotrimoxazole which helps in preventing infections and 
slowing down the progression of PCP. 
 
The median survival time for AIDS patients that did not receive treatment is 9 months. 
Clinical progression among HIV-infected patients varies widely, from 2 weeks to 20 
years (Barker, et al., 1998). There are many factors influencing this progression, such 
as age, the presence of co-existing infections and quality of health care. Genetic factor 
plays an important role as individuals resistant to special strains of HIV will show 
symptoms at a later stage of infection. There are even individuals that are totally 
immune to the viral infection. They carry the CCR5-delta-32 (a mutated cell surface 
marker), which prevents HIV from locking onto and invading their cells. This process 
may hold the key to future therapies which can be used to block infection in susceptible 
individuals. Scientists of today are hoping to understand this mechanism which can 
increase the resistance towards the virus (Hummel, Schmidt, Kremeyer, Herrmann, & 
Oppermann, 2005) . 
 
 
Figure 2.8. Natural history of HIV infection and pathogenesis of AIDS 10 
Source: (http://www.microbiologybytes.com/virology/AIDSI.html, 2009) 
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2.3.8  Detection of HIV antibodies 
  
Ethically, to conduct a blood test for an HIV infected person, a series of practice should 
be carried out such as signing informed consent, maintain confidentiality and 
accompanied by counselling (called 3Cs) (UNAIDS & WHO, 2004). Test to diagnose 
HIV has to be specific and sensitive. The percentage of positive result when HIV is 
present is called sensitivity and the percentage of the negative result when HIV not 
present is called specificity.  Diagnosis of HIV by using an algorithm that combines two 
tests for HIV antibodies is carried out in the United States. The first diagnostic test for 
HIV an enzyme immunoassay (EIA) or enzyme linked immunosorbent assay (ELISA) 
was approved by the Food and Drug Administration (FDA) in 1985 to screen 
transfusion donors to keep the blood supply safe. This method is used to detect positive 
antibodies. Second test comes in the form of test kit used to determine antigens binding 
to antibodies. The test applies procedure like Western blot. The combination of both 
methods is important to achieve a highly accurate HIV detection. Antibody test was 
specifically intended for routine diagnostic HIV testing for adult. During the window 
period (3 weeks to 6 months of HIV infection) this test may give false negative. After 
infection, antibodies can be detectable in a majority of people around 30 days and 97 
per cent the of people after 3 months HIV infection antibodies were detectable, it is rare 
with modern antibody testing of the 6 month window (CDC, 2006). For screening 
purpose, 2 blood samples will be taken on different occasions. These tests involve virus 
lysate antigens, recombinant protein antigens and chemically synthesized antigens, but 
EIA or ELISA testing alone is not sufficient for HIV diagnosis. The Supplemental test 
is Rapid Particle Agglutination (PA) had 99 per cent sensitivity and 98.9 per cent 
specificity compared with ELISA (Ramalingam, Kannangai, Raj A, Jesudason, & 
Sridharan, 2002). The Western Blot was used as a confirmatory test which detects HIV 
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antibody in human serum sample. It is also an analytical technique to detect specific 
protein from extract or tissue homogenate sample. Protein from HIV infected cells was 
obtained and dried on membrane. The serum was subjected to antibody incubation, free 
antibody was washed away and secondary anti human antibody associated with signal 
enzyme was added. The stained bands showed that patient’s protein serum contains 
antibody (CDC, 2006).    
 
In most health care settings in the United States of America (USA) an EIA or ELISA is 
used, followed by Western blot for confirmation.  In many global setting two to three 
rapid HIV test is used for screening and confirmation. Many people are not getting 
tested for HIV with varied reasons, such as poor access to HIV testing, unaware of their 
risk, many remain afraid to find out their test result or they avoid testing due to stigma. 
Either avoids testing because of a dislike of counselling or because of the anxiety 
associated with waiting for their test result. Some are unaware that they would have 
access to effective treatment for HIV and so see no point in testing (Holmes et al., 
2008). The screening procedure of HIV is as shown in Figure 2.9  
 
Figure 2.9. Screening procedure of HIV 11 
Source: (CDC, 2006)  
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2.3.9  Clinical Staging of HIV/AIDS  
 
 
HIV disease classification systems and staging are tools for monitoring and tracking the 
HIV epidemic. They provide patients and clinicians with important information about 
clinical management and staging of the HIV disease. Currently, two classification 
systems used in the world are Centres for Disease Control and Prevention (CDC) US 
and World Health Organization (WHO) Disease Classification System.  
 
a. CDC Classification System  
 
 
In 1986, CDC US published the majority accepted HIV infection classification system. This 
classification is primarily intended for use in public health practice and  is based on certain 
conditions associated with HIV cases (CDC, 1992). This classification system has been 
revised by CDC in 1993 to emphasize the clinical importance of the CD4 count in the 
categorization of HIV related clinical conditions. There were 3 clinical categories (A, B, C) 
and 3 ranges of CD4 counts represented by a matrix of nine mutually exclusive categories. 
There are three categories of CD4 count as follows (CDC, 1992):  
Category 1:  CD4 ≥ 500 cells/μL  
Category 2: CD4 200- 499 cells/μL  
Category 3: CD4 < 200 cells/μL  
 
Meanwhile HIV infection clinical categories are as follows:  
Category A, which consists of one or more of the listed below, with documented HIV 
infection. The conditions listed in categories B and C must not have occurred  
- Asymptomatic HIV infection  
- Persistent generalized lymphadenopathy  
- Acute HIV infection with accompanying illness or history of acute HIV infection  
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Category B, consists of symptomatic conditions in HIV-infected individuals, which do not 
include conditions listed in clinical Category C, and minimal one of these criteria: a) the 
condition attributed to HIV infection or defect in cell mediated immunity, b) conditions 
considered by physicians to have a clinical course or that require management due to 
complication of HIV infection. Meanwhile, Category C, includes the clinical conditions 
listed in the AIDS surveillance case definition. Based on the 1993’s revised classification 
system, CDC has also expanded the AIDS surveillance case definition to include all HIV 
infected individuals that have CD4 count less than 200/μL. The expansion includes the 
addition of 3 clinical conditions, PTB (pulmonary tuberculosis), invasive cervical cancer 
and recurrent pneumonia (CDC, 1992) 
 
 
b. WHO Clinical Staging   
 
 
In 1990, WHO developed a case definition and HIV clinical staging. It has been revised 
in 2007. It is based on clinical findings that guide the HIV/AIDS patients to make a 
diagnosis, to manage, to evaluate HIV patients and does not require a CD4 count. Many 
countries are using this staging to determine those eligible for anti-retroviral therapy. 
There are four categories of clinical stages that are stage 1, 2, 3 and 4, progressing from 
HIV infection till AIDS infection. These stages are defined by symptoms or specific 
clinical conditions and according to the WHO staging system, adolescents and adults 
are defined as individuals aged 15 years (WHO, 2007c). WHO clinical staging detail are 
found in Appendix F.   
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2.4  Epidemiology of HIV/AIDS 
 
 
AIDS was first identified in 1980s. Now, the disease is widespread all over the world. 
AIDS has become a global pandemic receiving extraordinary attention. HIV infection 
causes relentless destruction to the immune system thus leading to the onset of the 
AIDS. AIDS has led half of its victims to death (UNAIDS, 2010). All HIV-infected 
patients have the risk of illness and death from complications of opportunistic infection 
and neoplasm that cannot be avoided (Moss & Bacchetti, 1989).  
  
There are 4 stages of evolution of the AIDS pandemic. In the first stage, the spread of 
HIV increased from endemic rural to urban population. The second stage showed the 
spread of HIV in certain risk groups. The third stage is the continuation of second stage. 
It showed the spread depends on the behaviour of the risk group, such as sexual 
promiscuity and IDU. The fourth stage is development of stabilization in places such as 
Australia, North America and Western Europe, where control measures have a positive 
effect. However, some places like central Asia and Africa experienced increasing HIV 
epidemic since 1990 (CDC, 2001; Quinn, 1996). Even though HIV infection increased 
dramatically in the USA in 1980’s and peaked in the early 1990’s. Eventually it 
declined but the development of a reservoir of people infected with HIV requiring 
therapy has risen steadily since 1990’s and continued into the 21st century (CDC, 2001; 
Fauci, 1999). More than 21 million people in the world had died from AIDS, over 34 
million people living with HIV (PLWH) and over 95 per cent of HIV infected people 
stayed in developing countries at the end of the 20
th
 century (Gayle & Hill, 2001; 
Sepkowitz, 2001) 
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The reach of the AIDS pandemic has already caused serious problems in many sectors. 
For example health care system in many countries cannot cope with increasing AIDS 
patients, the loss of young to middle aged individuals gave a big impact to national 
economies as they are most productive economically. In the early 21
st
 century, about 95 
per cent of HIV (incidence and deaths) occurred in developing countries and two thirds 
of people living with HIV in the world were founded in sub Saharan Africa. Forty per 
cent of HIV incidence affected young people aged from 15 to 24 years old (Merson, 
2006). Half of the AIDS cases filed in the world are woman. Consequently, vertical 
infection from mother to child increased and this caused significant number of children 
born with HIV infection (Quinn, 1996). The cost effective therapies for individuals with 
HIV infection and complications are administered to prolong survival. In 1990’s, the 
amount spent for medical care of an HIV infected individual in United States was twice 
the amount earned (Bozzette et al., 1998). Although treatment using various drugs 
increases the survival of HIV infected individuals but the price of drugs are still high 
and it was difficult to reach majority people in the world. The years of useful life lost by 
the predominantly younger people infected by HIV gave an important economic impact 
(Whiteside, 2001). 
  
The epidemic had left behind 16 million AIDS orphans by the end of 2009 (WHO, 
2010b). These orphans are defined as those aged less than 18 years old and have lost 
both or one parent to AIDS. These victims have a tendency of getting HIV infection, 
being exploited and live in poverty. Usually, they were forced to find work and leave 
their education. Sometimes they also carry responsibility over their younger siblings and 
family. About 2.5 million children aged less than fourteen years old were infected with 
HIV in 2009 (WHO, 2010b). More than 90 per cent of children with HIV got the 
infection from their mother through birth or via mother’s breast milk. Almost nine 
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tenths of such transmissions developed in sub Saharan Africa. This region leads in 
mother to child transmission (MTC) of HIV. It still stays in first place despite the proof 
that HIV ultimately impairs women’s fertility. Which means once infected, a woman 
can be expected to bear 20 per cent lower children than she otherwise would. Anti-
retroviral treatment is able to decrease the risk of mother to child, but these are still out 
of reach in remote places where they are most needed. Ninety percent of PLWH stay in 
the developing countries. The proportion is set to rise even further as infection rate 
continue to grow in countries where low health care systems, poverty and limited 
resources for prevention and care fuel the transmission of the virus. Sub Saharan Africa 
(the area in South Africa of the Sahara desert) is the badly affected country in the world 
by the AIDS epidemic (WHO, 2010b).  
 
In 2009, there were 1.8 million people newly infected with HIV, 2.3 million children 
were HIV infected. This amount brought the total of PLWH in this region to 22.5 
million by the end of 2009. In 2009 AIDS killed around 1.3 million individuals in sub 
Saharan Africa only (WHO, 2010b). Anti-retroviral drugs can dramatically improve 
survival allowing years of healthy life, but still they are not available to most Africans 
(WHO, 2007a). 
 
These were around 32.8 (95% CI 30.9 - 34.7) million of PLWH, about 2.7 (95% CI 2.4 
- 3.0) million of new HIV infections and 2.0 (95% CI 1.7 – 2.4) million deaths due to 
AIDS related illnesses found worldwide, nearly 16 per cent of all new infections 
occurred among children below 15 years and 45 per cent of new infections developed in 
young people aged between 15-24 years at the end of 2008 (WHO, 2009). At the end of 
2009, there were 33.3 (95% CI 31.4 – 35.3) million of PLWH and 2.6 (95% CI 2.3 – 
2.8) million of new HIV infection (WHO, 2010b) 
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At the end of 2011, globally there were 34.0 (95% CI 31.4–35.9) million of PLWH,  0.8 
per cent of adults aged 15-49 years worldwide are living with HIV and 1.7 (95% CI 
1.5–1.9) million people died from AIDS-related causes (UNAIDS, 2012). The burden of 
the epidemic continues to vary considerably between countries and regions. In sub-
Saharan Africa reported that 71 per cent of the adults and children newly infected in 
2011(UNAIDS, 2012). The global HIV incidence and number of new infections by year 
are as shown in Figure 2.10 and Figure 2.11. The Malaysian HIV epidemic (1986-2009) 
is shown in Figure 2.12 
 
 
Figure 2.10. Estimation of HIV global incidence and number of new infection by 
year 12 
Source: (http://www.globalhealth.org/hiv_aids/global_view/) 
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Figure 2.11. Number of people living with HIV, number of new infection and 
number of AIDS death worldwide, 1990-2008 (in million) 13 
Source: (http://www.globalhealth.org/hiv_aids/global_view/) 
 
 
 
Figure 2.12. The Malaysian HIV epidemic (1986-2009) 14 
Source: (UNGASS, 2010) 
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In Asia, there were 4.7 (95% CI 3.8-5.5) million of PLWH in 2008, including 350 000 
(95% CI 270 000 - 410 000) new HIV cases last year (WHO, 2009). In 2008, there were 
330 000 (95% CI 260 000-400 000) death from AIDS in Asia. While the yearly total 
deaths from AIDS in South and South East Asia in 2008 was around 12 per cent, which 
is lesser than the mortality statistic in 2004. The rate of death from HIV or AIDS in East 
Asia showed a continued rise. In 2008, the total was three times higher compared to 
total death in 2000 (WHO, 2009). The total of PLWH in whole of Asia is 4.9 (95% CI 
4.5 – 5.5) million in 2009. Adult HIV prevalence is still less than 1 per cent in most 
countries in the Asia region, except Thailand the prevalence is close to 1 per cent 
(WHO, 2010b).  
 
In 2010, about 4.8 (95% CI 4.3–5.3) million PLWH in Asia, 11 per cent more than the 
4.2 (95% CI 3.8–4.6) million in 2001. HIV transmission rates have slowed in the larger 
epidemics, but expanded access to anti-retroviral therapy has increased the survival 
rates of PLWH. An estimated 3 100 (95% CI 2 600 – 3 400) people died from AIDS-
related causes in 2010, the largest death toll outside sub-Saharan Africa. That death toll 
has stayed relatively stable during the past decade in Asia overall, but in East Asia it 
doubled from 24 000 (95% CI 16 000 – 45 000) in 2001 to 56 000 (40 000 – 76 000) in 
2010 (WHO, 2011). In 2011, there were 4.0 (95% CI 3.1–4.6) million of adults and 
children living with HIV and 2.8 (95% CI 1.7–3.7) million adults and children newly 
infected with HIV In South and South-East Asia (UNAIDS, 2012) 
 
Seven countries reported 100,000 or more PLWH in 2009: India, China, and Thailand, 
Indonesia, Viet Nam, Myanmar and Malaysia (ranked by the number of PLWH in 
each). More than 90 per cent of the people with HIV in Asia live in these countries, with 
India alone accounting for 49 per cent of the PLWH in the entire region (WHO, 2011). 
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Malaysia already has HIV cases for the past 25 years. At the end of 2011, there were 
81,000 PLWH cases. The cumulative figure for the first HIV case in 1986 was 94,841, 
out of which 17,686 were AIDS cases  and 14,986 were deaths, thus giving reported 
PLHIV of 79,855 (UNGASS, 2012). The Ministry of Health reported the annual 
number of new HIV cases has been on a steady decline from a peak of 6,978 in 2002. In 
2011, there were 3,479 new cases reported to the Ministry of Health, approximately half 
of what was reported in 2002 with an average of 9 new cases each day. The notification 
rate of HIV also continues to experience a decrease from 28.4 in 2002 to 23.4 in 2005 
and to 12.2 cases per 100,000 populations in 2011(UNGASS, 2012). The epidemic in 
this country is concentrated within most-at-risk populations (MARPS) especially among 
IDU, sex workers and transgender population (UNGASS, 2012). 
 
2.5  Transmission of HIV 
 
HIV infection can spread via various body fluids and secretion. Generally HIV appears 
in high concentration in the blood, genital secretions and breast milk. These are 
significant HIV transmission route to other individuals. The low concentration of HIV 
in urine, sweat, saliva and tears, has low chances of spreading HIV to other individuals 
(Lifson, 1988). The main transmission source of HIV is unprotected sexual intercourse. 
Sexual transmission occurs when HIV secretion of infected individual gets in contact 
with genital mucous, rectal mucous or oral contact with another individual (Boily et al., 
2009). Primarily HIV was a sexually transmitted disease that affected a certain risk 
group in the population. It is different from the other infectious diseases where the 
whole population is at risk. The spread of HIV can develop from a man who has sex 
with woman, man who have sex with men (MSM) and a woman who have sex with 
men. HIV infections can be transmitted through sexual relationships with multiple 
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sexual partners, with men with sexually transmitted diseases (STD’s), with men who are 
not circumcised and without protection.  
 
Randomized controlled trials (RCT) have been conducted with uncircumcised men who 
were randomly chosen for circumcision with sterile condition and later given 
counselling. They were then compared with uncircumcised men. Analysis of data 
showed that sexually transmitted diseases percentage of men to women decreased 60 
per cent in South Africa (Williams et al., 2006), 53 per cent in Kenya (Bailey et al., 
2007) and 51 per cent in Uganda (Gray et al., 2007). Finally a recommendation was 
issued by a panel of experts from WHO and the UNAIDS secretariat that circumcision 
(on man) is an important intervention to decrease the risk of HIV infection in men 
through sexual relations (WHO, 2007d). Among MSM there is enough evidence that 
circumcised men may prevent transmission of HIV infection and sexually transmitted 
diseases (Millett, Flores, Marks, Reed, & Herbst, 2008). The unstable economic and 
political situation is many countries is becoming the barrier to HIV testing programs, 
treatment of sexually transmitted diseases, promotion of condom use and behaviour 
modification treatment. Antiviral drugs can decrease the viral amount and the risk of 
transmission to others.  
 
There are 3 variables that explain HIV transmission by sexual intercourse transmission 
efficiency, total number of sexual partners and total of infected individuals in a 
population. In developed countries, the exposure risk of women who have sex with men 
is 0.04 per cent per act and the exposure risk for men who have sex with women is 0.08 
per cent per act. These rates are 4 to 10 times higher in developing countries with 
various reasons such as condom use not controlled, higher of sexual transmitted 
infection, higher antenatal care HIV prevalence (Boily, et al., 2009).  
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In general HIV transmission can occur when the blood of HIV infected individuals gets 
contact with another person’s wound. For example, different modes of infection 
transmission are by IDU, blood transfusion, hemophiliacs and blood product recipients. 
It is also an important concern for those who received medical treatment using injection 
equipment in the region with low hygiene standards, for example, syringes are reused in 
third world countries due to lack of resources. Although the chances of accident 
occurrence are rare but health care workers such as nurses, laboratory workers, and 
doctors also face the risk of being infected with HIV.  Necessary precautions have to be 
taken to protect themselves from getting contact with HIV infected individual‘s blood 
(Lifson, 1988).  
 
2.6  Progression of HIV Infection   
 
HIV-infected patients will progress from AIDS to death.  CD4 cell counts have been 
used as indicators of disease staging in HIV-infected patients for over 20 years. CD4 
cell counts are predictors of disease progression, independent of disease duration of 
clinical symptom and can be used in conjunction with clinical symptoms to provide 
staging for an individual patient or a population of patients and to a comparison group 
of patients across different studies. The likelihood of specific opportunistic infections is 
related to the CD4 cell counts. In the context of HIV disease progression or response to 
therapy, the CD4 count or a change in the CD4 cell counts explains only a fraction of 
the clinical progression rates or clinical responses to anti-retroviral therapy. Including 
clinical symptoms in the algorithms improves the prognostic value of the observations 
from CD4 less than 200 cells/µL to CD4 more than 200 cells/µL (Holmes, et al., 2008).  
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AIDS will be diagnosed, when CD4 cells count fall lower than 200 cells/µL (Phillips et 
al., 1996). Even though CD4 cells count achieved show more than 200 cells/µL, one or 
more opportunistic infection diseases such as Pulmonary tuberculosis (PTB), PCP, 
toxoplasmosis, candidiasis and others infections, may be present, thus AIDS can be 
diagnosed (CDC, 1992). Decreased of CD4 less than 500 cells/µL omen the 
development of clinical AIDS and CD4 less than 200 cells/µL defines as AIDS and also 
indicates for AIDS with opportunistic infections or neoplasm. The CD4 more than 200 
cells/µL showed a lower risk of death from AIDS (Phillips, et al., 1996; Sterling et al., 
2001). Regarding the immunological factors as predictor of HIV progression, when 
compared to patients with CD4 more than 350 cells/µL, CD4 less than 50 had HR of 
13.0 (95% CI 3.8, 44.3), CD4 of 50-199 had HR of 5.1 (95% CI 1.6, 16.3) (Bonnet, et 
al., 2005). CD4 of 200-350 had HR of 1.72 (95% CI 0.92, 3.21), CD4 less than 200 had 
HR of 3.79 (95% CI 2.18, 6.57) (Jaén et al., 2008) 
 
There is a positive correlation between level of CD4 and hemoglobin level (Obirikorang 
& Yeboah, 2009). Rates of hemoglobin decrease also correlate with falling CD4 counts. 
Hemoglobin is the most widely used screening measures of anemia as a proxy for iron 
deficiency, because it is simple, quick and inexpensive.  Hemoglobin is a marker of 
nutritionally significant iron deficiency, it captures the more advanced stage and not 
detect in early stages of iron deficiency (O'Brien et al., 2005). Hemoglobin thresholds 
are used to define anemia which is based on WHO guideline for women with age more 
than 15 years and not pregnant (Hb 12 g/dl),  pregnant women (Hb 11 g/dl) and men 
with age more than 15 years (Hb 13 g/dl) (WHO, 2008). Anemia has been associated 
with progression to AIDS and shorter survival time for HIV-infected patients.  A study 
of EuroSIDA multicenter cohort showed that mild anemia (Hb 8-14 g/dl for men, and 
Hb 8 – 12 g/dl for women) and severe anemia (Hb < 8 g/dl) were associated with 
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clinical disease progression, with a relative hazard of disease progression of 2.2 (95% 
CI, 1.6–2.9) and 7.1 (95% CI, 2.5–20.1), respectively, compared with patients with no 
anemia (Hb > 14 g/dl for men and Hb > 12 g/dl for women) (Jens D. Lundgren & 
Amanda Mocroft, 2003). 
 
Total lymphocyte count (TLC) has a correlation with CD4 cell count (Spacek, 
Griswold, Quinn, & Moore, 2003). Based on WHO guidelines TLC can used as a 
surrogate marker for CD4 level, the cut-off  value TLC less than 1,200 cells/µL is 
similar with CD4 less than 200 cells/ µL (WHO, 2006b). In asymptomatic HIV-infected 
patients TLC correlates relatively poorly with the CD4 cell count but in combination 
with clinical staging it has been reported as a useful marker of prognosis and survival 
(WHO, 2006b). The finding of a United Kingdom (UK) study showed that a significant 
linear correlation between the CD4 count and TLC (Pearson’s correlation coefficient = 
0.70, p- value < 0.001). The cut-off value at which the error rate for TLC is at its lowest 
and the sensitivity maximal was 1,500 cells/µL, with further analysis identifying 1,700 
cells/µL being a more precise cut-off (Stebbing et al., 2005). Patients with TLC 1,000–
1,500 cells/µL were estimated to be at 40 per cent increased risk of developing an 
opportunistic infection but the area under the ROC curve for TLC was 10 per cent lower 
than CD4 count (Stebbing, et al., 2005). As a predictor of opportunistic infection, TLC 
is less reliable than CD4 count but in a resource limited setting or absence of expensive 
equipment for CD4 tes,t then the TLC test is useful. 
 
The number of viral load in peripheral blood is the best indication for laboratory 
examination as a sign of HIV progression to AIDS. CD4 cell count and adult’s age do 
not affect the predictive value of viral load levels. At this level, viral load would have 
generally decreased and continue to fluctuate from 6 to 9 months. The latent phase of 
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HIV infection contains relatively stable viral load. This condition depends on factors 
such as the strain of HIV, host immune response, total of CD4 cell count and 
macrophages that exist in the process of infection. In the cases of congenital HIV 
infection, the amount of virus in the blood may be higher at first but it could not be 
determined until the birth of the baby (Sterling, et al., 2001).  
 
Viral load is typically reported as copies of HIV in a millilitre (ml) of blood. Viral load 
can predict how long an individual will remain healthy or how quickly the disease will 
progress. The total number of viral load in the blood is associated with the progression 
of AIDS, they ranged from less than 50 to 1,000,000 copies/ml. The number of viral 
load can stay stable for months to years. Every HIV infected person may have a 
different viral load in the blood where it changes rapidly. The higher number of viral 
load will mark the progress to more definite AIDS. The HIV infected patient tested with 
a viral load of more than 100,000 copies/ml will be more prone to attain AIDS or death 
(Smurzynski et al., 2010). The presence of neoplasm and opportunistic infections can 
increase the risk of AIDS progression to death (Falster, et al., 2009; Mugavero et al., 
2007). Although the rates of progression to AIDS are similar among women and men 
but the initial viral load is different (Sterling, et al., 2001).  The CD4 cell count and viral 
load test are the gold standard markers for disease progression in monitoring HIV-
infected patients, measurement of these parameters is not possible in resource-limited 
settings, surrogate markers become important for use as markers for disease progression 
such as total lymphocyte count, hemoglobin and body mass index (BMI) (Zhou & 
Kumarasamy, 2005) 
 
HIV patients can be categorized into 3 groups which are typical progression, rapid 
progression and non-progression towards AIDS. Clinical appearance of AIDS can be 
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detected between 8 to 10 years after HIV infection (Beral et al., 2000). After an acute 
infection number, the viral load amount will fall and this is seen in HIV patients. 
Initially, HIV variants replicate slowly over time and replication becomes faster towards 
progression to AIDS.  On the average,  10 per cent of HIV infected people experience 
rapid progress to AIDS within 2 to 3 years after the first infection (Haynes, Pantaleo, & 
Fauci, 1996). This occurrence is due to high viral load in the acute phase of infection 
which do not decline after that or probably the individual was infected with more than 
one type of HIV virulent (Haynes, et al., 1996). Meanwhile, there are individuals with 
clinical symptoms of AIDS will certainly stand a chance to live for many years. 
Development of AIDS by HIV-infected patients is not caused by race, gender or 
pregnancy but it is the determinant of infection (Bessinger, Clark, Kissinger, Rice, & 
Coughlin, 1998; Chaisson, Keruly, & Moore, 1995).   
 
Hepatitis G virus (HGV) also known as GB virus C (GBV-C) is a single stranded RNA 
virus belonging to the Flaviviridae family. It is often found in co-infections with other 
viruses, such as hepatitis C virus (HCV), hepatitis B virus (HBV) and HIV. About 40 
per cent of the prevalence of GBV-C in HIV infected individuals and about 1.8 per cent 
in blood donors (Xiang et al., 2001). Co-infection HCV was determinant of HIV 
progression to AIDS or death who started HAART (HR 2.4, 95% CI 1.65 to 3.49) (Jaén, 
et al., 2008)  
 
Approximately 10 per cent of HIV infected individuals live longer and did not show 
significant decrease in immune system in the past ten years (Pantaleo et al., 1995). This 
is opposite to the majority of HIV infected individuals that progressed to AIDS. The 
group displays stable CD4 cells count, negative plasma cultures for HIV viral load, a 
strong virus inhibitory CD8 cells count response and fewer HIV infected cells. The viral 
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subtype is not associated with the increasing number of viral load, presence of 
neutralizing antibodies or viral growth kinetics (Pantaleo, et al., 1995). Although 
peripheral mononuclear blood cells containing HIV-1 replicates were detected and virus 
continued to live longer, the viral load remained low (Rosenberg et al., 1997). Some 
specific responses of CD4 cells count in HIV patients can  help in controlling viral load 
(Rosenberg, et al., 1997) 
 
There was evidence that there were sexual differences in survival and HIV progression 
and it depends on time calendar (Jarrin et al., 2008). Before 1997, there were no 
significant differences between men and women towards its progression to AIDS and 
death. But since 1997 onwards, women has lower risk of AIDS as compared to men 
with adjusted cumulative relative risk (aCRR) which is 0.76 (95% CI 0.63, 0.90) and 
death with adjusted hazard ratio (aHR) was 0.68 (95% CI 0.56, 0.82) (Jarrin, et al., 
2008). Progression to death in pre-1997, woman as compared to men aHR, was 0.89 
(95% CI 0.76, 1.05), in the 1997 onwards aHR was 0.68 (95% CI 0.56, 0.82) (Jarrin, et 
al., 2008). After 1997, women also experience low risks of AIDS mortality and non 
AIDS mortality. This is of benefits even though women have a smaller proportion in the 
use of HAART in every kind of HIV exposure risk compared with men (Jarrin, et al., 
2008). One study showed that women have a tendency of lower risk of mortality than 
men with a HR of 0.55 (95 % CI 0.28-1.07) (Alibhai et al., 2010). 
 
Gender differences play a role in HIV progression. Three years after HIV diagnosis 
showed that 45.9 per cent of IDU men did not progress to AIDS as compared with 54.9 
per cent of IDU women. Progression to death between IDU men and IDU women  when 
compared to MSM, had RR 1.16 and RR 1.57 respectively (Hall, McDavid, Ling, & 
Sloggett, 2006). Survival rate among IDU is worse as compared with MSM.  It may be 
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related to their high-risk lifestyle or co-morbidity, such as hepatitis C virus infection 
(Hall, et al., 2006; Porter, et al., 2003). After adjustment to anti-retroviral therapy, 
predictor of death included women (p- value = 0.02), age at HIV diagnosis (p- value = 
0.005), CD4 less than 200 cell/µL (p- value < 0.001), viral load more than 100,000 
copies/ml (p- value = 0.007) and opportunistic infections before admission or during 
follow up (p- value < 0.001) (Braga, Cardoso, & Segurado, 2007). The study done from 
1996–2004 in 33 US states which compared the  survival of IDU to other transmission 
categories showed 42.2 per cent (11,635) of 27,572 IDU were diagnosed late.  For IDU, 
after three years HIV diagnosis, the risk of progression to AIDS was higher for non-
whites, males and older individuals. Three-year survival after HIV diagnosis was lower 
for IDU men (87.3%, 95% CI 87.1–87.4) as compared with MSM (91.6%, 95% CI, 91.6 
- 91.7) and men exposed to heterosexual contact (91.9%, 95% CI, 91.8 - 91.9).  Survival 
was also lower for IDU women (89.5%, 95% CI, 89.4 - 89.6) as compared to women 
expose to heterosexual contact (93.3%, 95% CI, 93.3 - 93.4) (Grigoryan, Hall, Durant, 
& Wei, 2009).  The exposure risk as predictors of disease progression from several 
previous findings, IDU has faster progression to death with HR of 2.17 (95% CI 1.22, 3.87) 
(Pérez-Hoyos, et al., 2006), homosexual after CD4 less than 200 cells/µL with HR 2.12 
(95% CI 1.44, 3.11) (Wong, et al., 2004) and homosexual IDU with HR 1.33 (95% CI 
1.2, 1.5) (Schwarcz, et al., 2000)   
 
The incidence of opportunistic infection (OI) is significantly associated with morbidity 
and mortality of HIV-infected patients (Ghate, et al., 2011).  Previous studies showed 
that progression to death with a history of OI had HR of 1.97 (95% CI 1.8, 2.2) 
(Schwarcz, et al., 2000). The risk ratio for mortality in patients receiving HAART as 
compared with those who did not, RR 0.41 (95% CI 0.25, 0.67) and five leading OI are 
Oesophageal Candidiasis, PCP, TB, Herpes simplex and Cytomegalovirus (Hung, Chen, 
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Hsieh, Sheng, & Chang, 2000). Tuberculosis was the most common OI with an 
incidence of 15.4 (95% CI 12.2-19.2) per 100 person-years in India (Ghate, et al., 
2011). Tuberculosis is also the most common diagnosis of hospital admission as well as 
the leading cause of death in Nigeria HIV-infected patients (Agaba et al., 2011). The 
factor worsening the prognosis of HIV-infected patients in Spain is presented with 
opportunistic infection (tuberculosis or malignancy) (Batalla et al., 1989). Pneumocystis 
carinii pneumonia as a leading cause of death in HIV-infected patients in San Francisco, 
USA (Fei et al., 2009). Around 66 per cent of AIDS patients attending a large Indian 
health centre had more than one opportunistic infections (Kumarasamy, Solomon, 
Jayaker Paul, Venilla, & Amalraj, 1995) 
 
Another factor associated with increased risk of disease progression is advanced age. 
The findings of study done in developed countries showed that progression to death 
related to increase of age with,  HR of 1.21 by 10 years (95% CI 1.01, 1.51)  (Bonnet, et 
al., 2005). Progression to death of HIV-infected patients aged more than 40 years had 
HR of 1.43 (95% CI 1.31, 1.61) (Schwarcz, et al., 2000) and age more than 45 years 
with HR of 1.54 (95% CI 1.29, 1.85) (Li, et al., 2000), age 50-59 years had HR 3.66 
(95% CI 3.13, 4.27) compared to age under 20 years old (Hall, et al., 2006). In HIV-
infected patients who started anti-retroviral therapy in the Asia Pacific region, older age 
more than 50 years associated with an increased risk of non AIDS mortality (HR 4.29; 
95% CI 2.10, 8.79) (Falster, et al., 2009) 
 
Social economic status (SES) also has influence on disease progression. The risk of 
death greater for persons with lower SES with HR of 2.81 (95% CI 1.38, 5.76) in SES 
level III and HR of 2.55 (95% CI 1.27, 5.14) in SES level IV (lowest SES) as compared 
to the level I (highest SES), Females: in the level IV SES had a high risk of dying HR 
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4.85 (95% CI 1.05, 22.3), IDU: had a higher risk of dying in level III with HR 4.54 
(95% CI 1.08, 19.1) and in level IV with HR of 4.68 (95% CI 1.14, 19.2) (Rapiti, et al., 
2000). Prior study in San Francisco wants to examine the association AIDS patients 
between survival and neighbourhood socioeconomic such as income, housing, 
demographics, employment and education using census data. HIV-infected patients in 
the lowest socioeconomic neighbourhoods had a significant HR 1.4 greater mortality 
compared to higher socioeconomic neighbourhoods (Arnold, Hsu, Pipkin, McFarland, 
& Rutherford, 2009). In Spain, AIDS patients who are infected by IDU with university 
education level had a lower risk of death (RR 0.52; 95% CI 0.36, 0.77) as compared to 
those without education. Independent of HIV status, lower education predicts a higher 
risk of death in IDU and its impact is stronger after 1997 (HAART era). Education has a 
protective effect on most causes of death and it cannot be entirely attributable to the 
access or use of HAART (Jarrin et al., 2007). Prior study in Nigeria showed that AIDS 
patients with primary education (HR 2.064; 95% CI 1.043, 4.085) and unemployment 
(HR 1.79; 95% CI 1.21, 2.66) were significantly associated with increased risk of death 
(DeSilva et al., 2009) 
 
2.7  Survival time of HIV-infected patients 
 
Time taken for progression of HIV to AIDS or death may vary in each patient. 
Scientists have estimated that 50 per cent of HIV-infected patients would develop AIDS 
within the average of 8 to 10 years without any anti-retroviral therapy. About 10 per 
cent of HIV-infected patients would experience rapid progression to AIDS in less than 2 
to 3 years and 10 per cent do no progress to AIDS (CDC, 1997; Haynes, et al., 1996). 
From 1996 onwards, many new drugs have been developed to prevent or cure some of 
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the illnesses related to AIDS and HIV-infected patients are likely to develop illness and 
end with death (Li, et al., 2000) 
 
A study in Australia used the national surveillance to describe the survival of HIV 
progression to AIDS from 1991 to 1996. The median survival of AIDS progression to 
death was 17.7 months (Li, et al., 2000). The survival time achieved 16.0 months in 
1991 and increased to 27.7 months in 1996 (Li, et al., 2000) and other study in 
Amsterdam had 12.1 years. A 5-year prospective study was done in Taiwan and an 
estimation of survival after the introduction of Highly Active Antiretroviral Therapy 
(HAART) in the Asia Pacific region gave median duration of 497 days (mean 609 days 
range: 1-1825 days) (Hung, et al., 2000) and person had died after a median observation 
duration of 985 days (range 2-4.025 days) (Hung et al., 2006). Patients with HAART 
have a median survival duration of 720 days and patients without HAART achieved 205 
days (Hung, et al., 2000; Hung, et al., 2006). In a study done in Hong Kong showed in 
the pre-HAART era (1984-1996), median survival after AIDS was 29.8 months  and in 
the HAART era (1997- 2003) was more than 70 months (Pezzotti et al., 1999). A cohort 
study in China showed median survival time from HIV to AIDS was 9.2 years (Zhang, 
Shang, Wang, Cui, & Hu, 2010) and between 8.5 to 8.9 years (Li et al., 2010). Median 
survival time of HIV progression to death was from 8.8 to 10.7 years (Li, et al., 2010). 
Studies in Africa and China showed the median survival from developing AIDS to 
death was 9.2 months (Morgan, et al., 2002), 9.9 months (Zhang, et al., 2010), 1.2-2.0 
years (Li, et al., 2010) and 104.4 weeks (Alemu & Sebastian, 2010). Many factors may 
potentially result in shorter survival of HIV-infected patients in resource poor setting, 
including more frequent exposure to primary pathogens such as Mycobacterium 
tuberculosis, salmonella, and others, limited access to health care service, under 
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resourced medical services, poor nutritional status and others (Holmes, et al., 2008).  
Summarised median survival time is shown in Table 2.2 
 
Table 2.2 Median time to AIDS and death 2 
Authors Place Years Time to AIDS 
(months) 
Time to death  
(months) 
Mary Ireland 1997  19.2 
     
Maria Europe 1999 124.8   
     
Pezzotti Italy 1999  2.9 (before 1987) 
12.3(1987 - 1990) 
13.4 (1991 - 1993) 
11.4 (1994) 
17.6 (1995) 
     
Schwarcz San 
Fransisco 
2000  19.0 (monotherapy) 
17.0 (dual therapy) 
15.0 (ART without PI) 
31.0 (ART with PI) 
     
Li Y Australia 2000  27.7  
     
Morgan Uganda 2000 9.4  9.2  
     
Cautinho Amsterdam 2000 145.2   
     
Wong Hongkong 2004  29.8 (pre-HAART) 
> 70 (HAART) 
     
Hung Taiwan 2006  6.8 (non HAART) 
24.0 (HAART) 
     
Isidore Cameroon 2009  58.0  
     
Alemu Ethiopia 2010  26.1 
     
Zhang China 2010 110.5 9.91  
     
Li DM China 2010 102.0 - 106.8 14.4 - 24.0 
     
Dou China 2010 141.6 19.2 (non-ART) 
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2.8  Anti-retroviral treatment of HIV/AIDS  
 
All AIDS patients were recommended anti-retroviral treatment by The American 
National Institutes of Health and other organizations. The HAART is a therapy that 
consists of three or four drugs (WHO, 2006a). Patients receiving this treatment have to 
consume several medications for the rest of his life. The anti-retroviral treatment is 
given to decrease the viral load in the blood. This helps to repair the damage caused by 
HIV. It is recommended to carry out a basic clinical assessment before starting the anti-
retroviral treatment. Existing medical conditions such as tuberculosis, hepatitis, IDU, 
major psychiatric illness, pregnancy and body weight are identified to determine 
patient’s readiness for treatment. A person’s CD4 cells count too is used to determine 
when to start the treatment. Presence of opportunistic infections also had to be 
considered prior to starting treatment.  CD4 cell count is also a major clue in 
asymptomatic patients. Treatment should be started when the CD4 cell count is 200 to 
350 cells/µL (OARAC, 2011).  Several other factors such as symptoms, possible 
adherence, potential toxicity and patient’s concern should be considered in this matter 
(MOH, 2001b). Now generally CD4 less than 350 cells/µL should be offered therapy to 
HIV-infected patients. All patients with CD4 cell count less than 200 cells/µL and 
symptomatic HIV or late disease or severe recurrent HIV illnesses or patients with 
AIDS or tumor at any CD4 count, should start therapy (OARAC, 2011). The 
recommendation to start anti-retroviral therapy based on WHO guidelines 2006 is 
summarized in Table 2.3 
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Table 2.3 Recommendation an anti-retroviral therapy initiation 3 
Clinical Category CD4 count Recommendation 
Symptomatic 
AIDS defining illness 
Severe symptoms* 
Any value Treat 
   
Asymptomatic < 200 cells/mm
3 
Treat 
   
Asymptomatic > 200 but < 350 cells/mm
3
  Treat Recommended 
 
Source: (WHO, 2006a) 
 
Severe symptom* such as: Candidiasis oropharyngeal or Candidiasis vulvovaginal 
persistent more than 1 month, poorly responsive of treatment, more than 1 episode or 
involving more than 1 dermatome of Herpes Zoster: Cervical dysplasia, severe or 
Carcinoma in situ, Constitutional symptoms, example fever (> 38.5˚C) or diarrhea more 
than one month.  
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Table 2.4 Anti-retroviral therapy initiation between WHO guidelines in 2006 and 2010 40 
Target population 2010 ART guidelines 2006 ART guidelines 
HIV + asymptomatic < 350 cell/mm
3
 < 200 cells/mm
3
 
   
HIV + symptomatic WHO clinical stage 2 if  CD4 < 350 cells/µL 
WHO clinical stage 3 or 4 irrespective of CD4 cell  
WHO clinical stage 2 if  CD4 < 200 cells/µL 
WHO clinical stage 3 if  CD4 not available 
WHO clinical stage 4 if  CD4 irrespective of CD4 cell  
Consider treatment for WHO clinical stage 3 and CD4 
cell between 200 and 350 cells/µL 
   
HIV +  pregnant  CD4 < 350 cell/µL irrespective of CD4 cell or 
WHO clinical stage 3 or 4 irrespective of CD4 cell 
WHO clinical stage 1 or 2 if  CD4 < 200 cells/µL 
WHO clinical stage 3 or 4 if  CD4 < 350 cells/µL 
WHO clinical stage  4 irrespective of CD4 cell 
 
   
HIV/TB co-infection Presence of active TB disease, irrespective of CD4 
cell  
Presence of active TB disease and CD4 ≤ 350 cells/µL 
ART Initiation can be delayed if CD4 ≥ 200 cells/µL 
   
HIV/HBV co-infection Individuals who require treatment for their HBV 
infection*, irrespective of CD4 cell count 
No specific recommendation 
 
* The current diagnosis of chronic active hepatitis in well-resourced settings is based on histological parameters obtained by liver biopsy 
and/or the availability of HBV DNA testing, neither of which is usually available in resource-limited settings. A global definition of 
chronic active hepatitis in the context of resource-limited settings based on clinical signs and simpler laboratory parameters is under 
discussion.   
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2.8.1  Classes of drugs 
 
 
There are different classes of antiretroviral drugs classified based on different phases of 
the retroviral life cycle and inhibitors. Anti HIV medications are grouped into six 
classes and each class of medication blocks the virus in a different way (WHO, 2006a). 
1. NRTI (Nucleoside and nucleotide reverse transcriptase inhibitors) inhibit the 
transcription back in a way incorporated into newly synthesized viral DNA and 
prevent further elongation 
2. NNRTI (Non nucleoside reverse transcriptase inhibitors) inhibit the reverse 
transcriptase directly by binding to the enzyme and disrupting its function. 
3. PI (Protease inhibitors) targets viral assembly by inhibiting the activity of 
protease, an enzyme used by HIV to bypass nascent proteins for final assembly of 
new virions. 
4. Integrase inhibitors: inhibit the integration of the enzyme, it is responsible for 
integration of viral DNA into the DNA of infected cells.  
5. Entry inhibitors (or fusion inhibitors): disrupt binding, fusion and entry of HIV-1 
into host cells by blocking one of several targets. 
6. Maturation inhibitors: inhibit the final step in the processing of gag in which the 
virus capsid poly-protein cleaved, thereby blocking the conversion of the poly-
protein to the mature capsid protein (p24), because the virus particle has a core 
defect, which virions released consist mainly of non-infectious particles (WHO, 
2006a) 
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Using a combination of medications from different classes may increase the treatment’s 
effectiveness while decreasing the risk of drug resistance. The approved medication to 
treat HIV infection fact sheet, lists the food and drug administration (FDA) approved 
anti HIV medication by class, brand names, generic and date. Some are available as a 
combination pill of two or more different anti HIV medications from one or more 
classes (WHO, 2006a) 
 
Guidelines on anti-retroviral treatment have changed from time to time. Anti-retroviral 
drug were not available before 1987 and only HIV complications were treated then. 
After the introduction of anti-retroviral drugs, many clinicians agreed that HIV patients 
with lower CD4 cell counts should be treated (Levine, Dubler, & Levine, 1991). There 
were a lot of demand for new antiretroviral drugs and the process of drugs transfer from 
the laboratory to the pharmacy was conducted with strict supervision. Patients 
demanding anti-retroviral treatment aimed at labeled experiments and in some trials, 
subjects analyzed their treatment to know whether the drugs given to them were 
placebos or active ones. Later patients from the study shared active drugs with other 
patients causing consumption of additional or unapproved drugs. This violates the 
provisions of the protocol and compromised data validity. Furthermore, some HIV 
affected groups view the representation in the trials as discrimination rather than 
protection from risk or exploitation (Ho, 1995).  In 1995, several studies added his voice 
to those who have been demanding “hit hard, hit early” approach with aggressive 
treatment with multiple drugs early in the course of infection (Harrington & Carpenter, 
2000). A small group of vocal doctors (none who virologists) claimed the Concord 
study provides evidence that early intervention does not improve survival (Kitahata et 
al., 2009). Contrary to that, current studies have confirmed that mortality rates are 
almost two times higher when treatment is started until the CD4 count less than 500 
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compared to more than 500 (Rachlis & Zarowny, 1998). Experts have a consensus that 
once an antiretroviral therapy is started then it should not be discontinued (OARAC, 
2011). This is because incomplete suppression of viral replication in the presence of 
drug therapy may lead to selective inhibition of more sensitive drugs. This allows the 
drug resistant strains to become dominant.  Consequently, makes it more difficult to 
treat the infected patients. Finally, now anti-retroviral therapy is offered to all HIV-
infected patients who are ready to commit to take medication for the rest of his life 
(OARAC, 2011) 
 
2.8.2  Initiation of anti-retroviral therapy 
 
 
The most important issue in HIV treatment is the determination of the optimal time to 
initiate anti-retroviral.  Anti-retroviral treatment can be initiated after an appropriate 
time of commencement and combination of drugs to be used are decided. It will be 
influenced by many factors such as prior anti-retroviral history, stage of disease, 
concomitant therapies and illnesses, ability to tolerate and comply/adhere to certain 
combinations of drugs, adverse effects of the anti-retroviral agents, affordability and the 
cost of the regimen. It is very important that we ensure the patient is able to adhere to 
the anti-retroviral regimen that he is started on. The importance of reducing the 
development of resistant viral strains and good drug adherence in maintaining viral 
suppression was highlighted in current studies. Thus antiretroviral therapy should only 
begin when the patient is committed to long term treatment (WHO, 2006a). The 
guideline recommends that in developing countries, HIV infected adults and adolescents 
should start anti-retroviral therapy when one of the following conditions is present and 
HIV infection has been confirmed.  
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The WHO guidelines use new criteria to start HAART as below are (Hammer et al., 
2008): 
- Clinically advanced HIV disease 
- Irrespective of the CD4 cell count and WHO stage IV HIV disease 
- Consideration of using CD4 cell counts less than 350 cells/µl to assist decision 
making and WHO stage III disease  
- CD4 cell counts less than 200 cells/µl and WHO stage I or II HIV disease  
 
The majority of the current HAART regimens consisting of 3 drugs (2 NRTI + a 
NNRTI/PI). The first line drug which is used in initial regimens must have low side 
effects and high efficacy. Treatment guidelines for adult HIV-1 infected patients in the 
developed countries have been provided by the International AIDS Society (IAS) USA 
since 1996. The IAS-USA anti-retroviral guidelines therapy was developed by a panel 
of volunteer experts. The update was published in the Journal of American Medical 
Association in August 2008 (Hirsch et al., 2008).  
 
The panel recommended initiating treatment before CD4 cell count drop below 350 
cells/µl and treatments to be individualized according to the patient’s particular 
situation. It recommends 2 NRTI with an NRTI for initial therapy and a boosted PI or 
an integration inhibitor. For further treatment, suppression of HIV-1 RNA to below 
detection level was targeted (Cane et al., 2005). Resistance tests are recommended prior 
to initiation of treatment. This is important for urgent treatment needs and to handle 
high rates of baseline resistance in certain countries. Later the chosen treatment regimen 
can be started and adjusted further based on resistance test. In Britain, there are 11.8 per 
cent of moderate to high level of resistance at baseline to a combination of Efavirenz + 
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Zidovudine + Lamivudine and 6.4 per cent for medium to high level resistance to 
Stavudine + Lamivudine + Nevirapine (Althoff et al., 2010) 
 
The major guideline panels have raised the CD4 count threshold for recommended 
initiation of anti-retroviral therapy. In December 2009, the panel of the Department of 
Health and Human Services (DHHS) gave the strongest recommendation possible for 
initiation anti-retroviral therapy at less than 350 cells/µL. It is recommended for persons 
with CD4 level between 350 and 500 cells/µL. Opinion was divided on the strength of 
the recommendation, where 55 percent of the members gave strong recommendation 
and 45 percent gave a moderate one. For patients with CD4 more than 500 cells/µL, half 
of the panel gave a moderate recommendation and half thought it was optional (DHHS, 
2009). 
 
In early 2010, the European AIDS Clinical Society (EACS) guidelines issued HIV-
infected patients with CD4 count 350 to 500 cells/µL concluded treatment should be 
considered if there is a viral load of more than 100,000 copies/ml, if CD4 declines to 
more than 50-100 cells/µL per year, age more than 50 years, high cardiovascular risk 
and malignancy. For patients with CD4 having more than 500 cells/µL, deferred anti-
retroviral therapy. Treatment  can be offered if presence of co-morbid condition or 
patients seeking and ready for anti-retroviral therapy (European AIDS Clinical Society, 
2010) 
 
In July 2010, the panel of the International AIDS Society (IAS) in USA, issued a DHHS 
recommended anti-retroviral for all HIV-infected patients with CD4 count up to 500 
cells/µL.  For those above 500 cells/µL recommended for those losing CD4 more than 
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100 cells/µL per year, viral load more than 100,000 and age more than 60 years 
(Thompson et al., 2010) 
 
WHO in July 2010, updated the WHO 2006 guidelines and used new Grading of 
Recommendation Assessment Development and Evaluation (GRADE) to classify the 
quality of evidence for the recommendation. WHO gave a strong recommendation 
based on moderate evidence to treat all HIV-infected patients with CD4 less than 350 
cells/µL. This implication is difficult in poor countries for those previously anti-
retroviral therapy initiation with CD4 less than 200 cells/µL. For those with CD4 more 
than 350 cells/µL, WHO guidelines no have recommendations (WHO, 2010a) 
 
2.8.3  Switch second line anti-retroviral therapy 
 
 
Second line HAART regimes are indicated for patients who are forced to discontinue 
their initial treatment regime as consequence of treatment failure or severe toxicity. 
 
The recommendation of WHO (2010) when to switch ART is based on: 
1. Where available, use viral load to confirm treatment failure; 
2. Where routinely available, use viral load every 6 months to detect viral 
replication; 
3. A persistent viral load more than 5000 copies/ml confirms treatment failure; 
4. When VL is not available, use immunological criteria to confirm clinical failure; 
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Anti-retroviral therapy switching criteria (WHO, 2010a): 
1. Clinical failure : new or recurrent stage 4 condition (condition must be 
differentiated from an immune reconstitution inflammatory syndrome/IRIS; 
certain WHO clinical stage 3 conditions (PTB, severe bacterial infection) may be 
an indication of treatment failure; 
2. Immunological failure: - Fall or immunological to baseline or below; 
                                               - 50 per cent fall from on treatment peak value; 
                                               -  Persistent CD4 level below 100 cells/µL; 
3. Virological failure: viral load of more than 5000 copies/ml, the optimal viral load 
threshold for defining viral load failure has not been determined. Values of viral 
load which are more than 5000 copies/ml are associated with clinical progression 
and a decline in the CD4 cell count. 
 
 The targeted viral load strategy for failure and switching anti-retroviral therapy is 
displayed in Figure 2.13 
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Figure 2.13 Targeted viral load strategy for failure switching 15 
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2.8.4   Pre HAART and HAART era 
 
 
Pre HAART era started in early 1997 where there was limited usage of anti-retroviral 
drug on HIV-infected patients. Consequently, during the HAART era (1997 onwards), a 
combination of anti-retroviral drugs (triple therapy) have been introduced (Egger et al., 
1997). Anti-retroviral therapy has reduced morbidity and mortality rate of patients with 
HIV infection (Palella et al., 1998). HIV-infected patients who received the combination 
therapy for 1 year in short-term randomized controlled trials showed that  the rate of 
AIDS or death were halved as compared to patients who used only one class of 
antiretroviral drugs (Egger, et al., 1997). In the long term trial the clinical effect of 
combination therapy has not been studied but observational data showed that this 
treatment reduces the AIDS or death rate for many years. This applies to patient both 
with low or high CD4 cell count (Egger, et al., 1997; Palella, et al., 1998). The risk of 
death after AIDS HR of 1.54 (95% CI 1.17, 2.04) for mono therapy, HR of 0.61 (95% 
CI 0.46, 0.80) for double therapy and HR of 0.36 (95% CI 0.21, 0.62) for triple therapy 
as compared with no therapy (Pezzotti, et al., 1999).  Injecting drug user had a lower risk 
of progression to AIDS than MSM with HR of 0.74 (95% CI 0.64, 0.86) in the pre HAART 
(1997-1998) as compared to HR of 4.28 (95% CI 2.86, 6.41) in the HAART era (1999-
2001) (Porter, et al., 2003).  
 
The crude mortality rate declined from 117 deaths in 1,000 people in pre HAART 
(1984-1996) to 24 deaths of 1,000 people in HAART period (1997- 2003).  AIDS 
related death reduced from 90 per cent in a pre HAART era to 67 per cent in the 
HAART era. Cause of death related AIDS, such as PCP, Non Hodgkin Lymphoma 
(NHL) and MAC.  Cause of death in non-related AIDS increased from 10 per cent in a 
pre HAART era to 33 per cent in HAART era such cardiovascular disease, hepatic 
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disease and drug overdose (Krentz, Kliewer, & Gill, 2005).  The crude mortality rate 
also dropped from level of 10.8-30.4 per 100 midyear patient population in pre HAART 
to level of 0.8-6.9 per 100 midyear population in the HAART era and death rate in pre 
HAART 9.2 events/ 1000 person-months compare in HAART era 2.4 events/ 1000 
person-months (Chan, Wong, & Lee, 2006). Incidence of AIDS defining event (ADE) 
in period pre HAART era (1990-1995) compared to period HAART era (1996-2004) 
with CD4 level less than 50 cells/µL 39.3 events/ 100 person years in period HAART 
era and 76.4 events/ 100 person years in period pre HAART era, CD4 level less than100 
cells/µL 18 events/ 100 person years in period HAART and 65.2 events/ 100 person 
years in period pre HAART era, CD4 of 100- 200 cells/µL 7.8 events/ 100 person years 
in period HAART era and 34.5 events/ 100 person years in period pre HAART era 
(Gandhi, Wei, Amin, & Kazanjian, 2006). The incidence of opportunistic infections in 
pre HAART era period higher than the HAART era period in all levels of CD4 count, it 
is summarized in Table 2.5. Risk opportunistic infection with CD4 less than 200 
cells/µL prior to HAART initiation HR of 4.45 (95% CI 1.80, 10.90) for 1-12 month, 
HR of 3.95 (95%t CI 1.62, 9.63) for 13-24 month, HR 5.19 (95% CI 1.99, 13.5) for  25-
36 month,  HR 3.21 (95% CI 1.61, 10.8) for 37-48 month HAART.  Viral load more 
than 50000 copies/ml prior to HAART initiation HR of 3.77 (95% CI 1.68, 8.43) for 1-
12 month, HR of 2.78 (95% CI 1.04, 7.39) for 13-24 month, HR of 2.89 (95% CI 1.80, 
5.51) for  25-36 month HAART (Kazanjian, Wei, Brown, Gandhi, & Amin, 2005) 
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Table 2.5 The incidence of AIDS defining events in the pre HAART era and 
HAART era 5 
CD4 count (cells/µL) Pre HAART era  
(1990-1995) 
HAART era 
(1996-2004) 
<   50   74.4/100 person years 39.3/100 person years 
   
< 100  65.2/100 person years 18/100 person years 
   
100 – 200  34.5/100 person years  7.8/100 person years 
 
Source : (Gandhi, et al., 2006) 
 
Proportion of patients receiving combination antiretroviral with Protease Inhibitor (PI) 
to progressed AIDS or death was 6 per cent in PI contained regimen. In the regimen 
without PI progression was 11 per cent with HR of 0.50 (95% CI 0.33, 0.76). The 
mortality in the two groups was 1.4 per cent and 3.1 per cent respectively, with HR of 
0.43 (95% CI 0.19, 0.99). Thirty one AIDS defining event occurred among patients with 
Indinavir and 60 events among those without Indinavir (Hammer et al., 1997). Initiation 
of boosted PI had 21 per cent of decrease in the likelihood of viral suppression compared to 
initiation of NNRTI with HR of 0.79 (95% CI 0.75, 0.83) (Althoff, et al., 2010) 
 
Increased risk of disease progression associated with gender factor showed lower 
survival among women as compared to men.  Hazard Ratio of males in early 1997 was 
0.51 (95% CI 0.39, 0.66) and females HR of 0.80 (95% CI 0.51, 1.27) (Porta, et al., 
1999). Women with CD4 less than 200 cells/µL as compared to women with CD4 more 
than 350 cells/µL, risk of all causes of death was HR of 2.66 (95% CI 1.42, 4.99) and 
risk of AIDS death was HR of 47.61 (95% CI 5.69, 398.40) (Anastos, et al., 2004).  
Prior to HAART initiation, HIV-infected patients with CD4 less than 200 cells/µL have 
AIDS progression with HR of 2.25 (95% CI 1.13, 4.49) and death with HR of 2.29 
(95% CI 0.83, 6.33) (Jacobson, et al., 2002).  
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2.9  Viral load less than 50 copies/ml 
 
The goal of anti-retroviral treatment in HIV patients is to limit viral replication, slow the 
progression of HIV disease and increase the level of CD4 cell count. Viral replication is 
measured by the level of HIV viral load and the effectiveness of ART in reducing HIV 
viral load. Quantification of viral load is a sensitive indicator of the effectiveness of 
HAART.  Successful HAART is generally defined as suppression of viral load to below 
50 copies/ml (Jevtović et al., 2010).  The median time taken from initiation of HAART to  
achieving viral load less than 50 copies/ml was 0.99 years (Taiwo et al., 2009a) and 6.4 
months (Resino et al., 2003). After the initiation of HAART, the decrease of viral load (less 
than 50 copies/ml) was observed in varying periods of time in all 118 subjects studied, time 
to reach it was between 2 to 24 weeks  (Rizzardi et al., 2000). In the UK study which 
reported the median time from start of HAART to first achieved viral load than 50 
copies/ml stratified by regimen of 2 NRTI + 1 NNRTI was 0.3 years (3.6 months) 
(Geretti et al., 2008). After the implementation of HAART the risk of AIDS and death in 
HIV-infected patients with low CD4 cells count showed that patients with CD4 count 
less than 200 cells/µL as compared to more than 350 cells/µL, have a higher risk of 
attaining AIDS with HR of 5.96 (95% CI 0.40, 87.8) and CD4 cells of 201-350 cells/µL 
with HR of 5.44 (95% CI 0.47, 63.4). The risk of death at CD4 cells count was less than 
200 cells/µL attained HR of 22.8 (95% CI 1.89, 275) and the range of CD4 cells 201-350 
cells/µL, HR of 10.8 (95% CI 0.92, 127) (Taiwo, et al., 2009a). The study showed that after 
24 weeks of HAART initiation, 482 (73 per cent) of HIV-infected patients achieved viral 
load less than 50 copies/ml.  Use of viral load measured after 4 Weeks of HAART to 
predict virology outcome at 24 weeks for HIV-infected patients in univariate analysis 
showed that baseline viral load with HR of 0.76 (95% CI 0.60, 0.96) and in multivariate 
analysis was viral load at 4 weeks with HR of 0.35 (95% CI 0.27, 0.45) (Smith, et al., 
2004). A cohort study on risk factors of poor virological conditions in a workplace was 
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conducted for 12 months in South Africa. An anti-retroviral therapy program showed 
that a viral load in a range of 10,000-100,000 copies/ml was attained with HR of 3.63 
(95% CI 1.88, 7.00), and when it exceeds 100,000 copies/ml the HR of 3.54 (95% CI 
1.79, 7.00) (Fielding et al., 2008). An observational cohort study showed that there is an 
extensive virological failure to three original antiretroviral drug classes over long term 
follow up from the initiation of HIV therapy. A result of cohort study, 167 of 27,441 
patients that follow up developed extensive triple class failure, 129 (77 per cent) of 
those who developed extensive triple class failure had a viral load of less than 50 
copies/ml, previously (Phillips et al., 2007).   
 
2.10  Summary 
  
In this chapter, it is all about HIV infection such as its natural history, epidemiology, 
transmission, progression, survival and anti-retroviral therapy were reviewed and many 
evidences of research that have been done in various places in both developed countries 
and developing countries. The evidence from literature review showed that varies 
median survival time of HIV-infected patients and there are many predictors influenced 
the progression of HIV infected to AIDS and death, for example CD4 level, viral load, 
hemoglobin, total lymphocyte count, opportunistic infection, transmission route, gender 
differences, advanced age and socioeconomic status. HIV infected individual receiving 
anti-retroviral therapy based on WHO guidelines with recommendations for initiation of 
HAART and switch to second line criteria. Many evidences of antiretroviral therapy in 
HIV-infected patients can decrease morbidity, mortality, prolong survival in both 
developed and developing countries. 
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CHAPTER 3 
 
MATERIALS AND METHODS 
  
3.1  Introduction 
 
The materials and methods used in this study are described in this chapter. Section 3.1 is 
the introduction. Section 3.2 describes the design utilized in this study. The descriptions 
are continued in Section 3.3 the study area/site and the duration of this study are 
described in Section 3.4.  The study population is stated in Section 3.5 and the following 
Section 3.6 describes the setting of this study, while Section 3.7 is on the ethical 
approval was from the Medical Ethics Committee University of Malaya Medical Centre. 
The calculation of sample size is explained in Section 3.8. In Section 3.9 the sampling 
procedures are discussed. Section 3.10 describes the study variables, namely the 
independent and dependent variables. Section 3.11 explains the operational definition of 
variables. Section 3.12 and 3.13 presents the data collection method and data 
management, followed by Section 3.14 which is the summary of this chapter. 
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3.2  Study Design  
 
 
This is a cohort study (retrospective and prospective). The study commenced in 2007, 
with records of patients being investigated retrospectively in 1986 and followed 
prospectively until 2009. Data from medical records of HIV patients (alive and 
deceased) was seen at the Infectious Disease (ID) Clinic, University of Malaya Medical 
Centre (UMMC) starting from January 1986 to December 2006 and were recorded. 
New HIV/AIDS cases from January 2007 to December 2009 were also included in this 
study and followed up to December 2009 (see Figure 3.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Study design cohort retrospective and prospective 16 
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The cohort study design is the second best method of measuring the anti-retroviral 
treatment effectiveness on disease progression (Evans, 2003). The cohort study assesses 
associations between multiple exposures and outcomes over time while the randomized 
controlled trial demonstrates efficacy of an intervention (Carlson & Morrison, 2009). 
The hierarchy of study design in clinical research is summarized in Figure 3.2 
 
 
Figure 3.2 Hierarchy of study design in clinical research 17 
Source: (Evans, 2003) 
 
3.3 Study Area/Site 
 
This research was conducted at the Infectious Disease clinic (ID clinic), Department of 
Medicine in the University of Malaya Medical Centre in Petaling Jaya, which is an 
industrial area and a satellite township of Kuala Lumpur, located in the Petaling district 
of Selangor. It comprises mostly residential areas. It has an area of 97.2 km
2
 with a 
population of 480,000 in 2012 (MBPJ, 2012).  
 
University of Malaya Medical Centre is part of the University of Malaya and comprises 
two major components. One part is the medical centre, which comprises the main 
hospital building, the east wing and the trauma centre. The other part is the Faculty of 
Medicine, which is a building of its own in the south part of the medical centre. It is the 
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premier teaching hospital in Malaysia. It is the major training centre for various medical 
specialties and subspecialties. It is a modern medical facility with over 1,200 inpatient 
beds and function as a tertiary referral hospital in the Klang Valley and Malaysia. The 
Klang Valley stretches from Klang to Seremban. It is also the centre of industry and 
commerce in Malaysia and is also known as Greater Kuala Lumpur or Kuala Lumpur 
metropolitan area (MBPJ, 2012). It is geographically delineated on the north and east of 
the Titiwangsa Mountain Range and in the west by the Straits of Malacca. It covers an 
area of 2,793.27 km
2
. The conurbation has a total population of 6.8 million in 2012 
(MBPJ, 2012).  
 
The Infectious Disease Clinic at the University of Malaya Medical Centre provides 
treatment and follow-up for HIV/AIDS patients who are referred from all private 
clinics, government hospitals, infectious disease consultants, specialists and medical 
officers in the Klang Valley and other parts of Malaysia. The Clinic is open on Monday, 
Tuesday and Friday from 8.00 am to 12.00 pm. At the infectious disease clinic the 
patients are treated and consulted by four doctors who are Infectious Disease Specialists 
and Consultants. An average of 25-30 patients were attended in the clinic in a day. The 
clinic facilitated with more than 20 beds for admitting HIV/AIDS patients. These beds 
are located in the rooms of Wad Perubatan 1 (WP1) and Wad Perubatan 2 (WP2) at 
level 2 of the University of Malaya Medical Centre building. The location map of 
Petaling Jaya and the University of Malaya Medical Centre is shown in Figure 3.3 
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                                                                                                UMMC 
 
 
Figure 3.3. Map of Malaysia with location of Petaling Jaya and UMMC 18 
Source: www.dromoz.com (map of Malaysia) 
             www.tvsmith.com (map of Petaling Jaya)                                                                                  
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3.4 Study Duration 
 
The data collection began on January 2007 until December 2009 (3 years prospective). 
Records of patients treated or consulted from December 2006 until January 1986 (20 
year retrospective) were also extracted. 
3.5 Study Population    
 
The study population was HIV-infected patients who visited the infectious disease clinic 
at the University of Malaya Medical Centre from 1986 to 2009 for the first time, walk 
in, follow up cases or those HIV cases referred from other clinics 
Inclusion criteria 
i) Patients diagnosed as HIV positive using ELISA (enzyme-linked immunosorbent 
assay) methods and PA (particle agglutination) test,  
ii)  Adults aged twenty years old and above 
Exclusion criteria 
The exclusion criteria were HIV infected patients who had missing baseline CD4 count 
and viral load data  
 
3.6 Study Setting 
 
This cohort study focused on predictors of death and to achieve viral load less than 50 
copies/ml. Data of HIV-infected patients consisted of the socio-demographic 
characteristic at baseline and laboratory and clinical condition of patients at baseline and 
at start of anti-retroviral therapy. The anti-retroviral therapy efficacy was based on the 
ability to achieve viral load less than 50 copies/ml.  
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3.7 Ethical Approval 
 
Ethical approval was obtained from the hospital Medical Ethics Committee University 
of Malaya Medical Centre, which is an Independent Review Board (IRB), detail are 
found in Appendix B.  
  
3.8 Sample size 
 
The sample size was calculated by using the formula below (Rosner, 2000): 
 
 
 
 
 
 
 
 
n = required sample size 
 
zα = value of the standard normal distribution cutting off probability α in one tail for a 
one sided alternative or α/2 in each tail for a two sided alternative 
zβ = value of the standard normal distribution cutting of probability β 
P0 = estimated proportion of study outcome in the unexposed group 
P1 = estimated proportion of study outcome in the exposed group, based on literature 
review (Cole, 2003) risk of death after AIDS with HR 0.81 for HAART as compared 
with no HAART (Pezzotti, et al., 1999). In this study used values are:  
zα = 1.96 for α = 0.05;  zβ = 0.80 to 80% power; P0 = 0.19;  P1 = 0.81            
             
       P1 + P0          
P = --------- =  0.5      
            2                   
 
n1 = n2 = 438. Assuming 20 per cent missing data due to death or loss of follow-up 
with an alpha of 0.05 and power of 0.80, the minimum sample size = n1 + n2 + 20% = 
876 + 175 = 1050 
 
 
        [zα √ 2P(1-P1) + zβ √ P1 (1-P1) + P0 (1- P0)]
2 
n = ------------------------------------------------------  
       
                            
(P1 - P0)
2 
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Other approaches of calculating sample size based on survival time are (Rosner, 2000): 
1. Two median survival time option 
2. Median survival time on control patients and hazard ratio of the control group to 
experimental group option 
 
The sample size was calculated by the Power and Sample size calculations software 
(PS) version 3.0.43 (Dupont & Plummer, 2009). In this study approaches of calculating 
sample size based on median survival time on control patients and hazard ratio of the 
control group in the experimental group option was used  
n = sample size; Power (1- β) = 0.8; Significance level (α) = 0.05  
R = the hazard ratio of control relative to experimental treatment was determined by 
clinical expert opinion as obtained from the literature (Cole et al., 2003); R = 0.81  
m1 = median survival time of patients in control group relative to patients with HAART 
have median survival was 27.7 months (Li, et al., 2000); m1 = 27.7 months  
m = ratio of control to experimental patients (comparing one case and one control), m = 1:1.  
A = the accrual time during which patients were recruited, A = 36 months 
F= additional follow-up time after end of recruitment, F = 3 months  
Table 3.1 Sample size calculation 6 
                    Hazard ratio 
 
Median survival 
0.6  0.68  0.79  0.81  0.85  
24 months  121  219  610  769  1312  
26.1 months  128  231  645  814  1389  
27.7 months  133  240  672  848  1447  
31 months  143  260  728  918  1569  
70 months  270  495  1398  1767  3027  
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Figure 3.4 Sample size by software of Power and Sample size calculation 19 
 
Considering an estimated 20 per cent of missing data/loss to follow up an additional 20 per 
cent was added. The computed sample size was 848 (Figure 3.4), total sample size is n + 
20% n = 848 + 170 = 1018. The sample size for this study was 1314 patients, which is 
more than the minimum required sample size.  
 
3.9 Sampling procedure 
 
In this study, the study population is divided into three groups: 
- All AIDS patients  
- AIDS patients receiving HAART 
- AIDS patients not receiving anti-retroviral therapy 
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This information was obtained from the patient’s case notes available in the medical 
record folder. Follow up data of AIDS patients regarding the laboratory result such as 
CD4, viral load, hemoglobin, total lymphocyte count and liver function test, the 
incidence of opportunistic infection and a combination of anti-retroviral drugs were 
done every three months. Informed consent of participant was not required because this 
study used secondary data from University of Malaya Medical Centre and ethical 
approval also stated that the researcher would not be required to obtain the participant’s 
informed consent when secondary data is collected. This rule is similar to those used 
elsewhere developed country (University of South Florida, 2008). All data from this 
hospital is available for the research. The ethical approval included approval to check 
the mortality status of the patients using mortality data from the National Registration 
Department.  
3.10  Study Variables 
3.10.1  Independent Variables are  
 
 
A. Socio-demographic characteristics which include: 
 
- Age at first diagnosis of HIV: categorized into five age groups with 10 years interval: 
20-29, 30-39, 40-49, 50-59 and ≥  60 years  
- Gender : male or female 
- Ethnic group : Malay, Chinese, Indians, Others  
- Marital status : single, married, others  
- Educational level :  ≤ secondary, ≥  tertiary  
- Occupational type: unemployed, manual workers, professional and non manual 
workers 
- Monthly personal income : < RM 1000, RM 1000 – RM 3000,  > RM 3000 
 
3 Material and Methods 
 
90 
 
B.  Baseline laboratory which includes: 
 
- Baseline CD4 count (cells/µL): categorized into 2 groups: < 200 and  ≥  200 cell/µL  
- Baseline Viral load (copies/ml): categorized into 2 groups:  < 100000 and ≥  100000 
copies/ml 
- Baseline Hemoglobin (Hb g/dl): categorized into 2 groups: < 12 and ≥  12 g/dl  
- Baseline total lymphocyte count (TLC cells/µL): categorized into 2 groups: normal 
(≥  1200 cell/µL) and abnormal (< 1200 cells/µL)Baseline liver function test (LFT): 
categorized into 2 groups: normal  and abnormal; LFT based on 5 tests such as 
aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase 
(AP), transaminase bilirubin (Tbil) and gamma globulin 
    Liver function is considered normal if all the five liver enzymes examined falls 
within normal range. Liver function is said to be abnormal if at least two of the 
enzymes appears to have twice the normal value 
- CD4 at the start of HAART: categorized into 2 groups: < 200 and ≥ 200 cell/µL  
- Viral load at start of HAART: categorized into 2 groups: < 100,000 and ≥  100,000 
copies/ml 
- Hemoglobin at the start of HAART: categorized into 2 groups: < 12 and ≥  12 g/dl  
- Total lymphocyte count (TLC) at the start of HAART: categorized into 2 groups: 
normal (≥  1,200 cells/µL) and abnormal (< 1,200 cells/µL) 
- Liver function test (LFT) at the start of  HAART: categorized into 2 groups: normal  
and abnormal 
- CD4 recovers: CD4 recovers from less than 200 more than 200 cells/µL; categorized 
into 3 groups: yes, stable, no 
- Hemoglobin recovers: Hemoglobin recovers from less than 12 and more than 12 
g/dl; categorized into 3 groups: yes, stable, no  
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- Total lymphocyte count recovers: Total lymphocyte recovers from (less than 1,200 to 
more than 1,200 cells/µL;  categorized into 3 groups: yes, stable, no 
  
C. Clinical condition variables which include: 
- Exposure risk: heterosexual, homosexual, injection drug user (IDU) and others  
- WHO Clinical stage: stage 1, stage 2, stage 3 and stage 4 (WHO, 2007c) 
- Initial presentation: already diagnosed with HIV or AIDS on presentation to the 
clinic 
- Baseline Body Mass Index (BMI): categorized into 2 groups: < 18.5 and ≥ 18.5 
- Clinical presentation at the end of the study: categorized into 2 status: HIV or AIDS   
- Opportunistic infection (OI): negative or positive        
- Number of opportunistic infections: how many OI occurred in HIV-infected patients, 
categorized into 4 groups, 0, 1, 2 and ≥ 3 
- Living status: categorized into 2 groups: alive or died 
         
D.   Anti-retroviral treatment variables which include: 
- ART era: categorized into 2 groups: Pre HAART era and HAART era 
- Initial HAART: categorized into 3 groups: 2 NRTI + EFV, 2 NRTI +NPV and 2 
NRTI + PI 
- Need a second line of HAART: categorized into 2 groups: yes or no 
- Combination of HAART at the end of study: categorized into 2 groups: ART without 
PI and ART with PI 
- Achieved viral load less than 50 copies/ml: categorized into 2 groups: yes or no 
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3.10.2  The dependent variables  
 
The dependent variables are the outcomes that will be measured which included: 
- Survival time of HIV-infected patients 
- Time to death in all AIDS patients 
- Time to death in AIDS patients on HAART 
- Time to death in AIDS patients not on ART 
- Time to achieve viral load less than 50 copies/ml in AIDS patients on HAART 
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3.11  Operational definition of variables 
 
No Variable Definition Scale of Measurement 
1 Age at HIV 
diagnosis 
Patient’s  age (calculated from 
the date of HIV diagnosis 
minus the date of birth) in 
year  
Continuous: mean, median 
Categorical: 
1 =  20 - 29 years  
2 =  30 - 39 years  
3 =  40 - 49 years  
4 =  50 - 59 years  
5 =      ≥ 60 years 
    
2 Gender Sex as stated by patients Categorical: 
1 = Male 
2 = Female 
    
3 Ethnicity Ethnic group as stated by 
patients 
Categorical: 
1 = Malay 
2 = Chinese 
3 = Indian 
4 = Others 
    
4 Marital status Status of marital as stated by 
patients 
Categorical: 
1 = Single 
2 = Married 
3 = Others (Divorced, 
Separated, Widowed) 
    
5 Educational level The complete highest level of 
formal education of the 
respondent according to 
Malaysian education 
system(Mohe, 2010) 
Primary: Standard 1 to 
Standard 6 
Secondary: Awarded 
SRP/PMR/LCE and SPM/ 
MCE/O Level (Form 1 – 5). 
Tertiary: University, institute 
and college (Awarded, 
Diploma or Bachelor degree 
or Post Graduate Degree). 
Categorical: 
1 = ≤ Secondary 
2 = ≥ Tertiary 
 
    
6 Occupational 
type at the time 
of diagnosis 
As written in the record and it 
was created into 3 groups: 
Group 1: Housewife, student, 
retired and person not having 
an earning income job 
Categorical: 
1 = Unemployed 
2 = Manual workers 
3 = Professional and non- 
manual workers 
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Group 2: Manual skilled 
workers, intermediate and 
unskilled workers (Labour, 
maid, technician, etc) 
Group3: Upper and middle 
intermediate high, Doctor, 
accountant, supervisor, etc 
    
7 Monthly income Total income of patients per 
month 
Categorical: 
1 = < RM 1 000 
2 = RM 1 000 to 3 000 
3 = > RM 3000 
    
8 Baseline CD4 
count 
The first CD4 count of 
patients after HIV diagnosis 
Continuous: Mean, Median 
Categorical: 
0 = < 200 cells/µL 
1 = ≥ 200 cells/µL 
    
9 Baseline Viral 
Load (VL) 
The first plasma HIV viral 
load of patients after HIV 
diagnosis 
Continuous: Mean, Median 
Categorical: 
0 = < 100,000 copies/ml 
1 = ≥ 100,000 copies/ml 
    
10 Baseline 
Haemoglobin 
(Hb) 
The first Haemoglobin level 
of patients after HIV 
diagnosis 
Continuous: Mean, Median  
Categorical: 
0 = < 12 g/dl 
1 = ≥ 12 g/dl 
    
11 Baseline total 
lymphocyte 
count (TLC) 
The first total lymphocyte 
count of patients after HIV 
diagnosis 
Continuous: Mean, Median 
Categorical: 
0 = normal (≥ 1,200 cells/µL) 
1 = Abnormal (< 1,200 
cells/µL) 
    
12 Baseline liver 
function test 
(LFT) 
The first liver function test of 
patients after HIV diagnosis.  
LFT based on tests(Collier & 
Bassendine, 2002): Aspartate  
transaminase (AST), Alanine 
transaminase (ALT), Alkali 
phosphatase (AP), 
transaminase bilirubin (Tbil) 
and Gamma globulin. LFT 
normal if all tests in normal 
value range. LFT abnormal if 
at least 2 of the test have 
twice the normal value 
Categorical: 
0 = Normal 
1 = Abnormal 
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13 CD4 count at 
start HAART 
The CD4 count of patients 
when start HAART 
Continuous: Mean, Median 
Categorical: 
0 = <  200 cell/µL 
1 = ≥  200 cell/µL 
 
    
14 VL at start 
HAART 
The plasma HIV viral load  of 
patients when start HAART 
Continuous: Mean, Median 
Categorical: 
0 = < 100,000 copies/ml 
1 = ≥ 100,000 copies/ml 
    
15 Hb at start 
HAART 
The haemoglobin level of 
patients when start HAART 
Continuous: Mean, Median  
Categorical: 
0 = < 12 g/dl 
1 = ≥ 12 g/dl 
    
16 TLC at start 
HAART 
The total lymphocyte count of 
patients when start HAART 
Continuous: Mean, Median 
Categorical: 
0 = normal (≥ 1,200 cells/µL) 
1 = Abnormal (< 1,200 
cells/µL) 
    
17 LFT at start 
HAART 
The liver function test of 
patients when start HAART 
Categorical: 
0 = Normal 
1 = Abnormal 
    
18 CD4 recovers CD4 count recovers from < 
200  to ≥ 200 cell/µL 
Categorical: 
0 = No 
1 = Stable 
2 = Yes 
    
19 Hb recovers Hb level recovers from < 12 
to ≥ 12 g/dl  
Categorical: 
0 = No 
1 = Stable 
2 = Yes 
    
20 TLC recovers Total lymphocyte count 
recovers from  abnormal to 
normal (< 1,200 to ≥ 1200 
cells/µL) 
Categorical: 
0 = No 
1 = Stable 
2 = Yes 
    
11 Initial 
Presentation 
The status of patients when 
first coming to ID Clinic in 
UMMC 
Categorical : 
0 = HIV 
1 = AIDS 
    
22 Exposure risk The transmission route of 
HIV infection 
Categorical: 
1 = Heterosexual 
2 = Homosexual 
3 = IDU 
4 = Others 
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23 WHO Clinical 
Staging 
The WHO clinical staging and 
case definition of HIV for 
resourced constrained settings  
in 1990 and revised in 2006 
(WHO, 2007c) 
Categorical: 
1 = Stage 1 
2 = Stage 2 
3 = Stage 3 
4 = Stage 4 
    
24 Baseline Body 
Mass Index 
(BMI) 
The first measure of patient’s 
weight in relation to height 
after HIV diagnosis 
Continous: Mean, Median 
Categorical: 
0 = < 18.5 
1 = ≥ 18.5 
    
25 BMI at start 
HAART 
The Body Mass Index of 
patients when start HAART 
 
Continous: Mean, Median 
Categorical: 
0 = < 18.5 
1 = ≥ 18.5 
    
26 Opportunistic 
Infection (OI) 
Infections caused by a 
microorganism that does not 
normally in humans, such as 
TB, PCP, Candidiasis, and 
other infections, occurs in 
AIDS patients 
Categorical: 
0 = Negative 
1 = Positive 
    
27 Number of OI How many OI occurs in AIDS 
patients 
Categorical: 
0 = 0 
1 = 1 
2 = 2 
3 = ≥ 3 
    
28 ART era The time period of receiving 
ART, who received ART 
before 1997 is called Pre 
HAART era and from 1997 
and above is HAART era 
Categorical: 
0 =  Pre HAART era 
1 =  HAART era 
    
29 Initial HAART Initial combination of 
HAART (Highly Active Anti-
Retroviral Therapy) 
Categorical: 
1 = 2 NRTI + EFV 
2 = 2 NRTI + PI 
3 = 2 NRTI+ NPV 
    
30 Need second line 
of HAART 
Need or no need to switch 
second line of HAART 
Categorical: 
0 = No 
1 = Yes 
    
31 HAART at the 
end of study 
Combination of HAART at 
the end of study 
Categorical: 
0 = HAART without PI 
1 = HAART with PI 
    
32 Achieve VL ≤ 50 
copies/ml 
AIDS patients undergoing 
HAART and achieve VL ≤ 50 
copies/ml 
Categorical: 
0 =  No       
1 =  Yes 
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3.12  Data collection 
 
3.12.1  Medical record 
 
 
The first step of the data collection was to trace the registration numbers (RN) and 
names of the patients in the registration book of HIV patients at the Medical Records 
Department. After identifying the HIV patients the names and the respective registration 
numbers were listed in a special form and passed to the staff of medical records. After 3 
to 5 days the medical records staff would provide the patients’ folders and compact disk 
(CD). The folder’s cover is coloured red pink for deceased patients and yellow for 
patients who are still alive.  Data is also stored on CD especially for patients registered 
before 2007. The data stored on the CD can be retrieved using a special personal 
computer located at the Medical Records Department. All information about deceased 
patients is stored on the CD. Copying the CD was not permitted. A maximum of 20 
patient folders can be retrieved and examined per day. The patient folders were not 
allowed to be taken out from the medical record room. The Medical Records office is 
open from 8.00 am to 5.00 pm. During public holidays and weekends, the time to 
collect data is from 8.00 am until 4.00 pm.  In the patients’ folder the blue form 
indicates that the patient has been notified as a case of notifiable disease.  Patient’s 
information pertaining to socio-demographic variables such as identification number, 
name, address, date of birth, age, sex, ethnicity, occupational type, date of HIV 
diagnosis, AIDS date, partner notification and date of death were retrieved from the 
blue form.  
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3.12.2  Laboratory data 
 
 
The laboratory data such as baseline CD4 and viral load were also obtained from the 
patients’ folders. The blood test was done twice. First time, the blood sample was 
obtained to calculate the viral load using Amplicor reverse transcription polymerase 
chain reaction (RT-PCR). Simultaneously, the particle agglutination (PA) test was done 
for detecting HIV Ag/Ab Combo (Architect) and anti HIV ½ antibody (Axsym), 
reactive HIV ½ rapid test and reactive HIV ½ particle Agglutination reactive are used. 
The second time,  the blood sample was sent in 2 ethylenediamine tetra-acetic acid 
(EDTA) tubes to calculate the viral load using Cobas Taqman HIV-1 tests for 
confirmation. All these tests were done in the Microbiology laboratory in the University 
of Malaya Medical Centre. During follow up, if the blood test results were not in the 
patient records folder, the blood samples were taken 3 months later to obtain the viral 
load and CD4 count. 
3.12.3  Pharmacy data 
 
 
Information pertaining to anti-retroviral drugs administered to the patients was retrieved 
from the patients’ medical record folders. The data was cross-checked with the 
University of Malaya Medical Centre Pharmacy to verify their anti-retroviral treatment 
for the patients that were undergoing follow-up. An approval letter from the Supervisor/ 
Head of Department were addressed to the Head of Pharmacy University of Malaya 
Medical Centre and included the list of the patient’s name and their registration 
numbers that recruited in this study. After 1-2 weeks processing period, the data from 
the University of Malaya Medical Centre Pharmacy could be accessed, complete with 
anti-retroviral drug combination and its date.  The data was cross-checked and verified 
with the patients’ medical record.   
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3.12.4  National Registration Department records 
 
 
The pink covered folder indicates the death of the patient. The date of death and cause 
of death was traced from the death certificate in the folder. Living status of the HIV-
infected patients who have been treated in the University of Malaya Medical Centre but 
not doing their follow-up was traced, by sending the name list of patients and National 
Registered Identification Card Number (NRIC) to the National Registration Department 
of Malaysia in Putrajaya. After three weeks, National Registration Department delivered 
the data in a compact disk and this data was cross-checked with the patients’ medical 
records. The steps for data collection are shown in figure 3.5 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
Figure 3.5 The process of data collection 20 
 
Step 1 
• Medical Record 
• Registration book 
Step 2 
• New list (Registration number and name of patients) 
• Staff Medical Record 
Step 3 
• Folders 
• CDs 
Socio-demographic data 
 
Laboratory data 
Anti-retroviral data 
List of patients death 
Pharmacy data 
 
National 
Registration 
Department Record 
Clinical data 
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3.13  Data Management 
 
The operational definition of all variables was entered in the Statistical Package for the 
Social Sciences (SPSS) software. This included the name, description type, labels, 
values, and maximum field width for each variable. Coding of the information collected 
was done to make the data more consistent. All data sheets of HIV-infected patients 
were reviewed and relevant information was extracted and recorded in the data 
collection sheets. Each record was assigned a study identification number in place of 
patient initials and identity card number to ensure confidentiality. For the purpose of 
safekeeping, all files were backed up regularly. Files were also copied and stored on 
compact disc and universal serial bus (USB) flash drive. 
 
3.13.1  Data Entry 
 
 
Data was coded prior to entry into the computer except for the continuous variables. 
Complete data consisting of socio-demographic, laboratory, clinical and anti-retroviral 
information were checked. These data were entered into a personal computer using the 
SPSS software version 20.0. Later cross checking, cleaning and transformation were 
done. The data were validated and edited before it was analyzed. Initial data entry was 
done by using Microsoft Excel spreadsheet and subsequently imported into SPSS. 
Double data entry methods were used to ensure the quality of data.  The data were 
compared using Epi Info software to identify dissimilarity between two datasets. 
Mismatched data was cross-checked with original data set. Duplicate entries were 
identified and eliminated.  
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3.13.2  Data Cleaning  
 
 
Data cleaning involves steps to produce a clean dataset by removing typographical 
errors, correcting values against the original data set and removing duplicates. The aim 
of data cleaning is to make sure that the data is free from errors before analysis is 
carried out. The data were checked for accuracy during the data processing. The process 
of data cleaning consist of three stages, involving repeated cycles of screening, 
diagnosing and editing of suspected data abnormalities (Van den Broeck, Cunningham, 
Eeckels, & Herbst, 2005).  This process is summarized in Figure 3.6  
 
 
 
Figure 3.6 The process of cleaning data 21 
Source: (Van den Broeck, et al., 2005)  
 
 
 
 
Screening: 
- Lack/Excess of data 
- Outliers/inconsistencies 
- Strange pattern 
-Suspect analysis result 
Diagnosis: 
- Error, missing data 
- True extreme 
- True normal 
- No diagnosis, still suspect 
Editing : 
- Correction 
- Deletion 
- Leave unchanged 
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3.13.3  Data analysis 
 
The first step of data analysis involved calculating the frequency distribution of the 
variables, mean with standard deviation (SD) and median with inter-quartile range 
(IQR). Only complete data were included in the analysis in relation to the objectives of 
this study. Normality tests of relevant variables were conducted before analyzing the 
dataset. 
A. Descriptive analysis 
  
 
Variable distribution can be described using tables, histogram, box plots and stem-and-
leaf plots but in this study most variables were described by using tables. Values of 
variance, range, standard deviation, and inter-quartile range (IQR) were included in the 
measures of dispersion. Various assumptions of statistical tests were taken into 
consideration. One of the most common assumptions is the normal distribution of 
random variables. The ANOVA (Analysis of Variance) allows statistical analysis of 
whether the means of several groups are equal or not and hence, generalizes for more 
than two groups. The t-test assumes that the variable of interest follows a normal 
probability distribution. Normality assumptions were assessed using the Kolmogorov-
Smirnov test, Shapiro-Wilk tests, PP and QQ plots, box & whiskers plot, histograms 
(Park, 2008). The Levene’s test was used to test the homogeneity of variances. 
Normality testing has two ways, the first by graphical methods and second by numerical 
method. The differences between an empirical distribution and standard normal 
distribution or random variables distribution were visualized by graphical methods. The 
presentation of skewness and kurtosis was statistical tests of normality by numerical 
methods. Graphical methods were easy to interpret and numerical methods provide 
objective ways of examining normality (Park, 2008). If the distribution is skewed and 
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there are many outliers in the box plot so non parametric methods are more appropriate. 
The types of non-parametric methods depend on the data to be analysed. In 
investigations there is interested in evaluating the relationship between two variables. 
This depends on the type of data, different statistics are used to measure the relationship 
between two variables. The correlation coefficient is a summary statistic that describes 
the linear relationship between two numerical variables. Person’s correlation is often 
used to explore the relationship between two numerical data. It is an effective method to 
eliminate or reduce the effect of outliers (Rosner, 2000).  
 
Inferential analysis was performed after descriptive analysis to examine the relationship 
between each independent variable with the outcome. All the variables were tested for 
their relationships with the dependent variable using univariate and multiple logistic 
regression (Kleinbaum, Kupper, & Muller, 1998). 
 
In this study, the socio-demographic characteristic of the samples were described in 
descriptive analysis section. The continuous variables such as age, baseline CD4 count 
and baseline viral load were summarized by using the mean with standard deviation and 
median with inter-quartile range. Categorical variables like age group, gender, ethnicity, 
marital status, exposure risk, education level, personal income and occupational type 
were summarized by using proportion and percentage. Pearson’s correlation was used to 
illustrate the correlation between two variables. Percentage and proportion were used 
for comparison between two variables. 
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B. Survival analysis 
 
This analysis was used to examine the distribution of time between two events. Survival 
analysis is a collection of analytical procedures, for which the outcome of interest is the 
time until an event of interest occurs. 
 
The goals of survival analysis are (Kleinbaum & Klein, 1996): 
1. Estimate and interpret survival and/or hazard functions (Kaplan Meier) 
2. Compare survival and/or hazard functions (Kaplan Meier) 
3. Assess the relationship of explanatory variables to survival time (Cox Regression) 
Time: Years, month’s weeks or day from the beginning of follow up an individual until 
an event occurs. In this study, time (month) was used. The median survival time was 
first to observed with the percentage of cumulative survival is 50 per cent or less. This 
is preferred measurement as the S (t) value is not normally distributed. S (t) = 
proportion of individuals surviving until time t. It gives the probabilities of survival up 
to time t for each t ≥ 0 
 
 
 
Generally, time is equated as the survival time and event equates to failure of survival 
 
Event: death, disease incidence or relapse from remission, recovery or any designated 
experience of interest that may happen to an individual. In this study, two events are 
studied - viral load less than 50 copies/ml and death. 
 
 
 
Time Start follow up Event 
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Censoring 
What particularly distinguishes survival analysis from other statistical methods is to 
deals with issues involving censoring. Most longitudinal studies occur over a finite 
period of time; some patients may still be alive at the time of analysis. Those who do 
not achieve event, they were censored. There are many situations and types of data that 
may have been censored (cases which are not accounted for the second event) (Kleinbaum 
& Klein, 1996). This is based on the estimation of conditional probabilities at each time 
point when an event occurs and taking the product limit to estimate the probability of 
survival at some point in time. Censoring occurs when we have some information about 
the individual, but we do not know the exact survival time. There are reasons for 
censoring (Kleinbaum & Klein, 1996): 
1. The study ends, but the subject has no event yet 
2. Subject lost to follow up 
3. Subject withdraws from study 
 
Standard statistical techniques for analyzing 
Continuous data can be used if all survival times were known (i.e. no censored 
observations). It is right censoring, if the survival time is larger than the censored time. 
This is most common type of censoring. Left censoring occurs if, age is the time scale 
and subjects began to follow-up at a specific age. Interval censored data occur only 
when the subjects fail within an interval, but not when the exact time of failure. 
 
Assumptions for censoring 
- Assume censoring is independent of the true (unobserved) survival time 
- Assume that survival experience does not change during the course of the study 
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- Assumptions that censoring is non informative patients who are censored have the 
same underlying survival curve after their censoring as patients who are not 
censored.  
 
This may be valid when the study is terminated at a fixed date, when a patient moves to 
a new city or when a patient dies due to totally unrelated causes. Censoring is 
independent of exposure and event. It is very difficult to make correct inferences when 
this assumption is not true. 
 
Kaplan Meier Procedure (KM) 
 
The formula of Kaplan Meier estimation (Kleinbaum & Klein, 1996):    
 
 
 
S(t) = proportion of individuals surviving until time t.  
ni = the number of survivors just prior to time ti or the number of survivors less the 
number of losses/censored cases  
di = the number of deaths at time ti 
 
The Kaplan-Meier method is a nonparametric method, and it assumes there is no 
parametric form for the survival functions or hazard rate. The Kaplan-Meier estimate of 
the survival distribution starts with S (0) = 1 and drops off at the distinct failure times. 
The Kaplan Meier method estimates the time-to-event model in the presence of 
censored cases (Kleinbaum & Klein, 1996). The model estimates conditional 
probabilities at each time point when an event occurs and taking the product limit of 
                    ni - di 
S(t) =π ti <t  --------  
                     ni 
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those probabilities to estimate the survival rate at each point in time. The variable of time 
should be continuous data, and the variable of status can be continuous or categorical data 
but the variable of factors or strata should be categorical data. The probabilities for the 
event of interest should depend only on time after the initial event and they are assumed 
to be stable with respect to absolute time. This means, cases that enter the study at 
different times (for example, patients who begin treatment at different times) should 
behave similarly. There should also be no systematic differences between censored and 
uncensored cases. If for example, many of the censored cases are patients with more 
serious conditions, the results may be biased. The method of calculating life tables that 
estimated the survival or hazard function at the time of each event was the procedure used 
by Kaplan Meier (Kleinbaum & Klein, 1996) 
 
Plotting a Kaplan-Meier curve 
It is not really a curve, but a step function. Start at S (0) =1, stay flat until the next 
failure, and then drop down at the failure time. Repeat until last failure, after last failure, 
either stops, if no more observations or stay flat to last (censored) observation. Then the 
K-M estimate is undefined past the last censored observation. 
 
Basic specification 
-  The basic specification prints one survival table followed by the mean and median 
survival time with standard errors and 95% confidence interval. 
-   Three statistics test for two or more independent samples of survival data are the log 
rank (Mantel Cox), Breslow (Generalized Wilcoxon) and Tarone Ware test.  The 
main difference between these 3 tests is the weight given to the survival time 
-   The Log-Rank test gives equal weight to deaths throughout the survival times 
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-   Breslow test (Generalized Wilcoxon test) gives more weight to earlier deaths than 
later deaths 
-   Tarone –Ware test use weights which fall in between the Log rank and Breslow tests 
 
In this study, all the independent variables are skewed to the right after calculating the 
normality, allowing them to be analyzed using non parametric tests. Overall survival time 
HIV-infected patients to death, survival time HIV progression to AIDS and survival time 
AIDS progression to death were assessed by use of Kaplan Meier analysis and compared 
with log rank test (Kleinbaum & Klein, 1996). The log rank test is a very powerful method 
for analyzing data where the time to event is important rather than simply whether or not 
the event occurs. The associated factors of overall survival HIV progression to death, 
HIV progression to AIDS and death were obtained from Cox proportional hazard 
models, using both univariate and multivariate analysis. The results were presented as 
Hazard ratios (HR) and 95% confidence interval (CI). 
 
Hazard function 
Hazard function also known as hazard rate or the failure rate, mortality rate, or the force 
of mortality. The hazard rate at time t, h(t) is proportional to the instantaneous 
probability of failing at time t (per unit time) given that one has survived up to time t. 
The hazard function is a measure of the potential for the event to occur at a particular 
time t, given that the event did not occur yet. Larger values of the hazard function 
indicate greater potential for the event to occur. The proportional hazard regression 
model assumes that the time to event and the covariates are related through the 
following equation below (Kleinbaum & Klein, 1996): 
 
 
                         
h(t) = [h0 (t)] [exp (β1X1 + β2 X2 + … βn Xn) ] 
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h(t)   = hazards rate for the case at time t 
h0(t) = baseline hazard at time t 
β1, β2 = value of regression coefficients 
X1, X2 = value of the covariate 
n = number of covariates 
 
The baseline hazard function measures this potential independently of the covariates. The 
shape of the hazard function over time is defined by the baseline hazard, for all cases. The 
covariates simply help to determine the overall magnitude of the function. The value of the 
hazard is equal to the product of the baseline hazard and a covariate effect. When making 
comparisons, if the proportional hazard assumption is met, the baseline hazards term in the 
equation above will cancel each other. Thus, the hazard ratio is simply the ratio between the 
exponential terms in the above equation. 
C. Cox Regression Analysis 
 
 
The Cox proportional hazards regression or Cox regression analysis was used to study the 
effects of several risk factors on survival time (Kleinbaum & Klein, 1996). This is a method 
analogous to multiple logistic regressions where the time when an event occurs is 
considered rather than simply whether or not an event has occurred. The Cox regression 
with time dependent covariates used if covariates have different values at different point in 
time for the same cases. Cox regression provide estimated coefficients for each of the 
covariate, by handling the censored cases correctly and allowing assessment of the 
impact of multiple covariates in the same model. It is also used to examine the effect of 
continuous covariates. The Cox regression procedure is useful for modeling the time to 
a specified event, based upon the values of giving covariates. 
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In Cox regression analysis the dependent variable is time and the time variable should 
be independent and quantitative. Status variable can be continuous or categorical. A 
continuous status variable should be changed to categorical variable first before running 
the analysis because it must give the defining event for the status variable. The 
covariates of independent variables are categorical or continuous variables. The hazard 
ratio should be constant across time and the observation should be independent that is 
the proportionality of hazard from one case to another should not vary over time. This is 
known as the proportional hazard assumption. The Cox proportional hazards regression 
model assumes that the hazard ratio comparing any two specifications of predictors is 
constant over time. Equivalently, this means that the hazard for one individual is 
proportional to the hazard for any other individual, where the proportionality constant is 
independent of time (Kleinbaum & Klein, 1996). If the proportional hazards assumption 
does not hold, one may need to use the Cox regression with time dependent covariate 
procedure.   
 
Cox model building 
 
When the data set is ready, the first step was to perform univariate analysis to identify 
the association between survival time and all important covariates. For categorical 
variables, it includes the Kaplan Meier estimation of the group specific survivorship 
functions, and tabulation of the point and interval estimates of the median and quartiles 
of survival time. One or more of the significance tests is used to compare survivorship 
among the groups defined by the variable under investigation. Continuous covariates 
should be broken into quartiles (or other biologically meaningful group) and the same 
method applied to these groups. A multivariate model should contain at the outset all 
covariate significant in the univariate analysis with a p-value of 0.25 or lower and any 
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others that are thought to be of clinical importance. Any covariate that has the potential 
to be an important confounder must also be included. The p-value from Wald tests of 
the individual coefficients are used to identify covariates that might be deleted from the 
model. The partial likelihood ratio test with the p-value should confirm whether the 
eliminated covariate is significant. The removal of covariates is verified if it is causes 
significant changes in the coefficients in the remaining model. This is continued until no 
covariates can be deleted from the model. Covariates are deleted and added back into 
the model by working backwards. 
 
There were three different ways of performing multivariate Cox regression, the enter 
method, forward and backward method (Kleinbaum & Klein, 1996) . The enter method 
is the most simple technique and involves inserting all the variables in the regression 
model and testing the significance of all the variables in one go. The process of model 
building started with full model which included all the variables. Significance test used 
was the likelihood ratio test (-2LL). The difference between the likelihood ratio for the 
model developed and the likelihood ratio for a reduced model (Kleinbaum, et al., 1998). 
To develop the reduced models, the non-significant variables (starting with those with 
higher p-values) were removed. The value differences between the likelihood ratio test 
(-2LL) of the model developed was computed. To compare the fit of two models the 
likelihood Ratio Test was used. The subsequent reduced model developed was then 
checked with the value from the Chi-square table at the respective degree of freedom 
(df). In the final calculation of a statistic,  the number of values  free to vary was called 
degree of freedom (Rosner, 2000). If the p- value was not significant, the variables were 
removed. On the other hand, if the p-value was significant, the variables were forced 
back into the model. This process was done until a satisfactory model was obtained. 
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Stepwise regression, as the name suggests, requires several steps depending on the 
complexity of the model. Forward stepwise starts with just one significant variable. If 
the model is significant, the regression will keep adding variables until there are no 
more significant variables that can be added which will improve the model. Backward 
stepwise starts with all the variables in the model and then throws out the ones that are 
not significant. Then the model is tested to see whether it is still significant and whether 
there are other variables that are not significant. Non significant variables are then 
removed progressively until no more can be removed. 
  
In this study there are two parts, the first is concerned with determining factors of AIDS 
progression to death with the dependent variable being mortality status (alive/dead). The 
second part is concerned with determining predictors of ability to achieve viral load less 
than 50 copies/ml. Independent variables included socio-demographic characteristic, 
laboratory, clinical condition and anti-retroviral therapy variables. This study used the 
Enter method, when performing multivariate Cox regression as it allows one to select 
important (even if non-significant in univariate analysis) variables in the analysis while 
the Forward and Backward method relies solely on the software to select significant 
variables. The significant association and its precision were determined by 95 per cent 
confidence interval and the magnitude was determined by the Hazard ratio. 
 
Testing for proportional hazards assumption (PH assumption) 
Once a suitable set of covariate has been identified, it is wise to check each covariate to 
ensure that the proportional hazards assumption is valid. 
There are 2 ways of testing (Kleinbaum & Klein, 1996):  
1. Can be viewed using the Log –Minus-Log plot - one should get parallel lines  
2. Correlating the residuals and the survival time rank (more confirmatory test).  
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The procedure here involves testing the significant covariate from the Kaplan Meier 
procedure one by one. This is done by performing Cox regression with one variable 
(example age alone) as the covariate and saving the partial residuals. The time variable is 
ranked from 1 to the smallest value and then correlated with the residuals. If the correlation 
value is very small the proportional hazard assumption is met but if high the proportional 
hazard assumption is violated. Based on Cohen (1989) criterion, a correlation value of more 
than 0.3 is considered to be sizeable. 
 
If assumptions are violated, there are three ways of fitting the model 
1. Stratify on the variable that violates the PH assumption. The weakness of 
stratification is that one cannot estimate the total effect. 
2. Include a time varying covariate. Treat the violators as a time varying covariate by 
handling the variable as an interaction with time. 
3. Separate analysis for early and late time period 
 
Interaction  
An interaction term is a new variable that is the product of two other variables in the 
model. In etiological studies interaction is important if it involves the main exposure in 
question, in prognostic studies involving prediction, all interactions gain importance. 
The problems with interaction are the interpretation or stratify the model by the 
interacting covariate. 
 
Testing for interaction  
It is important to check for interaction in the final stages of modelling.  The effect of 
adding an interaction term should be assessed using the partial likelihood ratio test. All 
significant interaction should be included in the main effect model. Wald statistic p 
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values can be used as a guide to select interaction that may be eliminated from the 
model, with significance checked by the partial likelihood ratio test. A Likelihood Ratio 
Test should be performed to compare two models, the model without interaction 
compared with the model with the interactions. 
 
Comparability of Logistic regression and Cox Proportional Hazards Models 
- Logistic regression models cumulative incidence whereas proportional hazards 
regression models hazard rates 
- They give similar estimates if: the disease is rare, the risk factor is moderate and 
censoring rates are similar across covariates  
- Both models can accommodate updated covariates by creating new observations at 
regular intervals  
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In this study there are four Cox regression analysis:  
 
A. Cox regression analysis for All AIDS patients progression to death 
 
Time: date of patient’s death or the end of the study minus date of AIDS diagnosis 
calculating in month (continuous) 
Status: Alive and died (categorical)  
Covariate: 18 variables   
 
Figure 3.7 Covariate frame of all AIDS patients progression to death 22 
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B. Cox regression analysis for AIDS on HAART progression to death 
 
Time: date of patient’s death or the end of the study minus date of starting HAART 
calculating in month (continuous) 
Status: Alive and died (categorical)   
Covariate: 24 variables 
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Figure 3.8 Covariate frame of AIDS patients on HAART progression to death 23 
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C. Cox regression analysis for AIDS not on ART progression to death 
 
Time: date of patient’s death or the end of the study minus date of AIDS diagnosis 
calculating in month (continuous) 
Status: died and alive (categorical) 
Covariate: 17 variables  
 
 
Figure 3.9   Covariate frame of AIDS patients not on anti-retroviral therapy 
progression to death 24 
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D.    Cox regression analysis for AIDS on HAART to achieve viral load less than 50 
copies/ml 
 
Time: date of achieving viral load less than 50 copies/ml minus date of starting HAART  
calculating in month (continuous) 
Status: Achieve and not achieve viral load less than 50 copies/ml (categorical)   
Covariate: 23 variables 
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Figure 3.10  Covariate frame AIDS patients on HAART to achieve viral load less 
than 50 copies/ml 25 
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3.14  Summary 
 
This chapter deals with material and methods used in this study. From the literature 
search known that the cohort study is the next best study design for antiretroviral 
treatment after Randomized Controlled Trial which was chosen in this study. Data taken 
from HIV-infected patient’s folders from 1986-2009 in the medical record UMMC 
includes data of socio-demographic, laboratory, clinical condition, pharmacy data 
regarding anti-retroviral therapy and list of death patients checked the mortality status to 
the National Registration Department records. A total of 1314 patients were included 
for analysis using SPSS version 20.0. The total of 32 variables and 9 outcomes in this 
study. Regarding statistical analysis, firstly, done descriptive analysis of socio-
demographic, laboratory, clinical and anti-retroviral data. Secondly, the Kaplan Meier 
procedure is used in this study to estimating conditional probabilities at each time point 
when an event occurs and taking the product limit of those probabilities to estimate the 
survival rate at each point in time. Survival analysis divided into four models, survival 
analysis of all AIDS patients progression to death, AIDS patients on HAART to death, 
AIDS patients not on anti-retroviral therapy to death and AIDS patients on HAART to 
achieve viral load less than 50 copies/ml. Thirdly, to study the effects of several risk 
factors on survival time used Cox regression analysis. The Cox regression analysis will 
provide estimated coefficients for each of covariate, it will handle the censored cases 
correctly and allow assessment of the impact of multiple covariates in the same model. 
All the variables were tested for univariate and multivariate analysis of Cox regression 
analysis and log rank p-value less than 0.25 was set as cut off point, checking the 
interactions between the variables and checked and the proportional hazards assumption 
by Log –Minus-Log plot before achieved the final Cox regression model. 
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CHAPTER 4 
 
RESULTS 
 
4.1 Introduction 
 
 
This chapter presents the results of statistical analysis and divided into the descriptive 
analysis, survival analysis and Cox regression analysis. Section 4.1 is the introduction to 
this chapter. Section 4.2 comparison of socio-demographic characteristic between HIV- 
infected patients included and excluded from analysis. This continues in Section 4.3 
covers the distribution of characteristics of HIV-infected patients according to socio-
demographic characteristic, laboratory result, clinical condition and anti-retroviral 
therapy. Section 4.4 illustrates the survival time of HIV-infected patients. While Section 
4.4.1 looks at the time of death in all AIDS patients. Section 4.4.2 looks at the time to 
death in AIDS patients on HAART. The time of death in AIDS patients not on ART is 
spelled out in Section 4.4.3. The time for AIDS patients on HAART to achieve viral 
load less than 50 copies/ml is in Section 4.4.4 Progression to death in all AIDS patients 
is described in Section 4.5. Progression to death in AIDS patients on HAART are shown 
in Section 4.6. Progression to death in AIDS patients not receiving anti-retroviral 
therapy is explained in Section 4.7. AIDS patients on HAART achieved viral load less 
than 50 copies/ml are documented in Section 4.8. While Section 4.9 is a summary of 
this chapter 
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Figure 4.1 The process of selecting HIV-infected patients 26 
HIV-infected patients in UMMC from 1986-2009  
 
(n=1861) 
Aged below 20 years old 
(n = 68) 
Missing baseline CD4 count and viral load 
(n= 479) 
Total number analysed 
(n=1314) 
Anti-retroviral  therapy 
(n=845) 
Non Antiretroviral therapy 
(n=469) 
AIDS patients not on ART 
(n=330) 
AIDS patients on ART 
(n=659) 
On HAART 
(n=474) 
not on HAART 
(n=185) 
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4.2  Comparison of socio-demographic characteristic between HIV 
infected patient included and excluded from analysis 
 
 
A comparison of socio-demographic characteristics between HIV-infected patients 
included and excluded from analysis are summarized in Table 4.1. There were no major 
differences between these two groups and the characteristics were generally similar. 
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Table 4.1 Comparison of socio-demographic characteristic between HIV-infected 
patient included and excluded from analysis 7 
Variables Total included 
(n = 1314) 
n (%) 
Total excluded 
 (n = 479) 
n (%) 
Age Groups (years)   
20 – 29  420 (32.0) 172 (35.9) 
30 – 39 543 (41.3) 189 (39.5) 
40 – 49 219 (16.7) 64 (13.4) 
50 – 59 85 (6.4) 39 (8.1) 
≥ 60 47 (3.6) 15 (3.1) 
Median (IQR) 33.7 (12.0) 33.1 (12.4) 
   
Gender   
Male 1075 (81.8) 398 (83.1) 
Female   239 (18.2) 81 (16.9) 
Ratio male : female   4.5 : 1 4.9 : 1 
   
Ethnicity   
Malay 256 (19.5) 97 (20.3) 
Chinese 804 (61.2) 290 (60.5) 
Indian 167 (12.7) 65 (13.6) 
Others   87 (6.6) 27 (5.6) 
   
Marital status   
Single 594 (45.2) 218 (45.5) 
Married 575 (43.8) 210 (43.8) 
Others 145 (11.0) 51 (10.7) 
   
Educational level   
≤ Secondary  966 (73.5) 361 (75.4) 
≥ Tertiary  348 (26.5) 118 (24.6) 
   
Occupational type   
Unemployed 375 (28.5) 159 (33.2) 
Manual workers 372 (28.3) 144 (30.1) 
Professional and non manual worker 567 (43.2) 176 (36.7) 
   
Monthly income (RM)    
< 1000 451 (34.3) 163 (34.0) 
1000 to 3000 558 (42.5) 197 (41.1) 
> 3000  305 (23.2) 119 (24.9) 
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 4.3 Distribution of characteristic of HIV-infected patients 
 
The median age of the HIV-infected patients was 33.7 years (IQR 12.0) and AIDS 
patients was 34.1 (IQR 12.7). Most of them (73.3 per cent) were aged between 20-39 
years, male (81.8 per cent) and Chinese (61.2 per cent). Forty five point two per cent 
were single, 73.5 per cent had primary and secondary education, 43.2 per cent were 
professional or non-manual workers and 42.5 per cent earned between RM 1000 to 3000 
per month. The distribution of socio-demographic characteristic of HIV-infected 
patients are summarized in Table 4.2  
 
The distribution of laboratory and clinical variables show that 62.9 per cent patients had 
baseline CD4 count less than 200 cells/µL. Fifty one point one per cent had baseline 
viral load more than 100,000 copies/ml. Sixty two point five per cent had baseline 
hemoglobin more than 12 g/dl. Sixty two point seven per cent had normal baseline total 
lymphocyte count and 55.2 per cent had normal liver function test. The distribution of 
laboratory test of HIV-infected patients is highlighted in Table 4.3  
 
About 65.8 per cent of patients contracted HIV via the heterosexual route and 61.7 per 
cent presented with AIDS. Fifty four point two per cent already at the WHO clinical 
stage 4. Sixty three point nine per cent had opportunistic infection and 30.9 per cent had 
one opportunistic infection. Seventy four point four per cent had baseline body mass 
index more than 18.5 and 64.3 per cent patients receiving anti-retroviral therapy. At the 
end of the study, 36.4 per cent patients had died with majority due to AIDS related 
illness (79.7 per cent). The distribution of laboratory test and clinical condition of HIV-
infected patients is highlighted in Table 4.4  
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Table 4.2 Distribution of socio-demographic characteristic of HIV-infected 
patients 8 
Variables Total (n = 1314) 
n (%) 
Total AIDS (n = 989) 
n (%) 
Age Groups (years)   
20 – 29  420 (32.0) 308 (31.2) 
30 – 39 543 (41.3) 399 (40.3) 
40 – 49 219 (16.7) 173 (17.5) 
50 – 59 85 (6.4) 69 (7.0) 
≥ 60 47 (3.6) 40 (4.0) 
Median (IQR) 33.7 (12.0) 34.1 (12.7) 
   
Gender   
Male 1075 (81.8) 843 (85.2) 
Female   239 (18.2) 146 (14.8) 
Ratio male : female   4.5 : 1 5.8 : 1 
   
Ethnicity   
Malay 256 (19.5) 191 (19.3) 
Chinese 804 (61.2) 620 (62.7) 
Indian 167 (12.7) 123 (12.4) 
Others   87 (6.6) 55 (5.6) 
   
Marital status   
Single 594 (45.2) 448 (45.3) 
Married 575 (43.8) 425 (43.0) 
Others 145 (11.0) 116 (11.7) 
   
Educational level   
≤ Secondary  966 (73.5) 744 (75.2) 
≥ Tertiary  348 (26.5) 245 (24.8) 
   
Occupational type   
Unemployed 375 (28.5) 310 (31.3) 
Manual workers 372 (28.3) 288 (29.1) 
Professional and non manual worker 567 (43.2) 391 (39.5) 
   
Monthly income (RM)    
< 1000 451 (34.3) 337 (34.1) 
1000 to 3000 558 (42.5) 420 (42.5) 
> 3000  305 (23.2) 232 (23.5) 
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Table 4.3 Distribution baseline laboratory result of HIV-infected patients 9 
Variables Total (n = 1314) 
n (%) 
Total AIDS (n = 989) 
n (%) 
Baseline CD4 (cell/µL)    
< 200  826 (62.9) 746 (75.4) 
≥ 200           488 (37.1) 243 (24.6) 
Median (IQR) 105 (295) 52 (183) 
   
Baseline VL (copies/ml)   
< 100,000  643 (48.9) 392 (39.6) 
≥ 100,000  671 (51.1) 597 (60.4) 
Median (IQR) 100,000 (124,924) 100,000 (188,025) 
   
Baseline Hb (g/dl)   
< 12  493 (37.5) 420 (42.5) 
≥ 12  821 (62.5) 569 (57.5) 
Median (IQR) 12.8 (31.0) 12.4 (30.0) 
   
Baseline TLC    
Normal 824 (62.7) 547 (55.3) 
Abnormal 490 (37.3) 442 (44.7) 
Median (IQR) 1,410 (1,253) 1,280 (1,180) 
   
Baseline LFT    
Normal 725 (55.2) 500 (50.6) 
Abnormal 589 (44.8) 489 (49.4) 
Note: - VL = Viral load 
         - Hb = Hemoglobin 
         - TLC = Total lymphocyte count 
         - LFT = Liver function test 
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Table 4.4 Distribution clinical condition of HIV-infected patients 10 
Variables Total (n = 1314) 
n (%) 
Total AIDS (n = 989) 
n (%) 
Exposure Risk   
Heterosexual 864 (65.8) 665 (67.2) 
Homosexual 173 (13.2) 93 (9.4) 
IDU 250 (19.0) 211 (21.3) 
Others   27 (2.1) 20 (2.0) 
   
WHO Clinical stage   
Stage 1  117 (8.9) 0 (0.0) 
Stage 2 123 (9.4) 0 (0.0) 
Stage 3  362 (27.5) 304 (30.7) 
Stage 4  712 (54.2) 685 (69.3) 
   
Initial Presentation   
HIV 503 (38.3) 0 (0.0) 
AIDS 811 (61.7) 
 
989 (100.0) 
Baseline BMI   
< 18.5  336 (25.6) 285 (28.8) 
≥ 18.5  978 (74.4) 704 (71.2) 
   
Opportunistic Infection (OI)   
Negative 475 (36.1) 259 (26.2) 
Positive 839 (63.9) 730 (73.8) 
   
Number of OI   
0 475 (36.1) 259 (26.2) 
1 406 (30.9) 364 (36.8) 
2 274 (20.9) 242 (24.5) 
≥ 3 159 (12.1) 124 (12.5) 
   
Treatment   
Non ART 469 (35.7) 330 (33.4) 
ART 845 (64.3) 659 (66.6) 
   
Living status (at the end of the study)   
Alive 836 (63.6) 527 (53.3) 
Died 478 (36.4) 462 (46.7) 
   
Cause of death   
AIDS related illness 381 (79.7) 376 (81.4) 
Non AIDS related illness 97 (20.3) 86 (18.6) 
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4.4 Distribution of characteristic of AIDS patients on anti-retroviral 
therapy  
 
 
Total of AIDS patients receiving anti-retroviral was 659 patients with median age was 
34.2 years (IQR 13.6). AIDS patients receiving anti-retroviral have similar distribution 
with HIV-infected patients, however it differs from marital status variable, showing that 
married more than single in AIDS patients receiving anti-retroviral therapy. The 
distribution of socio-demographic characteristic of AIDS patients receiving anti-
retroviral and HAART are summarized in Table 4.5  
 
The laboratory and clinical variables at the start of HAART, 84.2 per cent had CD4 
counts less than 200 cells/µL and 64.8 per cent had viral load more than 100,000 
copies/ml. Fifty five point five per cent had hemoglobin more than 12 g/dl, 52.1 per cent 
had a normal total lymphocyte count and 57.4 per cent had normal liver function test. 
Three new variables added for AIDS patients on HAART were CD4 recovers, 
hemoglobin recovers and total lymphocyte count recovers. There was no progress of 
CD4 to achieve more than 200 cells/µL for 42.2 per cent of patients. Forty one point six 
per cent found no increment in hemoglobin level to achieve more than 12 g/dl and total 
lymphocyte count of 41.1 per cent patients had no recovers. The median time for CD4 
recovers, hemoglobin recovers and total lymphocyte count recovers were 9.7 months 
(IQR 13.9), 5.4 months (IQR 7.0) and 5.6 months (IQR 7.2).  
 
Body mass index more than 18.5 at HAART initiation was 73.8 per cent, patients with 
WHO clinical stage 4 was 67.9 per cent. Positive opportunistic infection was 78.3 per 
cent and with one opportunistic infection was 42.4 per cent, mainly infected with 
Tuberculosis (142 or 30 per cent).  
4 Results  
 
 
129 
 
Around 71.9 percent patients receiving anti-retroviral therapy in HAART era and 80.6 
per cent of HAART initiation with combination (2 NRTI + EFV), whereas 84.2 per cent 
of them did not need to switch second line of HAART. The median follow up measured 
from the date of starting HAART until the date of death or the end of the study was 37.5 
(IQR 55.6) months. At the end of the study, only 9.3 per cent changed to the HAART 
combination with PI. Seventy point five per cent achieved viral load less than 50 
copies/ml and 20 per cent die with cause of death AIDS related illness (PCP and 
Tuberculosis). From total HAART initiation with 2 NRTI + PI, those still continue until 
the end of study were 16 (61.5 per cent) and 10 (38.5 per cent) patients have stopped.  
The distribution of laboratory results and clinical of AIDS patients on anti-retroviral 
therapy and HAART is highlighted in Table 4.6 and Table 4.7  
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Table 4.5 Distribution of socio-demographic characteristics of AIDS patients 
receiving anti-retroviral therapy 11 
Variables Total ART (n = 659) 
n (%) 
Total HAART (n = 474) 
n (%) 
Age Groups (years)   
20 – 29  194 (29.4) 121 (25.5) 
30 – 39 262 (39.8) 200 (42.2) 
40 – 49 121 (18.4) 97 (20.5) 
50 – 59 49 (7.4) 32 (6.8) 
≥ 60 33 (5.0) 24 (5.1) 
Median (IQR) 34.2 (13.6) 35.0 (12.9) 
   
Gender   
Male 546 (82.9) 397 (83.8) 
Female   113 (17.1) 77 (16.2) 
Ratio male : female   4.8 : 1 5.2 : 1 
   
Ethnicity   
Malay 100 (15.2) 83 (19.3) 
Chinese 457 (69.3) 309 (62.7) 
Indian 70 (10.6) 59 (12.4) 
Others   32 (4.9) 23 (5.6) 
   
Marital status   
Single 278 (42.2) 198 (41.8) 
Married 305 (46.3) 219 (46.2) 
Others 76 (11.5) 57 (12.0) 
   
Educational level   
≤ Secondary  471 (71.5) 330 (69.6) 
≥ Tertiary  188 (28.5) 144 (30.4) 
   
Occupational type   
Unemployed 186 (28.2) 122 (25.7) 
Manual workers 163 (24.7) 110 (23.2) 
Professional and non manual worker 310 (47.0) 242 (51.1) 
   
Monthly income (RM)    
< 1000 203 (30.8) 156 (32.9) 
1000 to 3000 287 (43.6) 206 (43.5) 
> 3000  169 (25.6) 112 (23.6) 
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Table 4.6 Distribution laboratory result of AIDS patients receiving anti-retroviral 
therapy 12 
Variables Total ART (n = 659) 
n (%) 
Total HAART (n = 474) 
n (%) 
CD4 at the start of ART (cell/µL)   
< 200  545 (82.7) 399 (84.2) 
≥ 200  114(17.3)   75 (15.8) 
Median (IQR) 46 (138) 46 (125) 
   
VL at start of ART (copies/ml)   
< 100,000  250 (37.9) 167 (35.2) 
≥ 100,000  409 (62.1) 307 (64.8) 
Median (IQR) 100,000 (197,200) 100,000 (237,800) 
   
Hb at start of ART (g/dl)   
< 12  286 (43.4) 211 (44.5) 
≥ 12  373 (56.6) 263 (55.5) 
Median (IQR) 12.8 (31.0) 12.5(31.0) 
   
TLC at start ART   
Normal 372 (56.4) 247 (52.1) 
Abnormal 287 (43.6) 227 (47.9) 
Median (IQR) 1,300 (1,136) 1,200 (1,079) 
   
LFT at start of ART   
Normal 374 (56.8) 272 (57.4) 
Abnormal 285 (43.3) 202 (42.6) 
   
CD4 recovers   
No 299 (45.4) 200 (42.2) 
Stable 88 (13.4) 56 (11.8) 
Yes 272 (41.3) 218 (46.0) 
Time CD4 recovers (months)   
Median (IQR) 9.8 (13.9) 9.7 (13.9) 
   
Hemoglobin recovers   
No  296 (44.9) 197 (41.6) 
Stable 188 (28.5) 146 (30.8) 
Yes 175 (26.6) 131 (27.6) 
Time Hb recovers (months)   
Median (IQR) 5.6 (6.9) 5.4 (7.0) 
   
TLC recovers   
No 292 (44.3) 195 (41.1) 
Stable 196 (29.7) 153 (32.3) 
Yes 171 (25.9) 126 (26.6) 
Time TLC recovers (months)   
Median (IQR) 5.8 (7.5) 5.6 (7.2) 
Note: - CD4 recovers from  < 200 to  ≥ 200 cell/µL; Hb recovers from < 12 to  ≥ 12 g/dl; TLC recovers from < 1200 to  ≥ 1,200  
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Table 4.7 Distribution clinical condition and anti-retroviral therapy variables of 
AIDS patients receiving anti-retroviral therapy 13 
Variables Total ART (n = 659) 
n (%) 
Total HAART (n = 474) 
n (%) 
BMI at start of ART   
< 18.5 163 (24.7) 124 (26.2) 
≥ 18.5 496 (75.3) 350 (73.8) 
   
WHO clinical stage                  
Stage 3 199 (30.2) 152 (32.1) 
Stage 4 460 (69.8) 322 (67.9) 
   
Opportunistic Infection (OI)   
Negative 133 (20.2) 103 (21.7) 
Positive 526 (79.8) 371 (78.3) 
   
Number of OI   
0 133 (20.2) 103 (21.7) 
1 261 (39.2) 201 (42.4) 
2 170 (25.8) 120 (25.3) 
≥ 3 95 (14.4) 50 (10.5) 
   
ART era   
Pre-HAART era 185 (28.1) 0 (0.0) 
HAART era 474 (71.9) 474 (100.0) 
   
Initial combination of HAART   
2 NRTI+ EFV 382 (57.9) 382 (80.6) 
2 NRTI+ NVP   66 (10.0)   66 (13.9) 
2 NRTI+ PI   26 (3.9)   26 (5.5) 
Single and double drugs 185 (28.1)  
   
Need second line of HAART   
No 583 (88.5) 399 (84.2) 
Yes 76 (11.5) 75 (15.8) 
   
HAART at the end of study   
HAART without PI 567 (86.0) 430 (90.7) 
HAART with PI 92 (14.0) 44 (9.3) 
   
Achieve VL ≤ 50 copies/ml   
No 254 (38.5) 140 (29.5) 
Yes 405 (61.5) 334 (70.5) 
   
Living status (the end of the study)   
Alive 433 (65.7) 379 (80.0) 
Died 226 (34.3) 95 (20.0) 
Cause of death   
AIDS related illness 185 (81.9) 77 (81.1) 
Non AIDS related illness 41 (18.1) 18 (18.9) 
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4.5  Survival time of HIV-infected patients 
 
Survival time was measured from date of HIV diagnosis until the date of the patient’s 
death or the end of the study. For the total number of HIV-infected patients (1314), 
there were 36.4 per cent deaths. About 79.7 per cent of deaths were caused by AIDS-
related illnesses (Pneumocystis carinii pneumonia 35.4 per cent and Tuberculosisr 34.1 
per cent). The mean survival time was 159.1 (95% CI 150.6, 167.6) months and the 
median survival time were 142.4 months (95% CI 121.5, 163.5 months). There were 
64.3 per cent of total patients receiving anti-retroviral therapy and 35.7 per cent not 
receiving anti-retroviral therapy. The mean and median survival time of patients 
receiving anti-retroviral therapy was 168.6 (95% CI 157.6, 179.6) months and 177.5 
(95% CI 147.4, 207.6) months respectively. The mean and median survival time of 
patients not receiving anti-retroviral therapy was 123.5 (95% CI 111.4, 135.6) months 
and 73.2 (95% CI 62.0, 84.4) months respectively. The 5 and 10-year survival of the 
anti-retroviral therapy group (80.7 per cent and 64.5 per cent) was higher than non anti-
retroviral therapy group (55.6 per cent and 37.8 per cent). The Kaplan Meier survival 
curve for anti-retroviral therapy and the non anti-retroviral therapy group is presented in 
Figure 4.2. 
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4.5.1  Time to death in all AIDS patients 
 
Survival time was measured from the date of the AIDS diagnosis until the date of 
patient’s death or the end of the study. Total number of AIDS patients were 989 and 
46.7 per cent had died at the end of the study. About 81.4 per cent of deaths were 
caused by AIDS-related illnesses (Tuberculosis 45.5 per cent and Pneumocystis carinii 
pneumonia 40.7 per cent). The mean and median survival time was 119.9 (95% CI 
110.3, 129.5) months and 65.7 (95% CI 49.9, 81.3) months respectively. The 5 and 10-
year survival after being treated as AIDS patients were 51.8 per cent (95% CI 48.3, 
55.3) and 41.4 per cent (95% CI 36.9, 45.9).  
 
There were 66.6 per cent of total AIDS patients receiving anti-retroviral therapy and 
33.4 per cent did not. The mean survival time of AIDS patients on anti-retroviral 
therapy was 103.5 (95% CI 97.1, 109.9) months and the median survival time was 121.7 
months, those not on anti-retroviral therapy had mean and median survival time was 
62.2 (95% CI 50.2, 74.2) months and 15.0 (95% CI 11.7, 18.3). The 5 and 10-year 
survival of anti-retroviral therapy group (65.6 and 51.5 per cent) was higher than non 
anti-retroviral therapy group (23.6 and 18.9 per cent). The Kaplan Meier survival curve 
of anti-retroviral therapy and non anti-retroviral therapy in all AIDS patients are 
presented in Figure 4.3 
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Figure 4.2 The Kaplan Meier survival curve of HIV-infected patients progression 
to death according to received anti-retroviral therapy and not received 
27 
 
 
Figure 4.3 The Kaplan Meier survival curve of all AIDS patients progression to 
death according to received anti-retroviral therapy and not received 28 
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4.5.2  Time to death in AIDS patients on HAART 
 
Survival time was measured from the date of starting HAART until the date of patient’s 
death or the end of the study. There were 474 AIDS patients on HAART. Out of these 
20.0 per cent had died at the end of the study. The mean survival time was 105.8 (95% 
CI 100.4, 111.1) months. The median survival time was not calculated because the 
cumulative proportion of survival was still high (more than 50 per cent). The 5 and 10-
year survival were 76.7 per cent (95% CI 72.2, 81.2) and 70.6 per cent (95% CI 63.7, 
77.5). The Kaplan Meier survival curve of patients undergoing HAART is presented in 
Figure 4.4 
 
Figure 4.4 The Kaplan Meier survival curve of AIDS patients on HAART 
progression to death 29 
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4.5.3  Time to death in AIDS patients not on anti-retroviral therapy 
 
 
Survival time was measured from the date of the AIDS diagnosis until the date of 
patient’s death or the end of the study. The AIDS patients not on anti-retroviral therapy 
were 330, out of these 71.5 per cent died. The mean and median survival time was 62.3 
(95% CI 50.3, 74.2) months and 15.0 (95% CI 11.7, 18.3) months respectively. The 5 
and 10-year survival were 23.6 per cent (95% CI 18.3, 28.9) and 18.9 per cent (95% CI 
13.6, 24.2). The Kaplan Meier survival curve of AIDS patients not on anti-retroviral 
therapy is presented in Figure 4.5 
 
Figure 4.5 The Kaplan Meier survival curve of AIDS patients not on anti-
retroviral therapy progression to death 30 
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4.5.4  Time to achieve viral load less than 50 copies/ml in AIDS patients on 
HAART 
 
Survival time was measured from the date of starting HAART until the date of 
achieving viral load less than 50 copies/ml. There were 474 AIDS patients on HAART, 
of these 70.5 per cent achieved viral load less than 50 copies/ml. The mean time was 9.2 
(95% CI 7.9, 10.6) months and median time was 5.1 (95% CI 4.7, 5.6) months. The 
Kaplan Meier survival curve for patients on HAART to achieve viral load less than 50 
copies/ml is presented in Figure 4.6 
 
Figure 4.6 The Kaplan Meier survival curve of AIDS patients on HAART to 
achieve viral load less than 50 copies/ml 31 
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4.6  Progression to death in all AIDS patients 
 
Survival probabilities of all AIDS patient progression to death stratified by 
significant socio-demographic, laboratory and clinical variables 
 
Kaplan Meier was used to assess the impact of the various factors on the time 
progression to death according to socio-demographic, laboratory and clinical condition. 
The significant variables of socio-demographic characteristic and laboratory result 
were; education level (p-value < 0.001), occupational type (p-value < 0.001), monthly 
income (p-value = 0.002) and baseline hemoglobin (p-value = 0.020). Table 4.8 shows 
the 5 and 10-year survival from Kaplan Meier estimates of all AIDS patients 
progression to death stratified by significant socio-demographic characteristic and 
laboratory result. The Kaplan Meier curve for AIDS to death stratified by significant 
socio-demographic and laboratory variables is presented in Figure 4.7 
 
The significant variables of clinical condition were; exposure risk (p-value < 0.001), 
baseline body mass index (p-value = 0.013), opportunistic infection (p-value = 0.010), 
number of opportunistic infections (p-value < 0.001) and treatment (p-value < 0.001). 
Table 4.9 shows the 5 and 10-year survival from Kaplan Meier estimates of all AIDS 
patients progression to death stratified by significant clinical variables. The Kaplan 
Meier curve of all AIDS patients progression to death stratified by significant of clinical 
variables is presented in Figure 4.8 
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Table 4.8. The 5 and 10-year survival from Kaplan Meier estimates of all AIDS 
patients progression to death stratified by significant socio-
demographic and laboratory variables 14 
Variable n Survival 
(years) 
% Survival  
(95% CI) 
Median Survival  
 (95% CI) in months 
Log rank 
P-value 
Educational level                                                                                                  < 0.001 
≤ Secondary  744 5 48.8 (44.9, 52.7) 56.3 (40.9, 71.6)  
  10 38.3 (33.2, 43.4)   
≥ Tertiary  245 5 61.6 (54.6, 68.6) 65.7 (49.9, 81.3)  
  10 52.1 (42.7, 61.5)   
Occupational type                                                                                                < 0.001 
Unemployed 310 5 39.5 (33.4, 45.6) 39.1 (26.9, 51.3)  
  10 25.7 (17.9, 33.5)   
Manual 
workers 
288 5 43.9 (37.4, 50.4) 41.8 (26.9, 56.6)  
  10 33.7 (26.7, 40.7)   
Professional/
non manual 
worker 
391  5 67.3 (62.2, 72.4) (not calculated)*  
  10 56.2 (47.8, 64.6)   
Monthly income (RM)                                                                                            0.002 
< 1000 337 5 43.9 (37.8, 50.0) 46.3 (35.1, 57.5)  
  10 33.2 (23.8, 42.6)   
1000 to 3000 420 5 58.3 (53.2, 63.4) 96.6 (not calculated)  
  10 46.8 (40.3, 53.3)   
> 3000  232 5  49.2 (41.6, 56.8) 58.8 (42.9, 74.7)  
  10 38.1 (28.2, 48.0)   
Baseline Hb (g/dl)                                                                                                   0.020 
<12  420 5 49.2 (43.9, 54.5) 58.8 (28.2, 89.4)  
  10 38.8 (29.4, 48.2)   
≥12  569 5 53.6 (49.1, 58.1) 26.4 (19.6, 33.2)  
  10 41.3 (35.2, 47.4)   
* The median survival was not calculated because the cumulative proportion surviving was still high (> 50%)  
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a. Education level                                      b. Occupational type             
 
 
       c.   Monthly income                                         d. Baseline Hb       
Figure 4.7 The Kaplan Meier curve of all AIDS patients progression to death 
stratified by significant socio-demographic and laboratory variables 32 
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Table 4.9 The 5 and 10-year survival from Kaplan Meier estimates of all AIDS 
patients progression to death stratified by significant clinical variables 
15 
Variable n Survival 
(years) 
% Survival 
 (95% CI) 
Median Survival 
(95% CI) in months 
Log rank 
P-value 
Exposure risk                                                                                                       < 0.001 
Heterosexual 665 5 59.2 (55.1, 63.3) 74.5 (48.7, 100.3)  
  10 45.5 (40.2, 50.8)   
Homosexual 93 5 66.9 (55.1, 78.7) 100.4 (55.9, 144.7)  
  10 42.5 (17.0, 68.0)   
IDU 211 5 37.0 (29.2, 44.8) 40.9 (26.4, 55.5)  
  10 25.4 (17.0, 33.8)   
Others 20 5 **   (not calculated)*  
  10 **   
Baseline BMI                                                                                                          0.013 
< 18.5 285 5 47.0 (40.3, 53.7) 56.2 (37.4, 75.0)  
  10 33.8 (23.0, 44.6)   
≥ 18.5 704 5 53.4 (49.3, 57.5) 71.9 (49.9, 93.9)  
  10 42.8 (37.5, 48.1)   
OI        0.010 
Negative 178 5 58.0 (50.0, 66.0) (not calculated)*  
  10 50.4 (39.0, 61.8)   
Positive 811 5 50.2 (46.3, 54.1) 61.1 (47.4, 74.8)  
  10 39.5 (34.6, 44.4)   
Number of OI                                                                                                       < 0.001 
0 178 5 58.0 (50.0, 66.0) (not calculated)*  
  10 50.4 (39.0, 61.8)   
1 385 5 58.3 (52.8, 63.8) 112.5(not calculated)  
  10 49.4 (42.3, 56.5)   
2 268 5 47.5 (40.4, 54.6) 54.9 (36.7, 73.0)  
  10 36.4 (27.2, 45.6)   
≥ 3 158 5 33.0 (24.4, 41.6) 20.6 (12.8, 28.5)  
  10 18.4 (9.6, 27.2)   
Treatment     < 0.001 
Non ART 330 5 23.6 (18.3, 28.9) 15.0 (11.7, 18.3)  
  10 18.9 (13.6, 24.2)   
ART 659 5 65.6 (61.5, 69.7) 121.7(not calculated)  
  10 51.5 (44.8, 58.2)   
* The median survival was not calculated because the cumulative proportion surviving was still high (> 50%) 
** Probability of survival cannot calculate from  the survival table because  no patients survived 10 years 
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a. Exposure risk                                         b. Baseline BMI              
 
       c.   Opportunistic infection (OI)                 d. Number of OI 
 
        e.  Treatment ART and non ART 
Figure 4.8 The Kaplan Meier curve of all AIDS patients progression to death 
stratified by significant clinical variables 33 
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The Cox regression analysis was used to look for independent predictors of death. The 
log rank p-value less than 0.25 was set as cut off values to choose variables for 
univariate analysis. Fifteen variables have a log rank p-value of less than 0.25. That 
included are age groups, gender, marital status, education level, occupational type, 
monthly income, baseline CD4, viral load, hemoglobin, total lymphocyte count, body 
mass index, exposure risk, opportunistic infection, number of opportunistic infection 
and anti-retroviral therapy. These variables included in the univariate Cox regression 
analysis. All possible two way interactions between the variables in the main effect 
model were checked. No significant interaction term was identified. There were three 
variables not significant in the univariate Cox regression analysis (age groups, gender 
and monthly income).  
 
The proportional hazards assumption univariate was tested in two ways. First, by the log 
minus log estimated survivor function plotted against survival in variables. Twelve 
variables had parallel lines which indicated that the proportional hazard assumption was 
fulfilled. Four variables (baseline CD4, viral load, hemoglobin, total lymphocyte count) 
did not have parallel lines which indicated proportional hazard assumption violation. 
The viewing Log–Minus-Log plot of variables socio-demographic characteristic and 
clinical condition can see in Figure 4.9 and Figure 4.10.  
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      a. Marital status                                             b. Education level 
 
       c.   Occupational type                                  
 
 
Figure 4.9 The Log-Minus-Log plotted against survival time of all AIDS patients 
progression to death stratified by socio-demographic variables 34 
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a. Exposure risk                                          b. Baseline BMI 
 
      c. Opportunistic infection                               d. Number of OI 
 
       e.   Treatment non ART and ART 
Figure 4.10 The Log-Minus_Log plotted against survival time of all AIDS patients 
progression to death stratified by clinical variables 35 
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There are eight variables fulfilled the proportional hazard assumption and included in 
multivariate Cox regression analysis. The univariate Cox regression analysis of 
variables as predictors AIDS patients progression to death is presented in Table 4.10.  
 
Table 4.10 Univariate predictors of death in all AIDS patients 16 
Variable Crude Hazard Ratio 95% CI 
Marital status   
Single 1.0  
Married 0.97  0.79, 1.17 
Others 0.72  0.52, 0.99 
   
Educational level   
≥ Tertiary 1.0  
≤ Secondary 1.49  1.18, 1.88 
   
Occupational type   
Professional and non manual workers 1.0  
Manual workers 2.03  1.60, 2.58 
Unemployed 2.23  1.78, 2.79 
   
Exposure Risk   
Heterosexual 1.0  
Homosexual 0.64  0.43, 0.95 
IDU 1.52  1.23, 1.87 
Others 1.08  0.55, 2.09 
   
Baseline BMI   
≥ 18.5 1.0  
< 18.5  1.28  1.05, 1.56 
   
Opportunistic Infection    
Negative 1.0  
Positive 1.39  1.08, 1.80 
   
Number of OI   
0 1.0  
1 1.03  0.78, 1.37 
2 1.53  1.15, 2.05 
≥ 3 2.37  1.75, 3.21 
   
Treatment   
ART 1.0  
Non ART 3.33  2.77, 4.00 
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In a multivariate Cox regression analysis only three variables were significant 
(occupational type, number of opportunistic infection and anti-retroviral therapy). Table 
4.11 displays the multivariate Cox regression analysis of predictors of death in AIDS 
patients. The significant independent predictors of AIDS patients to death were being 
unemployed, manual workers, those who have three or more opportunistic infections 
and did not receive anti-retroviral therapy were more likely to die compared to their 
reference categories. 
 
 
Table 4.11 Multivariate predictors of death in AIDS patients 17 
Variable Crude  
Hazard Ratio 
95% CI Adjusted 
 Hazard Ratio 
95% CI 
Occupational type     
Professional and non 
manual worker 
 
1.0 
  
1.0 
 
Manual workers 2.03  1.60, 2.58 1.47  1.15, 1.87 
Unemployed 2.23  1.78, 2.79 1.59  1.26, 2.02 
     
Number of OI     
0 1.0  1.0  
1 1.03  0.78, 1.37 0.93  0.70, 1.24 
2 1.53  1.15, 2.05 1.30  0.97, 1.74 
≥ 3 2.37  1.75, 3.21 1.90  1.39, 2.58 
     
Treatment     
ART  1.0  1.0  
Non ART 3.33  2.77, 4.00 2.89 2.37, 3.47 
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4.7  Progression to death in AIDS patients on HAART 
 
Survival probabilities of AIDS patients on HAART progression to death stratified 
by significant socio-demographic, laboratory, clinical and HAART variables 
 
 
Table 4.12 shows the 5 and 10-year survival according to socio-demographic 
characteristic variables among AIDS patients on HAART. The significant variables 
were occupational type (p-value = 0.001) and monthly income (p-value = 0.029). The 
Kaplan Meier curve for AIDS to death according to significant variables of socio-
demographic characteristic is presented in Figure 4.11. 
 
Table 4.13 shows the 5 and 10-year survival of Kaplan Meier estimates AIDS patients 
on HAART progression to death stratified by significant laboratory variables. The 
significant variables were hemoglobin at HAART initiation (p-value = 0.036), CD4 
recovers (p-value < 0.001), hemoglobin recovers (p-value < 0.001) and total 
lymphocyte count recovers (p-value < 0.001). The Kaplan Meier curve for AIDS to 
death according to significant variables of laboratory result is presented in Figure 4.12. 
 
Table 4.14 shows the 5 and 10-year survival from Kaplan Meier estimates AIDS 
patients on HAART progression to death, stratified by significant clinical condition and 
HAART variables. The significant variables were numbers of opportunistic infection (p-
value < 0.043) and achieve viral load less than 50 copies/ml (p-value < 0.001). The 
Kaplan Meier curve for AIDS to death according to significant variables of clinical and 
HAART can be seen in the Figure 4.13. 
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Table 4.12 The 5 and 10-year survival from Kaplan Meier estimates of AIDS 
patients on HAART to death stratified by significant socio-
demographic variables 18 
Variable n Survival 
(years) 
% Survival  
(95% CI) 
Mean Survival  
 (95% CI)  
in months# 
Log rank 
P value 
Occupational type                                                                                                   0.001 
Unemployed 122 5 48.8 (40.8, 56.8) 87.9 (76.8, 99.2)  
  10 **   
Manual 
workers 
110 5 80.3 (71.7, 88.9) 106.6  
(97.4, 115.9) 
 
  10 **   
Professional 
and non 
manual worker 
 242 5 81.0 (75.1, 86.9) 110.9 
(103.9, 117.9) 
 
  10 73.2 (62.6, 83.8)   
Monthly income (RM)                                                                                            0.029 
< 1000 156  5 56.6 (48.8, 64.4) 95.5  
(85.8, 105.1) 
 
  10 42.5 (26.6, 58.4)   
1000 to 3000 206 5 69.0 (63.1, 74.9) 105.8 
(98.3, 113.4) 
 
  10 57.1 (48.1, 66.1)   
> 3000  112 5  64.0 (55.4, 72.6) 116.6 
(107.3, 125.9) 
 
  10 52.6 (39.9, 65.4)   
#Mean survival because most of the median survival was not calculated   
** Probability of survival cannot calculate from  the survival table because  no patients survived 10 years 
 
a. Occupational type                                   b. Monthly income             
 
Figure 4.11 The Kaplan Meier curve of AIDS patients on HAART to death 
stratified by significant socio-demographic variables 36 
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Table 4.13 The 5 and 10-year survival from Kaplan Meier estimates in AIDS 
patients on HAART to death stratified by laboratory variables 19 
Variable n Survival 
(years) 
% Survival  
(95% CI) 
Mean Survival  
 (95% CI)  
in months# 
Log rank 
P value 
CD4 at start HAART (cell/µL)                                                                                   0.753 
< 200  399 5 75.9 (71.0, 80.8) 105.7 (99.9, 111.5)  
  10 70.8 (63.2, 78.4)   
≥ 200  75 5 77.5 (65.3, 89.7) 104.4 (91.5, 117.4)  
  10 69.5 (54.4, 84.6)   
Hb at start HAART (g/dl)                                                                                            0.036 
< 12  211 5 71.9 (64.8, 79.0) 91.7 (84.6, 98.8)  
  10 **   
≥ 12  263 5 79.8 (73.7,85.9) 109.6(102.9, 116.2)  
  10 71.5 (62.1, 80.9)   
TLC at start HAART                                                                                                   0.930 
Normal 247 5 77.9 (72.0, 83.8) 105.9 (98.8, 113.1)  
  10 69.9 (60.9, 78.9)   
Abnormal 227 5 73.8 (66.5, 81.1) 105.3 (97.8, 112.9)  
  10 **   
CD4 recovers                                                                                                            < 0.001   
No 200 5 50.3 (39.7, 60.9) 74.4 (63.5, 85.4)  
  10 **   
Stable 56 5 84.6 (72.3, 96.9) 114.9(102.8, 127.0)  
  10 **   
Yes 218 5 91.1 (86.6, 95.6) 124.4(119.4, 129.4)  
  10 87.2 (79.8, 94.6)   
Hb recovers                                                                                                               < 0.001   
No 197 5 52.4 (42.5, 62.3) 73.9 (63.1, 84.9)  
  10 **   
Stable 146 5 93.8 (89.3, 98.3) 126.1(120.5, 131.6)  
  10 **   
Yes 131 5 85.2 (77.8, 92.6) 113.8(106.6, 121.0)  
  10 **   
TLC  recovers                                                                                                           < 0.001   
No 195 5 52.2 (41.6, 62.8) 76.4 (65.3, 87.4)  
  10 **   
Stable 153 5 89.8 (84.5, 95.1) 121.4(114.9, 127.8)  
  10 **   
Yes 126 5 86.5 (79.1, 93.9) 115.3(108.2, 122.3)  
  10 **   
Note: - CD4 recovers from CD4 < 200 cell/µL to CD4 ≥ 200 cells/µL 
          -  Hb = hemoglobin,  recovers from Hb < 12 g/dl to Hb  ≥ 12 g/dl 
          -  TLC = total lymphocyte count, recovers from TLC < 1,200 cell/µL   to TLC  ≥ 1,200 cells/µL          
#Mean survival because most of the median survival was not calculated   
** Probability of survival cannot be calculated from the survival table because no patients survived for 10 years 
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a. Hb at start HAART                                  b. CD4 recovers 
 
 
        c.  Hb recovers                                              d. TLC recovers             
 
 
Figure 4.12 The Kaplan Meier curve of AIDS patients on HAART to death 
stratified by significant laboratory variables 37 
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Table 4.14 The 5 and 10-year survival from Kaplan Meier estimates in AIDS 
patients on HAART stratified by significant clinical and HAART 
variables 20 
Variable n Survival 
(years) 
% Survival 
 (95% CI) 
Mean Survival  
 (95% CI)  
in months# 
Log rank 
P value 
Number of OI     0.043 
0 103 5 79.1 (70.1, 88.1) 98.3 (89.2, 107.4)  
  10 **   
1 201 5 79.5 (73.0, 86.0) 110.2 
(102.8, 117.5) 
 
  10 **   
2 120 5 74.0 (64.2, 83.8) 97.7 (87.1, 108.3)  
  10 **   
≥ 3 50 5 61.6 (41.4, 81.8) 82.2 (64.7, 99.8)  
  10 **   
Achieve VL ≤ 50 copies/ml                                                                                 < 0.001 
No 140 5 29.1 (9.5, 48.7) 52.3 (38.2, 66.5)  
  10 **   
Yes 334 5 87.1 (83.0, 91.2) 118.8  
(113.9, 123.7) 
 
  10 80.5 (73.1, 87.9)   
#Mean survival because most of the median survival was not calculated   
** Probability of survival cannot calculate from  the survival table because  no patients survived 10 years 
 
 
 
       a.  Number of OI                                             b. Achieve VL ≤ 50 copies/ml             
 
 
Figure 4.13 The Kaplan Meier curve of AIDS patients on HAART to death 
stratified by clinical and HAART variables 38 
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There were nine variables that met the criteria log rank p-value less than 0.25. It were 
occupational type, education level, monthly income, hemoglobin at start HAART, CD4 
recovers, hemoglobin recovers, total lymphocyte count recovers, number of 
opportunistic infections and achieve viral load less than 50 copies/ml. All these 
variables were included in the univariate Cox regression analysis. All possible two way 
interactions were checked and no significant interaction was found.  
 
The proportional hazard assumption was checked by two methods. First with the log 
minus log estimated survivor function plotted against survival showed the parallel line. 
Second with the correlation test between residuals and survival time showed correlation 
very small (less than 0.3). The variable education level did not show parallel lines which 
indicated a proportional hazard assumption violation, other variables had parallel line. 
The Log –Minus-Log plots of the variables are displayed in Figure 4.14 and Figure 
4.15.  
 
There were eight variables which fulfilled the proportional hazard assumption and were 
included in multivariate Cox regression analysis. The length of time taken to recover 
CD4 (p-value = 0.053), hemoglobin (p-value = 0.129) and total lymphocyte count (p-
value = 0.269) were not significant in this analysis. The univariate Cox regression 
analysis of significant variables as predictors of death in AIDS patients on HAART is 
presented in Table 4.15.  
  
Three significant variables in multivariate Cox regression analysis (Occupational type, 
CD4 recovers and achieve viral load less than 50 copies/ml). Table 4.16 displays the 
multivariate Cox regression analysis of death predictors in AIDS patients on HAART. 
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Significant independent predictors of death in AIDS patients on HAART were 
unemployed patients, those who’s CD4 never recovered to more than 200 cells/µL and 
those who were unable to achieve viral load less than 50 copies/ml. These patients were 
more likely to die compared to their reference categories. 
 
 
       a.   Occupational type                                    b. Monthly income 
 
       c.   Number of OI                                            d. Achieve VL ≤ 50 copies/ml 
 
 
Figure 4.14 The Log-Minus-Log plotted against survival time of AIDS patients on 
HAART stratified by socio-demographic, clinical and HAART 
variables 39 
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       a.   Hb at start HAART                                b. CD4 recovers 
 
       c.   Hb recovers                                              d. TLC recovers 
 
 
 
Figure 4.15 The Log-Minus-Log plotted against survival time of AIDS patients on 
HAART to death stratified by laboratory variables 40 
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Table 4.15 Univariate predictors of death in AIDS patients on HAART 21 
Variable Crude Hazard Ratio 95% CI 
Occupational type   
Professional and non manual workers 1.0  
Manual workers 1.06  0.61, 1.86 
Unemployed 2.14  1.37, 3.35 
   
Monthly income (RM)   
> 3000 1.0  
1000 to 3000 1.44  0.79, 2.64 
< 1000 2.14  1.16, 3.95 
   
Hb at start ART (g/dl)   
≥ 12 1.0  
< 12 1.53  1.02, 2.29 
   
CD4 recovers    
Yes 1.0  
Stable 1.76  0.73, 4.24 
No  7.54  4.39, 12.92 
   
Hb recovers    
Yes 1.0  
Stable 0.54  0.24, 1.22 
No  4.99  2.79, 8.89 
   
TLC recovers   
Yes 1.0  
Stable 0.95  0.45, 1.99 
No 5.14  2.77, 9.54 
   
Number of OI   
0 1.0  
1 0.96  0.55, 1.67 
2 1.43  0.79, 2.59 
≥ 3 2.15  1.08, 4.31 
   
Achieve VL ≤ 50 copies   
Yes 1.0  
No 8.08  5.21, 12.53 
Note: - CD4 recovers from CD4 < 200 cell/µL to CD4 ≥ 200 cell/µL 
          - Hb = haemoglobin,  recovers from Hb < 12 g/dl to Hb  ≥ 12 g/dl 
          - TLC = total lymphocyte count, recovers from TLC < 1,200 cell/µL  to ≥ 1,200 cell/µL          
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Table 4.16 Multivariate predictors of death in AIDS patients on HAART 22 
Variable Crude  
Hazard Ratio 
95% CI Adjusted 
 Hazard Ratio 
95% CI 
Occupational type     
Professional and non 
manual worker 
 
1.0 
  
1.0 
 
Manual workers 1.06  0.61, 1.86 0.77  0.44, 1.36 
Unemployed 2.14  1.16, 3.95 1.64  1.04, 2.57 
     
CD4 recovers     
Yes 1.0  1.0  
Stable 1.76  0.73, 4.24 1.56  0.65, 3.79 
No 7.54  4.39, 2.92 4.03  2.21, 7.35 
     
Achieve VL ≤ 50 copies     
Yes 1.0  1.0  
No 8.08  5.21, 2.53 4.39 2.69, 7.16 
Note: - CD4 recovers from CD4 < 200 cell/µL to CD4 ≥ 200 cell/µL 
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4.8 Progression to death in AIDS patients not on anti-retroviral 
therapy 
 
Survival probabilities of AIDS patients not on ART stratified by significant socio-
demographic, laboratory and clinical variables 
 
 
Table 4.17 shows the 5 and 10-year survival for AIDS patients not on anti-retroviral 
therapy stratified by significant socio-demographic characteristic variables. The 
significant variables were age groups (p-value = 0.030) and ethnicity (p-value = 0.003). 
The Kaplan Meier curves for AIDS patients not receiving anti-retroviral therapy 
progression to death stratified by significant socio-demographic characteristic variables 
are displayed in Figure 4.16.  
 
Table 4.18 shows the 5 and 10-year survival for AIDS patients not on anti-retroviral 
therapy stratified by significant laboratory and clinical variables. The significant 
variables were baseline CD4 (p-value < 0.001), baseline viral load (p-value = 0.009), 
WHO clinical stage (p-value < 0.001) and number of opportunistic infections (p-value = 
0.023). The Kaplan Meier curves for AIDS patients not on anti-retroviral therapy 
stratified by significant laboratory and clinical variables are displayed in Figure 4.17. 
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Table 4.17 The 5 and 10-year survival of Kaplan Meier estimates in AIDS patients 
not on anti-retroviral therapy stratified by significant socio-
demographic variables 23 
Variable N Survival 
(years) 
% Survival 
(95% CI) 
Median Survival 
(95% CI) 
in months 
Log rank 
P value 
Age Groups (years)                                                                                               0.030 
20 – 29  114 5 27.0 (18.0, 36.0) 20.6 (13.9, 27.3)  
  10 20.0 (11.6, 28.4)   
30 – 39 137 5 22.8 (14.6, 31.0) 14.5 (9.3, 19.8)  
  10 **   
40 – 49 52 5 23.1 (6.6, 39.6) 13.2 (0.1, 29.6)  
  10 **   
50 – 59 20 5 ** 5.8 (0.1, 14.1)  
  10 **   
≥ 60 7 5 ** 2.9 (0.1, 8.0)  
  10 **   
Ethnicity     0.003 
Malay   91 5 27.8 (17.0, 38.6) 23.2 (8.7, 37.7)  
  10 **   
Chinese 163 5 14.8 (8.7, 20.9) 12.8 (9.1, 16.5)  
  10 11.6 (5.9, 17.3)   
Indian 53 5 31.5 (17.4, 45.6) 14.1 (7.9, 20.3)  
  10 19.7 (3.8, 35.6)   
Others 23 5 ** (not calculated)*  
  10 **   
*The median survival was not calculated because the cumulative proportion surviving was still high (> 50%)  
** Probability of survival cannot be calculated from the survival table because no patients  reached 10-year survival 
 
 
 
a. Age group                                                 b. Ethnicity 
 
Figure 4.16 The Kaplan Meier curve of AIDS patients not on anti-retroviral 
therapy stratified by significant socio-demographic variables 41 
 
4 Results  
 
 
161 
 
Table 4.18 The 5 and 10-year survival of Kaplan Meier estimates in AIDS patients 
not on anti-retroviral therapy stratified by significant laboratory and 
clinical variables 24 
Variable N Survival 
(years) 
% Survival 
(95% CI) 
Median Survival 
(95% CI) 
in months 
Log rank 
P value 
Baseline CD4 (cell/µL)   < 0.001 
< 200  231  5 19.5 (13.4, 25.6) 10.1 (7.4, 12.8)  
  10 14.8 (8.1, 21.5)   
≥ 200   99 5 32.5 (21.9, 43.1) 41.6 (32.6, 50.5)  
  10 25.7 (15.3, 36.1)   
Baseline VL (copies/ml)      0.009 
< 100000   129 5 26.1 (17.7, 34.5) 25.8 (11.4, 40.2)  
  10 19.2 (11.0, 27.4)   
≥ 100000    201 5 22.6 (15.7, 29.5)  11.5 (8.5, 14.5)  
  10 18.9 (11.5, 26.3)   
WHO clinical stage                                                                                            < 0.001 
Stage 3 105 5 34.5 (23.7, 45.3) 41.6 (29.9, 53.4)  
  10 27.5 (16.7, 38.3)   
Stage 4 225 5 19.2 (13.3, 25.1) 9.4 (6.9, 11.8)  
  10 13.6 (7.1, 20.1)   
Number of OI        0.023 
0 45 5 ** 21.4 (9.2, 33.6)  
  10 **   
1 124 5 29.1 (19.9, 38.3) 21.0 (14.3, 27.7)  
  10 **   
2   98 5 25.5 (14.9, 36.1) 12.5 (4.5, 20.4)  
  10 14.9 (3.3, 26.5)   
≥ 3   63 5 16.4 (5.6, 27.2) 10.1 (5.1, 15.1)  
  10 **   
** Probability of survival cannot be calculated from the survival table because no patients attained 10-year survival 
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a. Baseline CD4                                           b. Baseline VL 
 
      c.   Baseline CD4                                          d. Baseline viral load 
 
       e.  Number of OI 
Figure 4.17 The Kaplan Meier curve of AIDS patients not on anti-retroviral 
therapy stratified by significant laboratory and clinical variables 42 
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There were eleven variables with log rank p-value less than 0.25. There were age 
groups, gender, ethnicity, marital status, education level, monthly income, baseline 
CD4, viral load, total lymphocyte count, WHO clinical stage and number of 
opportunistic infection. These variables included in the univariate Cox regression 
analysis. All possible interactions between the variables in the main effect model were 
checked with no significant interaction found. The proportional hazards assumption was 
checked using the Log –Minus-Log plots which showed parallel lines indicating that the 
proportional hazard assumption was fulfilled (Figure 4.18). There were six variables 
(gender, marital status, education level, monthly income, baseline total lymphocyte 
count and number of opportunistic infection) which did not show parallel lines.  
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a. Age group                                         b. Ethnicity 
 
      c.   Baseline CD4                                    d. Baseline VL 
 
d. WHO clinical stage 
 
Figure 4.18 The Log-Minus-Log plotted against survival time of AIDS patients not 
on anti-retroviral therapy stratified by socio-demographic, laboratory 
and clinical variables 43 
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 The five variables which fulfilled the proportional hazard assumption were included in 
the multivariate Cox regression analysis. There were age groups, ethnicity, baseline 
CD4, baseline viral load and WHO clinical stage. The univariate analysis of predictors 
AIDS patients not on anti-retroviral therapy progression to death is presented in Table 
4.19. In the multivariate Cox regression analysis, only three variables were significant 
(ethnicity, baseline viral load and WHO clinical stage). Table 4.20 shows the 
multivariate Cox regression analysis of predictors AIDS patients not on anti-retroviral 
therapy progression to death. Chinese patients, those with baseline viral load more than 
100,000 copies/ml and in WHO clinical stage 4 were more likely to die compared to 
their reference categories, the others ethnic group had a significantly lower risk of death 
(HR 0.35; 95% CI 0.15, 0.82) compared to Malays. 
Table 4.19 Univariate predictors of death in AIDS patients not on anti-retroviral 
therapy 25 
Variable Crude Hazard Ratio 95% CI 
Age groups   
20 – 29 1.0  
30 – 39 1.20 0.89, 1.61 
40 – 49 1.17 0.79, 1.74 
50 – 59 2.41 1.40, 4.16 
≥ 60 1.07 0.43, 2.63 
   
Ethnicity   
Malay 1.0  
Chinese 1.50 1.11, 2.04 
Indian 1.16 0.77, 1.75 
Others 0.42 0.18, 0.96 
   
Baseline CD4 (cell/µL)     
≥ 200            1.0  
< 200           2.13 1.59, 2.87 
   
Baseline VL (copies/ml)    
< 100000  1.0  
≥ 100000  1.42 1.09, 1.85 
   
WHO clinical stage   
Stage 3 1.0  
Stage 4 2.39 1.77, 3.22 
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Table 4.20 Multivariate predictors of death in AIDS patients not on anti-retroviral 
therapy 26 
Variable Crude  
Hazard Ratio 
95% CI Adjusted 
 Hazard Ratio 
95% CI 
Ethnicity     
Malay 1.0  1.0  
Chinese 1.50 1.11, 2.04 1.57  1.15, 2.15 
Indian 1.16 0.77, 1.75 1.12  0.74, 1.69 
Others 0.42 0.18, 0.96 0.35  0.15, 0.82 
     
Baseline VL (copies/ml)      
< 100000 1.0  1.0  
≥ 100000 1.42 1.09, 1.85 1.35 1.02, 1.79 
     
WHO clinical stage     
Stage 3 1.0  1.0  
Stage 4 2.39 1.77, 3.22 2.25  1.65, 3.06 
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4.9 AIDS patients on HAART achieving viral load less than 50 
copies/ml 
 
Survival probabilities of AIDS patients on HAART to achieve viral load less than 
50 copies/ml stratified by significant socio-demographic characteristic and 
HAART variables 
 
Table 4.21 displays the Kaplan Meier estimates to achieve viral load less than 50 
copies/ml stratified by significant variables of socio-demographic characteristic, 
laboratory and clinical condition. The significant variables were marital status (p-value 
= 0.018), education level (p-value = 0.016), monthly income (p-value = 0.012), total 
lymphocyte count at start HAART (p-value = 0.043), exposure risk (p-value = 0.007) 
and WHO clinical stage (p-value = 0.017). The Kaplan Meier curves for AIDS patients 
on HAART to achieve viral load less than 50 copies/ml stratified by significant socio-
demographic characteristic, laboratory and clinical variables are presented in Figure 
4.19. 
 
Table 4.22 shows the Kaplan Meier estimates to achieve viral load less than 50 
copies/ml stratified by significant variables of HAART. The significant variables were 
the initial combination of HAART (p-value = 0.010), needing second line of HAART 
(p-value < 0.001) and HAART at the end of the study (p-value = 0.009). The Kaplan 
Meier curves for AIDS patients on HAART achieving viral load less than 50 copies/ml 
stratified by significant HAART variables are presented in Figure 4.20. 
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Table 4.21 Kaplan Meier estimates to achieve viral load less than 50 copies/ml 
stratified by significant of socio-demographic, laboratory and clinical 
variables 27 
Variable n Median Survival time 
 (95% CI) in months 
Log rank 
P value 
Marital status   0.018 
Single 141 4.9 (4.0, 5.8)  
Married 152 5.3 (4.8, 5.7)  
Others   41 8.7 (4.3, 13.0)  
    
Educational level   0.016 
≤ Secondary  224 5.4 (4.8, 5.9)  
≥ Tertiary  110 4.8 (3.9, 5.6)  
    
Monthly income (RM)    0.012 
< 1000 99 6.0 (4.7, 7.3)  
1000 to 3000 151 5.4 (4.8, 5.9)  
> 3000  84 4.2 (3.3, 5.1)  
    
TLC at start HAART   0.043 
Normal 193 4.8 (4.2, 5.4)  
Abnormal 141 6.0 (5.0, 7.0)  
    
Exposure Risk    0.007 
Heterosexual 249 5.4 (4.8, 5.9)  
Homosexual   51 3.9 (2.6, 5.1)  
IDU 29 8.4 (3.7, 13.2)  
Others 5 5.1 (2.6, 7.6)  
    
WHO clinical stage    0.017 
Stage 3   117 4.4 (3.6, 5.2)  
Stage 4   217 5.5 (4.8, 6.2)  
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a. Marital status                                           b. Education level 
 
       c.   Monthly income                                     d. Lymphocyte at start HAART 
 
       e. Exposure risk                                           f. WHO clinical stage 
Figure 4.19 The Kaplan Meier curve of AIDS patients on HAART to achieve viral 
load less than 50 copies/ml stratified by significant socio-demographic, 
laboratory and clinical variables 44 
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Table 4.22 Kaplan Meier to achieve viral load less than 50 copies/ml stratified by 
significant of HAART variables 28 
Variable n Median Survival time 
 (95% CI) in months 
Log rank 
P value 
Initial combination of HAART   0.010 
2 NRTI+ EFV 276 4.9 (4.5, 5.3)  
2 NRTI+ PI 17 7.9 (4.2, 11.7)  
2 NRTI+ NVP 41 6.6 (4.9, 8.2)  
    
Need second line of HAART   < 0.001 
No 275 4.8 (4.4, 5.2)  
Yes 42 10.4 (7.2, 13.6)  
    
HAART at the end of study    0.009 
HAART without PI 302 5.0 (4.7, 5.4)  
HAART with PI 32 9.5 (7.2, 11.8)  
 
       a.   Initial combination of HAART             b.  Need second line of HAART 
 
       c. HAART at the end of study 
 
Figure 4.20 The Kaplan Meier curve of AIDS patients on HAART to achieve viral 
load less than 50 copies/ml stratified by significant HAART variables 
45 
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There were sixteen variables with log rank p-values of less than 0.25. It were ethnicity, 
marital status, education level, occupational type and monthly income, CD4, viral load, 
liver function test and total lymphocyte count at start HAART, hemoglobin recovers, 
total lymphocyte count recovers, exposure risk, WHO clinical stage, initial 
combinations of HAART, need a second line of HAART and HAART at the end of the 
study also included. These variables were included in the univariate Cox regression 
analysis. Six variables were not significant in univariate analysis. It was occupational 
type, (CD4, viral load and liver function test at start HAART), hemoglobin recovers and 
total lymphocyte count recovers. All possible interactions between the variables in the 
main effect model were checked and no significant interaction was found.  
 
The proportional hazards assumptions were checked. Log minus log plots showed 
parallel lines which indicated the proportional hazard assumption was fulfilled (Figure 
4.21). There were four variables (ethnicity, monthly income, total lymphocyte count at 
start HAART and WHO clinical stage) which did show parallel lines which indicated   a 
proportional hazard assumption violation. The univariate Cox regression analysis of 
predictors to achieve viral load less than 50 copies/ml in AIDS patients on HAART are 
displayed in Table 4.23. 
 
Total six variables included in multivariate Cox regression analysis, but three  variables 
were significant. Table 4.24 displays the multivariate Cox regression analysis of 
predictors to achieve viral load less than 50 copies/ml in AIDS patients on HAART. In 
this model, higher hazard ratio is better because achieving viral load less than 50 copies 
is a measure of the effectiveness of HAART. Patients who started HAART with 
2NRTI+NVP and who did not need a second line of HAART were more likely to 
achieve viral load less than 50 copies/ml compared to their reference categories. 
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Patients who were infected through the injecting drug user were less likely to achieve 
viral load less than 50 copies/ml compared to the heterosexual route  
 
Table 4.23 Univariate predictors to achieve viral load less than 50 copies/ml in 
AIDS patients on HAART 29 
Variable Crude Hazard Ratio 95% CI 
Marital status   
Single 1.0  
Married 0.89 0.71, 1.13 
Others 0.60 0.42, 0.86 
   
Education level   
≤ Secondary 1.0   
≥ Tertiary 1.32  1.05, 1.67 
   
Exposure Risk   
Heterosexual 1.0  
Homosexual 1.33 0.98, 1.79 
IDU 0.58 0.39, 0.87 
Others 1.19 0.49, 2.89 
   
Initial combination of HAART   
2 NRTI+ NVP 1.0  
2NRTI +PI   1.04 0.58, 1.84 
2 NRTI+ EFV 1.57 1.12, 2.20 
   
Need second line of HAART   
Yes 1.0  
No 2.29 1.70, 3.09 
   
HAART at the end of study   
HAART with PI 1.0  
HAART without PI 1.62 1.12, 2.34 
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a. Marital status                                             b. Education level 
 
       c.   Exposure risk                                              d. Initial combinations of HAART 
 
       e. Need second line of HAART                     f. HAART at the end of study            
Figure 4.21 The Log-Minus-Log plotted against survival time of AIDS patients on 
HAART to achieve viral load less than 50 copies/ml 46 
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Table 4.24 Multivariate predictors to achieve viral load less than 50 copies/ml in 
AIDS patients on HAART 30 
Variable Crude  
Hazard Ratio 
95% CI Adjusted 
 Hazard Ratio 
95% CI 
Initial combination of 
HAART 
    
2 NRTI+ NVP 1.0  1.0  
2NRTI +PI   1.04 0.58, 1.84 1.03 0.58, 1.83 
2 NRTI+ EFV 1.57 1.12, 2.20 1.56 1.10, 2.20 
     
Need second line of 
HAART 
    
Yes 1.0  1.0  
No 2.29 1.70, 3.09 2.59  1.59, 4.21  
     
Exposure Risk     
Heterosexual 1.0  1.0  
Homosexual 1.33 0.98, 1.79 1.29 0.95, 1.76 
IDU 0.58 0.39, 0.87 0.54 0.35, 0.80 
Others 1.19 0.49, 2.89 0.99 0.41, 2.39 
 
4.10  Summary  
 
Factors identified as predictors of death in all AIDS patients were unemployed patients, 
manual workers, those who had three or more opportunistic infections and who did not 
receive anti-retroviral therapy. Predictors of death in AIDS patients on HAART were 
unemployment, those whose CD4 did not recover to more than 200 cells/µL and those 
who were unable to achieve viral load less than 50 copies/ml. Predictors of death in 
AIDS patients not on anti-retroviral therapy were Chinese ethnicity, those with baseline 
viral load more than 100,000 copies/ml and who stay in WHO clinical stage 4. Finally, 
predictors to achieve viral load less than 50 copies/ml were patients who started 
HAART with 2NRTI+EFV and who did not need a second line of HAART, patients 
who were infected through the injecting drug user were less likely to achieve viral load 
less than 50 copies/ml compared to the heterosexual route.  
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CHAPTER 5 
 
DISCUSSION 
  
5.1   Introduction 
 
 
This chapter presents the results of discussion. Section 5.1 is the introduction. Section 
5.2 discusses the profile of study subject based on socio-demographic characteristic, 
laboratory, clinical and anti-retroviral therapy and comparison to other studies. Section 
5.3 discusses the median survival time from AIDS progression to death. This continues 
in Section 5.4 which discusses the predictors of death in all AIDS patients, AIDS 
patients on HAART and AIDS patients not on anti-retroviral therapy. Section 5.5 
discusses the time and predictors to achieve viral load less than 50 copies/ml in AIDS 
patients on HAART. Section 5.6 revealed the strengths and limitations of the study and 
Section 5.7 is a summary of the chapter 
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5.2  Profile of the study subject 
 
5.2.1  Socio-demographic 
 
 
Generally, the most productive age is affected by HIV infection. Approximately 76.1 
per cent of the reported HIV/AIDS cases in Malaysia occur in the age group of  between 
20–39 years, the younger and potentially most productive segment of the nation’s 
population (MOH, 2012). This is consistent with the results of this study in which 73.3 
per cent of HIV patients are between the age group of 20-39 years and the median age 
were 33.7 years (IQR 12.0) which is similar to others studes in Asia (Thailand and 
Taiwan) (Fregonese, et al., 2012; Hung, et al., 2006). However, this study shows a 
slightly younger age group compared to the developed countries (Fielding, et al., 2008; 
Hulgan et al., 2007). 
 
This study also shows that the majority of the patients are male, which reflects the fact 
that HIV-infected patients in Malaysia are predominantly male (MOH, 2012). This is in 
agreement with other studies in Malaysia and Hong Kong (Lee et al., 2011; 
Vicknasingam, Narayanan, & Navaratnam, 2009). This study also reveals a higher male 
to female ratio of 4.5 : 1. This is similar to the HIV population in Malaysia with the 
ratio of 4 : 1 (MOH, 2012). The HIV infected patient ratio  in the whole of Malaysia is, 
higher than the ratio of India which is 2.6 : 1 (Kumarasamy et al., 2003).  
 
The majority of HIV-infected patients in the University of Malaya Medical Centre are 
Chinese followed by Malays, Indians and other ethnic groups.  However, it is different 
from the general HIV population in Malaysia, where the Malays predominates other 
ethnic groups (UNGASS, 2010). This could largely be due to the UMMC’s status as a 
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tertiary hospital where cases are being referred from the private and government clinics 
from the neighboring cities of Kuala Lumpur and Petaling Jaya where  the majority of 
the population are Chinese (Department of Statistic, 2010). This is consistent with 
previous reports in Hong Kong (Lee, et al., 2011) and Singapore (Wong, Lye, Lee, & 
Leo, 2011) 
 
There is not much difference in percentage between single patients and married 
patients. Among the AIDS patients who receive HAART, there are more married 
patients than singles. This is similar to a  study in South Africa (Shisana et al., 2004) 
and in India where married patients are more than the singles (Vallabhaneni, Chandy, 
Heylen, & Ekstrand, 2012). The discrepancy may be caused by married patients 
receiving more support and care from their spouses or families thus avoiding delays in 
seeking treatment. AIDS is a chronic disease. Partners, families and friends are an 
important source of support for AIDS patients and it correlates with a reduction in 
stress, hopelessness and depression (Shanthi, Damodharan, & Priya, 2007). 
 
Socioeconomic status, whether assessed by income, education, or occupation, is linked 
to a wide range of health problems, including HIV/AIDS. Lower socioeconomic status 
is associated with higher mortality. In this study the majority of patients had primary 
and secondary education. The rest of them work as professional and non manual 
workers and earned between RM 1000 to 3000 per month. It is similar to studies in 
India and Africa (Rougemont, Stoll, Elia, & Ngang, 2009; Vallabhaneni, et al., 2012) 
but Spain and Barcelona report lower education levels than this study (Jarrin, et al., 
2007; Lima et al., 2006). 
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Unemployment in HIV-infected patients is likely to be the result of a debilitating effect 
of HIV infection on workforce participation (Dray-Spira, Gueguen, Ravaud, & Lert, 
2007). This is reflected as socio-demographic or behavioural disadvantages in the 
workforce participation (i.e., female gender, advanced age, low educational level, 
manual occupation, foreign nativity, injection drug use) existing prior to HIV infection 
(Dray-Spira, et al., 2007). Developed country studies reported the unemployment rate 
among HIV-infected patients as ranging from 45 to 65 per cent (Dray-Spira, Lert, 
Marimoutou, Bouhnik, & Obadia, 2003; Rabkin, McElhiney, Ferrando, Van Gorp, & 
Lin, 2004). In this study, the proportion of unemployed HIV-infected patients were 
lower than the Nigerian study (28.5 compared to 34.0 per cent) (DeSilva, et al., 2009).  
 
As far as monthly income is concerned, these findings cannot be directly compared with 
the India and Cameroon studies due to differences in categories used in India 
(Vallabhaneni, et al., 2012) and in Cameroon (Rougemont, et al., 2009). The profile of 
socio-demographic of AIDS patients receiving anti-retroviral therapy is similar to the 
entire sample of HIV-infected patients except marital status as married patients receive 
more anti-retroviral therapy compared to single patients. This is similar to the India 
study in that the majority of married patient adhered to anti-retroviral therapy because 
of better support from family compared to singles (Sarna et al., 2008).   
 
The comparison of socio-demographic characteristic findings and other studies are 
summarized in Table 5.1  
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Table 5.1 Comparison findings of this study and other studies 31 
Findings of this study  Findings of other studies 
Median age: 
HIV-infected patients 33.7 years (IQR 12.0)  
AIDS patients was 34.1 years (IQR 12.7) 
 
 
Median age: 
Thailand:  33 years (28-38) 
Taiwan : 34 years (15-83) 
North Carolina : 38 years (18-82) 
South Africa: 41years (35-46) 
Gender: 
HIV-infected patients: male 81.8% 
AIDS patients: male 85.2 % 
 
Hong Kong : male HIV patients 80.6 % 
India : male HIV patients 72.9 % 
 
Ethnicity: 
HIV-infected patients: Chinese 61.2 % 
AIDS patients : Chinese 62.7 % 
 
 
Hong Kong : Chinese HIV patients 77.7 
% 
Singapore : Chinese HIV patients 88.0% 
 
Marital status: 
HIV-infected patients: 45.2 % 
AIDS patients : 45.3 % 
 
 
South Africa: Unmarried HIV patients 
59.2 % 
India : married HIV patients 70.0 % 
 
Education level: 
Primary and secondary education: 73.5% 
 
 
India : Primary and secondary : 72 %  
Cameroon : Primary and secondary   
                    education: 79% 
Spain : Primary education : 55.8%   
Barcelona : Deprived neighborhood and  
                    low education: 32.4%  
Occupational type: 
Unemployment : 28.5% 
 
Nigeria : Unemployment : 34%   
 
Monthly income: 
RM 1000 to 3000 : 42.5% 
 
Cameroon :  < USD 50 : 46 %  
India :  < 5000 Rs : 48%  
 
5.2.2  Laboratory results 
 
The level of CD4 cell count is related to the immune status and indicates the stage of 
HIV infection, guides treatment, and predicts the progression of HIV-infected patients. 
This study shows more than 60 per cent of HIV-infected patients presented with 
baseline CD4 of less than 200 cells/µL and more than 82.7 per cent of AIDS patients 
started anti-retroviral therapy with CD4 less than 200 cells/µL. CD4 less than 200 
cells/µL in HIV-infected patients and AIDS patients both are high. It is not difficult to 
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explain the high proportion of AIDS patients starting anti-retroviral therapy with very 
low CD4 counts as this is a criteria for starting therapy but the very high proportion of 
HIV patients presenting with low CD4 counts is probably because HIV infection in the 
early stages is asymptomatic. People may be seeking care because they had symptoms 
due to low immunity or opportunistic infection. Elsewhere in Nigeria a similar picture 
emerges where 81.4 per cent of patients had baseline CD4 less than 200  cells/µL  
(Agaba, et al., 2011). Another study in the US showed  64 per cent of HAART initiation 
with CD4 less than 200 cells/µL (Fox et al., 2010). The initial presentation of HIV-
infected patients to medical care continues to occur in an advanced stage of immune 
suppression (Ndiaye et al., 2011). In the medical literature, there are multiple definitions 
of delayed HIV diagnosis or late presentation. For example the United Kingdom 
Collaborative HIV Cohort (UK CHIC) Steering Committee defines presentation at a 
stage when there is a substantial risk of death (CD4 counts less than 200 cells/µL or 
clinically-defined AIDS) as presenting with advanced HIV disease. The presentation 
with a CD4 less than 350 cells/µL, resulting in a delay in treatment initiation is defined 
as a late presentation (The UK Collaborative HIV Cohort Steering Committee, 2010). 
The consequences of a late presentation are unknown risk of transmission and a poor 
prognosis or a higher level and cost of use of medical resources (Toure et al., 2012). 
Future research on this is needed especially in Malaysia. 
 
On the other hand, baseline viral load more than 100,000 copies/ml occur in 51.1 per 
cent of HIV-infected patients and in 64.8 per cent of AIDS patients when they start 
HAART. The CASCADE collaboration from 20 cohorts in Europe and Australia has 
shown this correlation between lower CD4 and a higher viral load (Phillips & Pezzotti, 
2004). CD4 count has an inverse relationship with viral load. When CD4 drops, viral 
load increases (Phillips & Pezzotti, 2004). CD4 and viral load are the two most 
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commonly used prognostic indicators of the clinical progression of HIV and as a 
measure of anti-retroviral treatment response (Gilks et al., 2006; Hammer, et al., 2008; 
Thompson, et al., 2010). The viral load measurement has limitations and is not done 
routinely in all hospitals because of poor access to viral load facilities. Commonly 
patients who are initiated with HAART are sent for viral load measurements especially 
in developing countries. In this study more than 50 per cent of patients come in 
advanced stages with low CD4 and high viral load. 
 
Based on the Pearson's correlation, there was a significant and positive correlation 
between the hemoglobin level and their CD4 counts (Obirikorang & Yeboah, 2009). 
Measurement of hemoglobin levels is simple. It would be difficult to use this simple test 
as a replacement for CD4 count as the correlation between hemoglobin and CD4 is low 
but where flow cytometry is not available, this does give a rough indication of the 
immune status of the patient. Flow cytometry is an expensive technique which is 
unavailable in many developing countries (Obirikorang & Yeboah, 2009). 
 
Furthermore, in resource limited settings total lymphocyte count appear useful in 
predicting who would be eligible for anti-retroviral therapy based on CD4 count criteria 
(Moore et al., 2007). A cut-off total lymphocyte count (TLC) 1,200 cells/µL is 
considered to be normal value according to the WHO criteria and this is comparable 
with a CD4 count of 200 cells/µL (WHO, 2004). According to this study, 62.7 per cent 
of HIV-infected patients and 57.4 per cent of AIDS patients had normal baseline total 
lymphocyte count and at HAART initiation. The Johns Hopkins HIV observational 
cohort study in USA found that total lymphocyte count less than 1,200 cells/µL and 
hemoglobin less than 12 g/dl significantly predicted CD4 less than 200 cells/µL 
(Spacek, et al., 2003). Several studies revealed reasonably adequate sensitivity and 
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specificity to consider total lymphocyte count as a surrogate measure for CD4 (Alavi, 
Ahmadi, & Farhadi, 2009; Bedell et al., 2003; Jacobson et al., 2003). A study in Europe 
indicated that despite the minimal reliability of total lymphocyte count as a surrogate 
for CD4, total lymphocyte count is an important tool in the absence of expensive 
equipment especially in the developing countries to measure CD4 (Stebbing, et al., 
2005). The sensitivity and specificity of total lymphocyte count as a surrogate for CD4 
in Malaysia not clearly known. Further research needs to be done to evaluate how well 
the inexpensive total lymphocyte count functions as a surrogate marker to predict CD4 
count. 
 
Routine liver function tests (LFT) is important, because in HIV-infected patients there 
is frequent co-infection with the hepatitis C virus, especially where HIV infection is 
caused injecting drug use (Macias et al., 2003). Some anti-retroviral drugs are also 
associated with liver enzyme elevations (Bonacini, 2004) although in this study more 
than fifty per cent of patients had normal liver function test at baseline and at HAART 
initiation.  HIV-infected patients with poor immune status are at risk of infections and 
the liver function test is needed to detect any infection (Mata-Marin et al., 2009). In 
those taking anti-retroviral therapy, liver function tests help to assure that the treatment 
is working well and make sure that any unwanted side-effects do not develop. The liver 
plays a key role in breaking down and processing the medicines used to treat HIV and 
other infections (Jain, 2007; Mata-Marin, et al., 2009) 
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5.2.3  Clinical condition 
  
The scenario of exposure risk at the University of Malaya Medical Centre is different 
from the rest of the country.  Instead of intravenous drug usage being the main exposure 
risk as in the whole of Malaysia (70.6 per cent) (MOH, 2010),  the majority of patients 
contracted the infection through the heterosexual route (65.8 per cent). This seems to be 
congruent with findings worldwide where heterosexual transmission is the most 
common mode of transmission. The route of transmission as seen in the University of 
Malaya Medical Centre may be indicative of the future when Malaysia reaches the 
status of a developed nation where the HIV epidemic in Malaysia may no longer be a 
concentrated epidemic. This is cause for concern as heterosexual transmission as the 
most common route of HIV transmission in Malaysia is yet to be acknowledged 
officially. Furthermore, the comparison between sexual transmission route and injecting 
drug user has changed over the time in Malaysia among the HIV population. The ratio 
of sexual transmission compared to injecting drug user was 1 : 9 in 1990, 2 : 8 in 2000, 
3 : 6 in 2009, 5 : 5 in 2010 and 6 : 4 in 2011 (MOH, 2012). The implementation of harm 
reduction programmes since 2005 has been able to reduce the number of HIV infection 
through sharing needles (MOH, 2012). On the other hand, the ratio of sexual 
transmission compared to injecting drug use transmission in HIV-infected patients in 
the University of Malaya Medical Centre is 3 : 1. 
 
In this study, the proportion of AIDS patients in WHO clinical stage 3 and stage 4 was 
30.7 per cent and 69.3 per cent respectively. Patients in WHO stage 4 accounted for 
67.9 per cent of patients initiated on HAART. The findings from a study in Nigeria 
found 53.5 per cent of those initiating anti-retroviral therapy in stage 3 and 3.4 per cent 
in stage 4 (Odafe et al., 2012). In Ethiopia 54 per cent are in stage 3 and 16 per cent in 
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stage 4 (Alemu & Sebastian, 2010). The proportion of patients with stage 4 in this study 
was much higher than those reported in both those other studies. The reasons for 
advanced stage presentation or delay in seeking care is probably because HIV-infected 
patients with good immunity are asymptomatic, fear of diagnosis as well as treatment 
and other financial problem. Further studies are required to ascertain specific reasons 
for the high proportion of patients in WHO stage 4 in Malaysia 
 
HIV-infected patients show a substantial weight loss during the course of infection and 
thus poor nutritional status is considered an unfavourable prognostic factor of survival 
(Malvy, Thiebaut, Marimoutou, & Dabis, 2001). Body mass index (BMI) is commonly 
used to measure the nutritional status and long-term monitoring of this can predict  
disease progression (Langford, et al., 2007). The findings of this study are that 74.4 per 
cent of patients had a baseline body mass index more than 18.5 kg/m
2
 and 73.8 per cent 
had this at the start of HAART. There is a significant but low Pearson’s correlation 
between hemoglobin and body mass index. A body mass index of less than 18.5 kg/m2 
is strongly associated with increased risk of disease progression consistently and may 
prove to be a valuable indicator of the need for HAART (Langford, et al., 2007). 
 
From the total of HIV-infected patients, 63.9 per cent patients are positive for 
opportunistic infection and 30.9 per cent presented with one opportunistic infection. At 
the start of HAART, 78.3 per cent of AIDS patients had opportunistic infections and 
42.4 per cent had one opportunistic infection. Opportunistic infections in AIDS patients 
are associated with lower CD4 counts. Eighty-six point one percent of patients with 
CD4 counts less than 200 cells/µL at baseline and 81 percent of patients at HAART 
initiation had positive opportunistic infections. This was also demonstrated in a study in 
South Africa where those with CD4 less than 200 cells/µL had a higher incidence of 
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opportunistic infection compared to those with CD4 more than 200 cells/µL (8 versus 
3.1 per cent) (Fox, et al., 2010). 
 
At the end of the study, 36.4 per cent of HIV-infected patients and 20 per cent of AIDS 
patients on HAART were dying with most causes of death being AIDS related illness.  
The leading causes of death in HIV-infected patients and in AIDS patients on HAART 
were AIDS related illness especially PCP and tuberculosis. 
5.2.4  Anti-retroviral therapy 
 
Single drug and double drug anti-retroviral therapy were more common in the pre 
HAART era (before 1997). It has proven less effective than the triple drugs of HAART 
(1997 and later) in reducing viral load to less than 50 copies/ml (Geretti, et al., 2008; 
Schwarcz, et al., 2000). In this study, 71.9 per cent of AIDS patients received anti-
retroviral therapy in the HAART era and 29.1 per cent in the pre HAART era. 
 
Generally, the decision to start anti-retroviral therapy depends on the clinical or 
immunological criteria. Clinical criteria are based on the presence of one or more severe 
opportunistic infections, categorized by the WHO as stage 3 and 4. All developed and 
developing country guidelines recommend starting anti-retroviral therapy if a patient 
presented with stage 3 or 4 though decisions based on such clinical criteria alone are 
generally only used in resource limited settings where laboratory capacity is limited 
(WHO, 2010a). Commonly, the decision to start anti-retroviral therapy is based on 
immunological criteria, as defined by the level of CD4 count. According to current 
WHO guidelines, all HIV-infected patients with a CD4 less than 350 cells/µL must be 
started on HAART (WHO, 2010a). In this study, 84.2 per cent of patients started 
HAART with CD4 less than 200 cells/µL.  
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A decision about when to initiate anti-retroviral therapy on a public health level must be 
balanced between any expected population level benefits of initiating treatment at 
higher CD4 counts with the cost implications of potentially increased demand for 
treatment. If treatment thresholds are raised, any possible cost savings associated with 
earlier treatment including reduced hospitalization and treatment of opportunistic 
infections are lost (Walensky et al., 2009).  
 
Anti-retroviral therapy programs in developing countries follow a public-health 
approach rather than an individualized approach. Guidelines for developed countries 
cover individual patient management delivered by specialist doctors prescribing from 
the full range of anti-retroviral drugs, supported by routine high-technology laboratory 
monitoring. This approach is not suitable in resource-limited settings where doctors are 
scarce, laboratory infrastructure is not adequate and the procurement and supply-chain 
management is frail. This difficulty in translating guidelines from developed to 
developing nations caused concerns over whether anti-retroviral therapy scale-up in 
poor countries is feasible, affordable and cost-effective (Gilks, et al., 2006).  
  
WHO began to develop a public-health approach to providing anti-retroviral therapy 
based on experience of using the Directly Observed Treatment Short-course (DOTS) 
approach for tuberculosis. This approach took into account country requirements, the 
realities of weak health systems, and the experiences of pioneering anti-retroviral 
therapy programs (WHO, 2003). The key tenets were standardization and simplification 
of regimens to support efficient implementation also ensuring anti-retroviral therapy 
programs that are based on the most rigorous scientific data and equity aiming to set 
standards for treatment that should be accessible by all in need. The key conceptual 
shift was the move from an individual based approach to a population based one, 
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recognized as the only way to make anti-retroviral therapy rapidly accessible to the 
millions in need (Beaglehole, Bonita, Horton, Adams, & McKee, 2004).  
 
The most important achievement is to standardize first-line and second-line treatments.  
Issues of potency, durability of efficacy, ease of administration, tolerability and toxicity 
need to be balanced with cost and availability (Gilks, et al., 2006). There are three 
classes of oral anti-retroviral available, nucleoside and non-nucleoside reverse 
transcriptase (NRTI and NNRTI) inhibitors and protease inhibitors (PI). Public-health 
therapy readily accommodates the use of two sequential triple drug anti-retroviral 
therapy regimens. On the basis of available data, the initial consensus was to use one 
NNRTI in first-line treatment, supported by an NRTI (WHO, 2004), which remained in 
the year 2006 recommendations (WHO, 2006b). Protease inhibitor is reserved for 
second line therapy, supported by 2 NRTI to minimize cross-resistance (WHO, 2010a) 
 
In this study, 80.6 per cent of HAART initiation was with 2 NRTI + EFV, 13.9 per cent 
with 2 NRTI + NVP and 5.5 per cent with 2 NRTI + PI. The NNRTI based HAART 
regimes especially Efavirenz (EFV) and Nevirapine (NPV) are commonly used as 
components of first line regimens worldwide (Ananworanich et al., 2005). The choice 
between EFV and NPV is based on toxicity, interaction with other drugs, and cost 
(WHO, 2010). Rash, Stevens-Johnson syndrome and hepatic toxicity are adverse drug 
reactions associated with NVP but it is better for HIV infected women during the first 
semester of pregnancy (WHO, 2010) while EFV is well tolerated but more costly. 
Toxicities to the central nervous system (CNS) and mild rash are caused but self-
resolving after 2−4 weeks. Efavirenz should be avoided for severe psychiatric patients 
and women in their first semester of pregnancy. Efavirenz is the choice in individuals 
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with TB/HIV (WHO, 2010). In this study there are 30 per cent of AIDS patients on 
HAART with tuberculosis co-infection.   
 
Furthermore the findings showed that most of the patients still continue with the first 
line regimen and it was not necessary to switch to second line drugs. Only 15.8 per cent 
need to switch to second line drugs. Unfortunately in this study, we could not determine 
the reasons for switching to second line drugs because we relied on secondary data from 
medical records. To determine the reasons it would be necessary for further primary 
research. The recommendations for changes in treatment differ according to its 
indication. Based on WHO recommendations, the criteria to switch anti-retroviral 
therapy include clinical failure, immunological failure and virological failure (WHO, 
2010). Persistent viral load more than 5,000 copies/ ml confirms treatment failure and in 
the absence of viral load measurement, an immunological criteria is used to confirm 
clinical failure. In these guidelines, protease inhibitors remain reserved as second line 
therapies, mainly due to cost, higher pill burden,  drug interactions and refrigeration 
requirements (WHO, 2010a) 
 
The end result of the study shows that 90.7 per cent HAART combination were without 
PI, and only 9.3 per cent of HAART had PI. There were 5.5 per cent patients with first 
line combination with PI. Of them 61.5 per cent were still on first line drugs until the 
end of study while 38.5 per cent stopped without any clear reason. The majority of 
AIDS patients on HAART in the University of Malaya Medical Centre majority still 
used first line drugs because these are free while the second line drugs are not. 
 
The period of follow up of this study was very long which had the potential to be 
affected by changes in the management policies of HIV/AIDS patients. This was 
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however, not likely to affect the outcome of study because most AIDS patients 
presented at a late stage and HAART was consistently initiated when CD4 was < 200 
cell/µL, although WHO guidelines in 2010 recommended for HAART initiation when 
CD4 was < 350 cell/µL. Tests for proportional hazards did not show any significant 
change in hazard over time which supports this assertion. 
 
5.3  Median Survival time 
  
The findings of this study show that median survival time from the HIV diagnosis had 
improved in those receiving anti-retroviral therapy. The median survival of 177.5 
months in HIV-infected patients receiving anti-retroviral therapy is far higher than the 
73.2 months in those who did not receive anti-retroviral therapy. The median time from 
AIDS diagnosis to death was 65.7 months. This study shows that median survival in 
anti-retroviral initiation from HIV diagnosis is better than from AIDS diagnosis. This 
result is consistent with other Asian studies (Hung, et al., 2006; Wong, et al., 2004) and 
in developed countries (Li, et al., 2000; Schwarcz, et al., 2000). Before 1997 (pre-
HAART era), the median survival duration ranged from 15 months to 31 months in San 
Francisco (Schwarcz, et al., 2000), 2.9 months to 17.6 months in Italy (P. Pezzotti, et al, 
1999), and 17.7 months in Australia (Li, et al., 2000), 29.8 months in Hong Kong 
(Wong, et al., 2004). After 1997 (HAART era) median survival increased e.g.  in a 
study carried out in Hong Kong where this was more than 70 months (Wong, et al., 
2004), 24  months in Taiwan (Hung, et al., 2000),  58 months in Cameroon (Sieleunou, 
Souleymanou, Schonenberger, Menten, & Boelaert, 2009), 26.1 months in Ethiopia 
(Alemu & Sebastian, 2010), 9.91 months and 14.4 - 24 months in China (Li, et al., 
2010). On the other hand, the median survival for the non anti-retroviral therapy group 
in Taiwan was only 6.8 months (Hung, et al., 2006) and in China 19.2 months (Dou et 
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al., 2010). The median survival time from AIDS to death varies among Asia, Africa and 
developed countries due differences in the inclusion criteria of the sample, study time, 
study design and sample size. In this study, only adults aged 20 years and above were 
included while in other studies adult and adolescents were included in the analysis 
(aged 16 years at HIV diagnosis). This present study followed patients from 1986 to 
2006 (retrospective) and from 2007 to 2009 (prospective), a longer follow-up study 
period when compared to others. In addition, the present study is hospital based while 
the study in San Francisco was population based (Schwarcz, et al., 2000). 
 
5.4  Predictors of death 
 
5.4.1  Predictors of death in all AIDS patients  
 
Socio-demographic characteristics such as education level, occupational type and 
marital status are univariate predictors of death in this study. Clinical predictors of death 
are exposure risk, baseline body mass index, presence of opportunistic infections, 
number of opportunistic infections and type of treatment.  
 
Univariately speaking, those with primary and secondary education were more likely to 
die compared to those with tertiary education. The same group also had 5 and 10-year 
survival rates of 48.8 per cent and 38.3 per cent respectively. However, it is not 
significant in the multivariate analysis probably because of low power. A retrospective 
cohort study conducted in Ethiopia showed that 61 per cent of HIV-infected patients on 
anti-retroviral therapy had less than secondary education and patients with primary 
education seem to be at higher risk of death (Biadgilign, Reda, & Digaffe, 2012). 
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According to a previous study report, the lower educational level is associated with a 
higher risk of mortality (Jarrin, et al., 2007; Wood et al., 2002). 
  
Occupational type was significant in univariate and multivariate analysis.  Unemployed 
patients are more likely to die compared to those working as professional or non-
manual worker. A study in Nigeria showed that unemployed HIV-infected patients and 
patients with primary education were shown to be significantly associated with 
increased mortality (DeSilva, et al., 2009).  Unemployment has a correlation with 
income and it is a strong predictor of socioeconomic status. A study carried out in Italy 
showed that the increased risk of death following AIDS was more obvious among 
patients with lower socioeconomic status (Rapiti, et al., 2000). Occupational types were 
associated with the duration and severity of HIV infection (Dray-Spira, et al., 2003). It 
is depending on disease stage, the patients with the highest risk of losing their job were 
those with physically demanding work, those who had low control over the pace and 
scheduling of their work activities (Dray-Spira, et al., 2003; Yelin, Greenblatt, 
Hollander, & McMaster, 1991).  
 
In the pre-HAAR era, developed country studies showed that 28 per cent of patients had 
stopped working within a year after HIV diagnosis, 48 per cent by two years, 69 per 
cent from four years and no one was still employed by 10 years of HIV infection (Yelin, 
et al., 1991). Moreover mental and physical demands of job have a significant impact 
on employment loss of HIV-infected patients. The loss of earnings will reduce monthly 
income by 75 per cent (Dray-Spira, et al., 2007; Massagli, Weissman, Seage, & Epstein, 
1994). 
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Since 1996 with wide scale diffusion of HAART, HIV infection has become a chronic 
disease and the HIV epidemic has shifted toward more socially vulnerable population 
(Dray-Spira, et al., 2007). Employment is a major factor in maintaining income levels 
and living conditions among patients with chronic diseases. Discrimination at work of 
HIV-infected patients are still reported but not associated with occupational status. In 
HIV-infected patients, low education level is associated with decreased workforce 
participation but this does not happen among those with high education level (Dray-
Spira, et al., 2007). Further research needed to determine the impact of HIV-infected 
patients and employment in Malaysia  
 
Previous studies showed inconsistency with regards to exposure risk of HIV infection as 
a predictor of death in AIDS patients (Langford, et al., 2007). The CASCADE 
collaboration examined the change in morbidity and mortality between the pre and post 
HAART periods and showed mortality reduction in the post HAART era among 
homosexual and heterosexual patients but there was no such change in injecting drug 
users (Porter, et al., 2003). In this study, patients infected through the injecting drug 
user route are more likely to die (HR=1.52) and those who are infected by the 
homosexual route have a lower chance to die (HR=0.64) compared to the heterosexual 
route. This is an interesting finding but we cannot offer any explanation. It warrants 
further investigation in future research. This finding is similar to developed country 
studies (Europe, Australia and Canada), where injecting drug users had increased risk of 
death (HR= 4.28) (Porter, et al., 2003). Another study carried out in Spain showed 
injecting drug user had increased risk of death with  HR of 2.17 (Pérez-Hoyos, et al., 
2006). This variable is only significant in univariate but not in multivariate analysis. 
Other factors e.g. opportunistic infections play a larger role in clinical deterioration than 
the mode of transmission (Porter, et al., 2003). 
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Not many articles reported opportunistic infection as a predictor of death in AIDS 
patients. One study in San Francisco showed that AIDS patients with a history of 
opportunistic infections had increased risk of death with HR of 1.97 (Schwarcz, et al., 
2000). In this study, opportunistic infection and number of opportunistic infection were 
significant in univariate analysis as predictors of death. However, in the multivariate 
analysis, only the number of opportunistic infection fitted in the final model. AIDS 
patients with three or more opportunistic infections had increased risk of death 
(HR=1.90). The 5 and 10-year survival of patients with one opportunistic infection was 
58.3 per cent and 49.4 per cent. Those who had two opportunistic infections had 5 and 
10-year survival of 47.5 per cent and 36.4 per cent while patients with three or more 
opportunistic infection had 5 and 10-year survival of 33.0 per cent and 18.4 per cent. 
That the number of opportunistic infection influences hospitalization and the survival of 
AIDS patients is a fact that cannot be denied. It is therefore unsurprising that the 
reduction of survival with the increased number of opportunistic infection is supported 
by a Brazil study (Candiani et al., 2007).  
 
A study in India showed that the number of opportunistic infection in AIDS patients 
increased when there is a significant increase in the mean viral load and decrease in the 
CD4 counts and high viral loads and low CD4 were seen in AIDS patients with multiple 
opportunistic (Nagalingeswaran et al., 2000). 
 
 This study shows that the increased number of opportunistic infection caused AIDS to 
be exacerbated and increased mortality. Prevention of opportunistic infection is thus 
very important. Counselling, chemoprophylaxis and active management of 
opportunistic infection were important in the care of AIDS patients especially in 
developing countries. 
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This study shows that PCP and tuberculosis are the leading causes of AIDS related 
death in HIV-infected patients. This is consistent with a study in Brazil where 
tuberculosis is the primary cause of death in 9.0 per cent of all AIDS-related deaths 
while PCP accounted for 4.7 per cent of a total 8,601 AIDS-related deaths (Saraceni, et 
al., 2008). Throughout the developing world, the rate of co-infection with tuberculosis 
and PCP are high, ranging from 25 per cent to 80 per cent (Fisk, Meshnick, & 
Kazanjian, 2003). In the industrialized nations, viral hepatitis, non-AIDS related 
malignancies and cardiovascular events are now more common causes of death (Crum 
et al., 2006; Porter, et al., 2003). Although it is well known that HAART reduces the 
incidence of opportunistic infection and mortality of AIDS patients. PCP occurs mainly 
in patients with CD4 count less than 200 cells/µL, while tuberculosis occur in low and 
high CD4 counts.  Future research is needed regarding this discrepancy between PCP 
and tuberculosis in AIDS patients associated with level CD4 
 
In this study, the risk of death is higher in the non anti-retroviral therapy group as 
compared to those who in the anti-retroviral therapy group (HR=2.89). This is 
consistent with another study where the usage of HAART decreased the risk of death by 
almost 50 per cent (Hung, et al., 2006) and an India study with HR of 5.60 (Ghate, et 
al., 2011).  The India study used a prospective cohort from 2002-2004 and collection of 
demographic and clinical information. Structured questionnaires were captured at each 
follow up visit (primary data) consisted of pre-test and post-test counselling and 
informed consent.  
  
Other studies show that more than 50 per cent patients initiated anti-retroviral therapy 
when they are in WHO clinical stage 3 and 4 (Auld et al., 2011) Despite the fact that the 
WHO clinical stage 4 is a strong predictor of death in the first month of treatment 
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(Jerene, Endale, Hailu, & Lindtjorn, 2006). Thus early diagnosis and anti-retroviral 
therapy are needed to improve program outcomes (Lawn, Harries, Anglaret, Myer, & 
Wood, 2008). The campaigns of mass HIV testing needs earlier entry into HIV care, pre 
anti-retroviral therapy care retention in order to reduce absolute numbers of late starters.  
It is also appropriate to initiate anti-retroviral therapy at raised CD4 threshold compared 
to current practice. HAART initiation in adult patients with WHO stage 1 or 2 and CD4 
from 200 – 250 cells/µL based on WHO criteria in 2008 and CD4 from 250-350 
cells/µL based WHO criteria in 2010 (WHO, 2010a), should reduce the proportion of 
patients initiating anti-retroviral therapy with end stage disease.   
5.4.2  Predictors of  death in AIDS patients on HAART 
 
This study shows the CD4 count less than 200 cells/µL, viral load more than 100,000 
copies/ml and hemoglobin less than 12 g/dl are significantly associated with increased 
risk of death. This is consistent with studies in developed countries demonstrating the 
same outcomes with  lower CD4 count and higher viral load (Egger, et al., 1997; 
Mellors et al., 1997; Smurzynski, et al., 2010; Sterling, et al., 2001) and lower 
hemoglobin (Jean D Lundgren & Amanda Mocroft, 2003; Obirikorang & Yeboah, 
2009). Low hemoglobin level is prognostic of HIV infection. Regular measurements of 
hemoglobin level could help to determine patients who are at greatest risk of disease 
progression allowing these patients to be identified for closer monitoring or therapeutic 
intervention (Obirikorang & Yeboah, 2009). Hemoglobin level, hematocrit and body 
mass index as parameters which are conventionally thought to be proxies for general 
nutritional status. Anemia (hemoglobin less than 12 g/dl) is a known predictor of HIV 
related mortality in resource-limited settings (Harris et al., 2008; Melekhin et al., 2012; 
Obirikorang & Yeboah, 2009). Recovery from anemia is associated with improved 
survival (Lifson et al., 2012; Melo, Lacerda, Campelo, Moraes, & Ximenes, 2008). 
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Unfortunately not many studies have looked into hemoglobin recovery in HIV-infected 
patients. Further studies are required in Malaysian HIV-infected patients 
  
CD4 levels which never recover to more than 200 cells/μL were significantly associated 
with death (HR=7.54). This is consistent with studies in Spain (Jaen et al., 2008) with 
HR of 3.7 and in Kenya (Brown et al., 2009) with HR of 11.5. Patients with CD4 counts 
less than 200 are more likely to die compared to those with more than 350 cells/μL. The 
previous study finding in Kenya seems to indicate that the magnitude of risk attributed 
to this factor is higher than that found in this study.  However, in Kenya study, only 
pregnant women were studied which might affect the underlying immune status of the 
patients involved. In addition, CD4 was measured 8 months after initiating HAART in 
the Kenya study. In contrast, the CD4 count was taken at the time the AIDS diagnosis 
was made before initiating HAART in this study.  
  
In this study, patients with low hemoglobin  and  who never recover to more than 12 
g/dl after the use of HAART are more likely to die. A similar study in Tanzania 
reported an increased risk (HR=2.21) of AIDS related death for patients with moderate 
anemia (Hb 8.5-10.9 g/dl) (O'Brien, et al., 2005).  Those with severe anemia (Hb < 8.5 
g/dl) had even higher risk of death (HR=3.31) compared to normal hemoglobin 
(O'Brien, et al., 2005). There are possible explanations for the findings of the Tanzania 
study. Women enrolled in the previous cohort were pregnant, so their hemoglobin levels 
at the baseline visit may have been lowered as a result of pregnancy. Seventy eight per 
cent of participants were at least 16 weeks pregnant at the time of enrolment and the 
mean hemoglobin for these women was significantly lower compared to those less than 
16 weeks pregnant. One measurement of hemoglobin taken during pregnancy may not 
be accurate as a predictor of AIDS progression. For this study, adult HIV-infected 
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patients (men and women) with at least two repeated measures of hemoglobin level at 
baseline and at HAART initiation were used. A study in Brazil reported that AIDS 
patients with an initial presentation of normal hemoglobin showed the highest rate of 
survival and that AIDS patients with hemoglobin less than 10 mg/dl had  lower survival 
(Melo, et al., 2008). This is supported by a collaborative cohort study using data from 
11 sites in Asia Pacific region which reported that lower levels of hemoglobin have 
been shown to be associated with an 88 to 91 per cent increase in the risk of death 
(Zhou & Kumarasamy, 2005). AIDS patients who can improve their hemoglobin levels 
will make it possible to have improved survival (Volberding et al., 2004) 
 
Unemployment and manual employment were predictors of death in AIDS patients on 
HAART. It is not difficult to explain why unemployed patients with no any source of 
income have a higher risk of death as similar results have been found elsewhere 
(DeSilva, et al., 2009). A study in San Francisco demonstrated the effect of household 
income of neighborhood of residence on survival after AIDS diagnosis (McFarland, 
Chen, Hsu, Schwarcz, & Katz, 2003). Persons living in poor neighborhoods were less 
likely to use HAART at any time in the past compared to persons in wealthier 
neighbourhoods. AIDS survival in the HAART era was worse for people living in poor 
neighborhoods compared to wealthier neighborhoods as a result of unequal access to the 
use of HAART (McFarland, et al., 2003; Wood, et al., 2002). Both of these studies have 
similarities in that data was collected both retrospectively and prospectively and used 
Kaplan Meier analysis for survival and Cox regression for prediction of survival but 
there are differences in sources of data. The previous studies used population-based data 
while this study used hospital-based data. 
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CD4 counts that never recovers more than 200 cells/µL and an inability to achieve viral 
load less than 50 copies/ml have high hazard ratios in the progression from AIDS to 
death (patients on HAART). The CD4 cells play an important role in the human 
immune system as CD4 less than 200 cells/µL defines a patient as having AIDS and as 
a predictor of disease progression (Hulgan, et al., 2007). A higher CD4 was associated 
with a much greater decrease in the risk of progression compared to a patient had a CD4 
less than 200 cells/µL (COHERE, 2012) while the current CD4 count was the strongest 
predictor of the development of opportunistic infection (Podlekareva et al., 2006). 
Furthermore the inability to achieve viral load less than 50 copies/ml was associated 
with increased risk of death (Taiwo et al., 2009b). This may explain two main clinical 
implications. First, they add to the evidence that suggests, to facilitate immune system 
recovery, combination anti-retroviral therapy should be started when a patient's CD4 
count is between 350 and 500 cells/µl, the current recommended range for combination 
anti-retroviral therapy initiation. Unfortunately, most patients in this study started 
HAART when their CD4 cell count was less than 200 cells/µl. Secondly, these findings 
suggest that patients with sustained viral suppression with low CD4 count should be 
monitored regularly to ensure that any life threatening AIDS defining events are dealt 
with quickly and effectively. The European cohort study reported that patients on anti-
retroviral therapy with a CD4 count more than 200 cells/µL had a lower risk of death 
(HR= 0.75). Those with CD4 more than 350 cells/µL had a lower risk of death (HR= 
0.68) compared to CD4 less than 200 cells/µL (COHERE, 2012). This finding shows 
that AIDS patients whose CD4 count recovers to more than 200 cells/µL and whose 
viral load is less than 50 copies/ml will improve their chances of survival. 
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5.4.3  Predictors of death in AIDS patients not on ART  
 
The median survival of AIDS patients not on anti-retroviral therapy in this study 
decreased with increased age. The median survival for age groups 20-29, 30-39, 40-49, 
50-59 and 60 years and above were 20.6, 14.5, 13.2, 5.8 and 2.9 months respectively. 
Patients in age groups of 50-59 years had higher risk of progression to death (HR= 
2.41). The USA study showed an even higher risk of death than this study (HR= 3.66) 
for age group 50-59 years (Hall, et al., 2006). Both studies differ in reference group and 
terms of age of participants. The US study included adult and adolescents while the 
current study includes only adults. Univariate analysis produced a similar finding where 
there was a higher risk of progression to death with increased age (Babiker, Peto, 
Porter, Walker, & Darbyshire, 2001; Schwarcz, et al., 2000). Increased age and AIDS 
are associated with a diminished immune response. With consequent high viral load and 
increased probability of opportunistic infections, it is therefore not surprising that these 
factors increase the risk of death (May et al., 2007).  
 
In the multivariate analysis, Chinese ethnicity, WHO clinical stage 4 and viral load 
more than 100,000 copies/ml were independent predictors of death in AIDS patients not 
on anti-retroviral therapy. The Chinese had a shorter median survival (12.8 months) 
compared to the Malays (23.2 months) and Indian (14.1 months). A study in USA has 
investigated the differences in the risk death by race/ethnicity and reported no 
racial/ethnic differences in clinical progression of HIV (Anastos et al., 2005). A 
California study confirms that in settings with similar access to integrated care for HIV 
infected persons, there is no difference with respect to clinical outcomes for 
racial/ethnic minorities (Silverberg, Leyden, Quesenberry, & Horberg, 2009). Other 
studies indicated that Black and Hispanic patients had higher mortality rates compared 
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to White patients (McGinnis et al., 2003). Another study indicated higher mortality 
rates for Hepatitis C co-infected White compared with Black patients (Merriman, 
Porter, Brensinger, Reddy, & Chang, 2006). It is difficult to explain why Chinese 
patients are more likely to die compared to Malay or Indian patients. One possible 
explanation could be that the majority of patients in the University of Malaya Medical 
Centre are Chinese and who seek medical care or whether the Chinese patients were 
sicker than other ethnic groups. Further research is needed to evaluate this finding. 
 
The 5 and 10-year survival decrease rapidly with more advanced WHO clinical stage. In 
this study, 5 and 10-year survival in WHO clinical stage 3 (34.5 per cent and 27.5 per 
cent respectively) were higher compared to stage 4 (19.2 per cent and 13.6 per cent 
respectively). Those in WHO clinical stage 4 when compared to stage 3 had an 
increased risk of death (HR= 2.25). Some studies have provided similar evidence that 
WHO clinical staging is a factor associated with disease progression (Jerene, et al., 
2006; Palombi et al., 2009) so this comes as little surprise. 
 
Those with viral load more than 100,000 copies/ml had a significantly increased risk of 
dying (HR= 1.35) and a shorter median survival (11.5 months) compared to those with 
viral load less than 100,000 copies/ml (25.8 months). Studies in Kenya and Spain 
demonstrated viral load and CD4 as predictors of mortality (Brown, et al., 2009; Jaen, et 
al., 2008). In addition, an independent effect of viral load on progression to death was 
also found after adjusting for other covariates, including CD4 count (Phillips & 
Pezzotti, 2004).  
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5.5  Time and predictors achieved viral load less than 50 copies/ml 
 
The goal of anti-retroviral therapy in HIV-infected patients is to limit viral replication, 
slow the progression of HIV disease and increase the level of CD4 count (MOH, 
2001c). Viral replication is measured by the level of viral load. The effectiveness of 
anti-retroviral therapy is reflected by its ability to reduce viral load to less than 50 
copies/ml. In this study for a total of 474 patients receiving HAART, 70.5 per cent 
achieved viral load less than 50 copies/ml. The mean time to achieve this was 9.2 
months and the median time was 5.1 months. These findings were not as good as the 
findings from  a study in the United Kingdom where 482 of 656 (73 per cent) patients 
managed to achieve viral load less than 50 copies/ml within 6 months after the initiation 
of HAART (Smith, et al., 2004). Similarly, in the European Collaborative study of 
pregnant women, undetectable viral load were achieved by 73 per cent (175 of 240 
pregnant women) at the time of delivery (the median time to achieve undetectable viral 
load was 9.5 months). It was noted that all pregnant women in the study had received 
initial HAART based on two combinations; 65 per cent with 2 NRTI + PI (Nelfinavir) 
and 35 per cent with 2 NRTI + NVP (Nevirapine) (Patel, Cortina-Borja, Thorne, & 
Newell, 2007). The differences in time taken to achieve viral load less than 50 
copies/ml between the patients in this study and the stated two studies could be 
attributed to the initial status of anti-retroviral therapy used by the patients. In another 
study from a Multicenter AIDS Cohort, the median time taken from HAART initiation 
to first achieve viral load less than 50 copies were 11.8 months (Taiwo, et al., 2009b). 
The median time to achieved viral load less than 50 copies in this study was 5.1 months. 
This finding is shorter than the multicentre AIDS cohorts study (MACS) due to the 
different study design and sample size. The MACS study applied a prospective cohort 
design with a small sample size of men (n= 121) infected among men who have sex 
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with men route compared to this study. Our study applied both retrospective and 
prospective cohort design and which included men and women infected via the 
heterosexual, homosexual, IDU and other routes and a larger sample size. The findings 
of this study are similar to those from the observational study conducted in Salvador 
(Resino, et al., 2003). In Italy a study on predicting the duration of anti-retroviral 
therapy needed to suppress the viral load (Rizzardi, et al., 2000) showed that  after 
HAART initiation with baseline CD4 more than 250 cells/µL and baseline viral load 
more than 5000 copies/ml, a decreased viral load to less than 50 copies/ml was 
observed after varying periods of time. All 118 subjects studied took between 2 and 24 
weeks to achieve viral load less than 50 copies/ml (Rizzardi, et al., 2000).  
Those who received initial HAART with 2 NRTI + EFV had higher chance to achieve 
viral load less than 50 copies/ml compared to initial HAART with 2 NRTI + PI.  
Patients who did not need to switch to second line of HAART had higher chance to 
achieve viral load less than 50 copies/ml compared to those who needed to switch to a 
second line of HAART. There are similar findings in developed countries on initial 
HAART (Geretti, et al., 2008). Patients who were infected by injecting drug use had a 
lower chance of achieving viral load less than 50 copies/ml and increased risk of death. 
This is supported by a study done using pooled data from the CASCADE Collaboration 
and European study that demonstrated that injecting drug user had an increased risk of 
death (Borrell et al., 2006; Schwarcz, et al., 2000).  
  
Most adult HIV-infected patients achieve viral load less than 50 copies/ml within a year 
of starting anti-retroviral therapy. Patients who start anti-retroviral therapy when they 
have a high CD4 count tend to do better than people who start treatment when they have 
a low CD4 count. A Collaboration of Observational HIV Epidemiological Research in 
Europe (COHERE) study estimated the association between CD4 and progression to 
5 Discussion 
 
203 
 
AIDS and death among patients who have achieved viral suppression on anti-retroviral 
therapy. The finding was that a higher CD4 is associated with a reduced risk of AIDS 
and death in patients on anti-retroviral therapy with a suppressed viral load (COHERE, 
2012).  
 
This finding gives hope to patients with terminal AIDS if their CD4 can recover to more 
than 200 cells/µL, hemoglobin more than 12 g/dl, normal total lymphocyte count and 
undetectable viral load (less than 50 copies/ml) as the chances of survival are improved 
in these patients. 
 
5.6  Strengths and limitations of study 
 
This study has several strengths. Firstly, this is the first study to report survival time of 
AIDS progression to death and to achieve viral load less than 50 copies in the 
University of Malaya Medical Centre. Secondly, this is a  cohort (combined prospective 
and retrospective) study of HIV patients which is rare in Malaysia and second in only to 
randomised control trials to study anti-retroviral therapy effectiveness on disease 
progression after (Evans, 2003). Thirdly, the relatively large sample size of HIV-
infected patients (n = 1314) and AIDS patients (n = 989) for a Malaysian study gives it 
sample power to test associations. Fourthly, there were four sources of data, socio-
demographic characteristic, laboratory, clinical and anti-retroviral therapy and a large 
number of variables (n = 32). Finally, is the fact that the University of Malaya Medical 
Centre is a major referral centre and our ability to accurately crosscheck with mortality 
records of the National Registration Department 
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There are some limitations in this study. Firstly, this study used secondary data. This 
limitation led to some gaps in information about the uncertainty of the exact time of 
HIV infection and history of prior anti-retroviral therapy before having treatment in the 
University of Malaya Medical Centre. It is difficult to ascertain the route of infection 
except to rely on the patient’s history. The reasons to switch to second line HAART 
therapy might be clinically relevant which would in itself explain the poorer outcomes 
in patients who had to switch to second line treatment. Secondly, the scenario at the 
University of Malaya Medical Centre is different from the rest of Malaysia. In the 
University of Malaya Medical Centre the main exposure route is by the heterosexual 
route, most patients are Chinese and come from an urban population whereas in the rest 
of the country, injecting drug use is the main exposure route and most HIV patients are 
Malays. The patients in the University of Malaya Medical Centre was relatively 
affluent, largely due to the catchment area that the hospital is serving and because the 
University of Malaya Medical Centre caters to a predominantly middle class urban 
population owing to its location. 
 
5.7  Summary  
  
Inability to achieve viral load less than 50 copies/ml is the most important predictor of 
death in AIDS patients on anti-retroviral therapy followed by CD4 counts which never 
recovers to more than 200 cells/µL and unemployment. Unemployment has a strong 
correlation with income. It is a strong predictor of socioeconomic status but how much 
income is required for better survival in Malaysia is unknown and requires further 
research. Patients with terminal AIDS but whose hemoglobin recovers to more than 12 
g/dl and those with normal total lymphocyte count (more than 1,200 cells/µL) has a 
better chance of survival. Further research is required on the role of hemoglobin level 
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and total lymphocyte count as surrogate markers to predict CD4 counts in resource 
limited settings. Most findings from this study are consistent with other Asian, African 
and developed country studies but two things still remain unclear the lower survival of 
Chinese patients compared to Malays and Indian and the reason why AIDS patients 
infected via the injecting drug use route in the University of Malaya Medical Centre had 
a lower chance to achieve viral load less than 50 copies/ml.  
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CHAPTER 6 
 
CONCLUSIONS AND RECOMMENDATIONS 
  
6.1   Introduction 
 
This chapter presents conclusions and recommendations of this study. Section 6.1 is the 
Introduction. Section 6.2 presents major findings of this study, including the 
characteristics of HIV-infected patients seen at the University of Malaya Medical 
Centre stratified by socio-demographic, laboratory, clinical and anti-retroviral therapy 
in section 6.2.1 Section 6.2.2 is a summary of the observation about survival time and 
the 5 and 10-year survival. Section 6.2.3 is a summary of the predictors of death in all 
AIDS patients, AIDS patients on HAART and AIDS patients not on anti-retroviral 
therapy. Section 6.2.4 is about the time and predictors to achieve viral load less than 50 
copies/ml. This continues in Section 6.3 where the recommendations and need for 
further studies are summarized. Contributions of the study are spelled out in Section 
6.3.1,implications of study in Section 6.3.2 and conclusion in Section 6.4 
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6.2  Major findings of this study 
 
 
The purpose of this study was to determine predictors of progression and survival of 
HIV-infected patients who received follow up treatments at the University of Malaya 
Medical Centre.  
 
6.2.1  The characteristics of HIV-infected patients  
 
Socio-demographic studies have shown that 73.3 per cent of HIV-infected patients were 
20-39 years old with median age of 33.7 years (IQR 12.0). The majority were male, 
Chinese, single, had primary and secondary education, work as professionals and non-
manual workers and earned between RM 1,000 to 3,000 per month. The socio-
demographic profile of AIDS patients receiving anti-retroviral therapy was similar to 
the HIV-infected patients except for marital status, i.e. most AIDS patients were 
married with median age of 34.1 years (IQR 12.7). 
 
The majority of HIV-infected patients and AIDS patients on anti-retroviral initiation 
had CD4 less than 200 cells/µL, viral load more 100,000 copies/ml, meaning they were 
in at an advanced infection stage, but hemoglobin more 12 g/dl, normal total 
lymphocyte count and normal liver function test.  
 
The majority of HIV-infected patients and AIDS patients on anti-retroviral therapy 
initiation contracted infection via the heterosexual route, with WHO clinical stage 4, 
body mass index more 18.5 kg/m2, positive opportunistic infection and presented with 
one opportunistic infection. 
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The majority of HAART started with 2 NRTI + EFV, and there was no need to switch 
to second line drugs. At the end of the study 90.7 per cent of these patients were on 
HAART without PI and only 9.3 per cent of HAART needed a PI. There were 5.5 per 
cent patients with first line combination with PI and out of them 61.5 per cent are on 
first line drugs until end of the study while the other 38.5 per cent stopped without a 
clear reason. 
  
The major cause of death in these patients is recognized as an AIDS related illness and 
among them, PCP and Tuberculosis are the leading cause. 
 
6.2.2  The survival time and the 5 and 10 year survival 
 
 
The survival time of HIV-infected patients and AIDS patients were greatly improved by 
anti-retroviral therapy. The median survival time was 177.5 months for receiving anti-
retroviral therapy, 73.2 months of not receiving anti-retroviral therapy in HIV-infected 
patients. In AIDS patients, 121.7 months for those receiving anti-retroviral therapy, 15.0 
months of not receiving anti-retroviral therapy. 
The 5 and 10-year survival of AIDS patients were 51.8 and 41.4 per cent for those with 
anti- retroviral, 23.6 and 18.9 per cent for patients non anti-retroviral therapy    
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6.2.3  Predictors of death 
 
 
a. Predictors of death in all AIDS patients 
  
Unemployed patients, those with three and above of opportunistic infection and non 
receiving anti-retroviral therapy are the predictors of death in all AIDS patients. These 
findings are consistent with previous studies that have found HIV-infected patients with 
unemployed as predictors of death in Nigeria and San Francisco (DeSilva, et al., 2009; 
McFarland, et al., 2003). The number of opportunistic infection as predictors of death 
consistent in developed countries studies (Candiani, et al., 2007; Schwarcz, et al., 
2000). Asia studies (China and India) shows that AIDS patients those not receiving anti-
retroviral therapy as predictors of death (Ghate, et al., 2011; Hung, et al., 2006)  
 
 
b. Predictors of death in AIDS patients on HAART 
 
The WHO guidelines in 2010 for anti-retroviral therapy initiation when patients with 
CD4 less than 350 cells/µL (WHO, 2010a). While the majority of patients in this study 
start HAART with CD4 less than 200 cells/µL because come in the clinic in late stage. 
The predictors of death in AIDS patients on HAART are unemployed patients, those 
with CD4 never recovers to more than 200 cells/µL and inability to achieve viral load 
less than 50 copies/ml. These findings consistent with previous studies in developed 
countries (COHERE, 2012; Hulgan, et al., 2007; Taiwo, et al., 2009b)  
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c. Predictors of death in AIDS patients not on anti-retroviral therapy  
 
 Chinese patients in WHO clinical stage 4 with baseline viral load more than 100,000 
copies/ml are predictors of death in AIDS patients not on anti-retroviral therapy. 
Advanced clinical staging and higher viral load as predictors of death on AIDS patients 
not on anti-retroviral therapy are consistent with previous studies in Africa and 
developed countries (Brown, et al., 2009; Jaen, et al., 2008; Palombi, et al., 2009), but 
difficult to explain that Chinese as predictors of death, needed further research 
 
 
6.2.4  The time and predictors to achieve viral load less than 50 
copies/ml 
 
The mean time to achieve viral load less than 50 copies/ml was 9.2 months and the 
median time was 5.1 months. Initial combination of 2 NRTI + EFV, lack of necessity  
switch to second line of HAART and infection through injecting drug use are predictors 
to achieve viral load less than 50 copies/ml. These findings are consistent with previous 
studies (Smith, et al., 2004; Taiwo, et al., 2009b).  
 
The findings of this study are consistent with studies from other developed and 
developing countries. However, there are several findings which warrant further 
research as they seem to be peculiar to Malaysia. Every effort needs be made to ensure 
all HIV-infected patients in Malaysia are able to achieve a CD4 count of more than 200 
cells/µL, viral load less than 50 copies/ml and have access to triple drug anti-retroviral 
therapy as these are significant modifiable predictors of death in Malaysian HIV 
patients. 
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6.3   Recommendations and further studies 
 
 
6.3.1 Contribution of study 
 
 
There are two majors contribution of this study. This includes a contribution to building 
of knowledge in HIV-infected patients and a contribution to public health policy 
 
a. Building knowledge 
 
 
This study helps in building the knowledge of disease progression and survival of HIV 
infected patients receiving anti-retroviral therapy in the University of Malaya Medical 
Centre. It is hoped that findings of this study will provide meaningful information that 
can be used to create a better treatment setting in the University of Malaya Medical 
Centre. This is potentially useful to nurses and clinicians who look after HIV-infected 
patients so that they are able to intervene early with anti-retroviral therapy and closely 
monitor the treatment regimes of patients. The success of HAART to improve survival 
and quality of life should be based on an individualized approach, with timely 
monitoring of laboratory indicators and health education especially with respect to 
adherence, nutrition and life style factors. 
The outcome of this study will help to guide health care providers in Malaysia to have a 
better understanding of the predictors of AIDS progression to death in the local context 
by providing awareness for routine examination of CD4, viral load and anti-retroviral 
adherence. This may help to achieve better survival for AIDS patients. It will also help 
to determine the predictors of progression in AIDS patients and its accompanying 
complications which could have an impact on Malaysian Clinical Practice Guidelines 
(CPG) in AIDS treatment. 
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b. Public health policy 
 
The Ministry of Health Malaysia had set the target of reducing the notification rate of 
new HIV infection of 11 cases per 100,000 and later adjusted it to 9 cases per 100,000 
population by 2015 (Prime Minister's Department Malaysia & United Nations Country 
Team, 2010). There needs to be a focus in terms of prevention, care and support to 
reduce the rate of HIV infection.  
 
The surveillance and screening mechanism has grown extensively in Malaysia. Groups 
routinely screened for HIV are women receiving antenatal care in government facilities, 
blood donors, inmates in drug rehabilitation centres, high-risk prison inmates, drug 
users, sex workers, confirmed tuberculosis cases, sexually transmitted infections cases, 
patients with suspected clinical symptoms, traced contacts of confirmed persons with 
HIV, premarital couples, migrant workers, and participants in harm-reduction 
programmes (Prime Minister's Department Malaysia & United Nations Country Team, 
2010). There needs to be increased HIV counselling in the community because HIV 
infection still a stigma in Malaysia to reduce late presentation and underreporting.  
The Ministry of Health conducts a routine HIV surveillance system but intensive 
surveillance is required in most at risk populations (MARPs) in Malaysia including 
injecting drug users, female sex workers, men who have sex with men and the 
transgender population because the trend of the HIV epidemic in Malaysia is slowly 
changing to that of a sexually transmitted epidemic. 
 
On a practical level, although anti-retroviral therapy is available free of charge by the 
Malaysian government, monitoring of laboratory testing as prescribed by the WHO 
guidelines is chargeable and causes the treatment and management of HIV infection to 
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be costly. The burden of this expense falls largely on the patients. Quality initiatives 
based on clinical outcomes will continue to be a requirement. While morbidity and 
mortality have dropped dramatically since the introduction of HAART, these reductions 
are not uniform across populations. It is imperative that the reasons for these inequities 
are identified, and strategy for improvement in access and quality be implemented. 
Collaboration with non-governmental organizations are needed for the program to 
succeed and to decrease the burden of HIV-infected patients 
 
6.3.2 Implications of the study  
 
The findings of this study highlight several things for further research in AIDS 
progression such as:  
 
Further research should seek to investigate why patients who were infected by injecting 
drug use had a lower chance of achieving viral load less than 50 copies/ml. 
 
Further research is recommended to look into why Chinese patients had lower survival 
compared to Malays and Indian. 
 
Further research is needed to look into the usefulness of hemoglobin recovery in HIV-
infected patients as an independent predictor of death especially in resource limited 
settings.  
 
Further research would be helpful to confirm total lymphocyte count as surrogate 
markers to predict CD4 counts in resource limited settings. It is still unclear, whether 
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the cut off value of total lymphocyte counts less than 1,200 cells/µL can predict CD4 
less than 200 cells/µL is suitable in developing countries especially in Malaysia. 
 
Further research is needed to look into the impact of HIV infection on employment 
status and how long the HIV-infected patients can continue to work after being 
diagnosed with HIV/AIDS. 
 
Further research will be helpful to investigate the influence of unemployment as a 
predictor of death in AIDS patients. This is necessary to determine how much funding 
is required by an HIV-infected patient for better survival in Malaysia. 
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note that the deadline for registration fee payment for presenter (oral or poster) 
is 31st May 2012. The presenter who did not pay for the registration fee after 
the deadline will be regarded as self-withdrawal from the presentation and the 
abstract will not be included in the conference proceedings. If you make 
payment before 30th April 2012, you can enjoy the early bird rate as stated in 
our conference website (http://apceebm.um.edu.my).  
 
Please note that the main theme of your paper may have changed following 
our review of your abstract. We will be informing you of further details 
regarding the poster presentation guidelines within the next few weeks. 
 
We thank you for submitting your abstract for consideration at our conference 
and we look forward to meeting you in Kuala Lumpur. 
 
Yours sincerely, 
Assoc. Prof.Dr. Wong Yut Lin 
Chairman of Scientific Committee 
1st Asia-Pacific Clinical Epidemiology and Evidence Based Medicine 
Conference 
Julius Centre University of Malaya 
c/o Department of Social and Preventive Medicine 
Faculty of Medicine, University of Malaya 
50603 Kuala Lumpur, Malaysia 
 
Tel: +603-7967-3793/3797 Fax: +603-7967-4975 
Email:apceebm1@ummc.edu.my 
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To: Dr Rahayu Lubis 
Department of Social and 
Preventive Medicine 
University of Malaya 
Malaysia 
 
 
26th October 2010 
 
 
RE: Acceptance letter of abstracts for ASIALINK-CE & EBM conference: 
‘Clinical Epidemiology and Evidence-Based Medicine in Global Perspective’ 
 
Dear Dr Rahayu Lubis, 
 
We are delighted to inform you that your abstract “Progression to AIDS in HIV 
patients seen in the University of Malaya Medical Centre”  has been 
accepted for oral presentation at the Asialink conference ‘Clinical 
Epidemiology and Evidence-Based Medicine in Global Perspective’.  
 
Please register your attendance to the Scientific Congress as soon as possible 
if you have not done so.  Information regarding registration, housing, program 
and presentation guidelines can be found at our website www.asialink-
ce.org.  
 
We look forward to welcoming you in Bali. 
 
With regards, 
 
Professor Sudigdo Sastroasmoro 
ChairmainAsiaLink-CE Indonesia 
Professor of Pediatrics 
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41st APACPH Conference-Acceptance Notice 
 
Tuesday, September 15, 2009 10:38 AM 
 
From: "41st APACPH Conference Secretariat" judychou@elitepco.com.tw 
 
To:rahayu_lubis@yahoo.com  
 
Acceptance Notice for Poster Presentation September 15, 2009  
 
Dear Dr. Rahayu Lubis,  
 
On behalf of the 41st APACPH Conference Organizing Committee, I am very pleased to 
inform you that your following abstract has been accepted as one of the 41st APACPH 
Poster Presentation.  
 
Please reply & confirm your participation (by completing the reply form below) before 
September 25, 2009 for our following preparation of the program. Please be aware that, 
there should be at least one author to complete the registration process before October 15, 
2009 for your abstract; if no registration is done by the deadline, the presentation will NOT 
be scheduled for the conference.  
 
Please feel free to contact us if you have any further inquiry or assistance required.  
 
Yours sincerely,  
 
41st APACPH Conference Secretariat 
Judy Chou 
Tel: +886-2-8502-7087 ext. 27 
Fax: +886-2-8502-7025 
E-mail: apacph2009@elitepco.com.tw 
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Tentative date and time of oral presentation in APACPH Conference  
 
Tuesday, 14 October, 2008 15:41 
From: 
"Moy Foong Ming" <moyfm@ummc.edu.my> 
To: 
rahayu_lubis@yahoo.com 
 
Dear Sir/Madam, 
  
Please find the file for the tentative schedule of your oral presentations.  
  
Please be reminded that the presentation and inclusion of abstracts in the proceedings are 
subjected to your payment of registration fees. 
  
The deadline of payment has been extended to 20 October 2008. 
  
Thank you. 
  
Regards, 
Dr Moy FM 
Secretariat 
APACPH Conference 
 
  Date Session/Room Time starts Time ends Theme Theme Title  
8-Nov F12 1115 1300 C HIV/AIDS prevention and control 
      FNAME SNAME REGISTER KL ID REQUEST   Day 
Rahayu Lubis Oral KL_O_071  8-Nov 
TITLE THEME 
A 21-Year Review Of Hiv/Aids Patients Seen In The University Of Malaya Medical Centre C 
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Appendix F: WHO Clinical Staging   
Source: (WHO, 2007b, 2007c)  
 
 
 
Primary HIV Infection 
 
Asymptomatic  
Acute retroviral syndrome 
 
Clinical Stage 1 
 
Asymptomatic  
Persistent generalized lymphadenopathy 
 
Clinical Stage 2 
 
Moderate unexplained weight loss (<10% of presumed or measured body weight)  
Recurrent respiratory infections (sinusitis, tonsillitis, otitis media, and pharyngitis)  
Herpes zoster  
Angular cheilitis  
Recurrent oral ulceration  
Papular pruritic eruptions  
Seborrheic dermatitis  
Fungal nail infections 
 
Clinical Stage 3  
 
Unexplained severe weight loss (>10% of presumed or measured body weight)  
Unexplained chronic diarrhea for >1 month  
Unexplained persistent fever for >1 month (>37.6°C, intermittent or constant)  
Persistent oral candidiasis (thrush)  
Oral hairy leukoplakia  
Pulmonary tuberculosis (current)  
Severe presumed bacterial infections (eg, pneumonia, empyema, pyomyositis, bone or joint 
infection, meningitis, bacteremia)  
Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis  
Unexplained anemia (hemoglobin <8 g/dL)  
Neutropenia (neutrophils <500 cells/µL)  
Chronic thrombocytopenia (platelets <50,000 cells/µL) 
 
Clinical Stage 4 
 
HIV wasting syndrome, as defined by the CDC (see Table 3, above)  
Pneumocystis pneumonia  
Recurrent severe bacterial pneumonia  
Chronic herpes simplex infection (orolabial, genital, or anorectal site for >1 month or 
visceral herpes at any site)  
Esophageal candidiasis (or candidiasis of trachea, bronchi, or lungs)  
Extrapulmonary tuberculosis  
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Kaposi sarcoma  
Cytomegalovirus infection (retinitis or infection of other organs)  
Central nervous system toxoplasmosis  
HIV encephalopathy  
Cryptococcosis, extrapulmonary (including meningitis)  
Disseminated nontuberculosis Mycobacteria infection  
Progressive multifocal leukoencephalopathy  
Candida of the trachea, bronchi, or lungs  
Chronic cryptosporidiosis (with diarrhea)  
Chronic isosporiasis  
Disseminated mycosis (eg, histoplasmosis, coccidioidomycosis, penicilliosis)  
Recurrent nontyphoidal Salmonella bacteremia  
Lymphoma (cerebral or B-cell non-Hodgkin)  
Invasive cervical carcinoma  
Atypical disseminated leishmaniasis  
Symptomatic HIV-associated nephropathy  
Symptomatic HIV-associated cardiomyopathy  
Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis   
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Appendix G  Evidence Table 
 
Question: HIV/AIDS progression, Risk factors of death, Survival time, Achieving VL ≤ 50 copies/ml 
Authors Years Place Study design sample Outcome 
Lifson, et al 2012 USA Retrospective 
cohort 
1600 Risk of death: 
Age > 40: HR 1.32 
OI: HR 1.93 
CD4 < 50 : HR 2.97 (ref. CD4 > 500) 
VL: HR 1.36 per log 10 increase 
Hb < 12: HR 1.36 
 
Fregonese, et al 2012 Thailand Prospective cohort 1578 Median age: 33 years 
Risk of death: 
Anemia: HR 4.90 
CD4 < 50: HR 3.1 
VL > 1000: HR 2.8 
 
Toure, et al 2012 France Prospective cohort 3569 Risk of death: 
CD4 < 200: HR 5.81 (ref. CD4 > 200) 
Male: HR 1.28 (ref. Female)  
Age: 30-39: HR 1.72 (ref. Age < 30 years) 
         40-49: HR 2.14 
         50-59: HR 2.03 
          >  60: HR 4.75 
 
Jim Young, et al 2012 Europe Retrospective and 
Prospective Cohort   
75336 Reduce risk of death: 
CD4 < 200: HR 0.35 
CD4 200 - < 350: HR 0.81 
CD4 350 - < 500: HR 0.74 
CD4 > 500: HR 0.96 
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Rougemont, et al 2012 Myanmar 
and 
Zimbabwe 
Retrospective 
cohort 
1090 Mortality rate of TB-HIV:  
28.9 per 100 person years 
Risk of death: 
Low BMI: HR 4.05 (ref. High BMI) 
 
Ghate,  
et al 
2011 India Prospective cohort  
 
457 Risk of death: 
Age > 35 years : RR 1.97  
CD4≤ 100: RR 33.20  
TB: RR 2.38  
ART naive: 5.60  
 
Auld, et al 2011 Mozambique Retrospective 
cohort 
2596 Median age: 34 years 
Risk of death: 
Male: HR 1.5 (ref. Female) 
Weight < 45 kg: HR 2.1(ref. > 60 kg) 
WHO stage 4: HR 1.7 (ref. Stage ½) 
 
Althoff,  
et al 
2010 USA Prospective cohort  
 
12196 Immune response decreased with increasing 
age (ref. 18- < 30 years)  
(30-<40): HR: 0.91   
(40-<50): HR: 0.86  
(50-<60): HR: 0.90  
(≥ 60 yr):HR: 0.81  
 
Obirikorang, et al 2009 Ghana Prospective case 
control comparative 
228 Positive Pearson’s correlation Hb and CD4 
(r
2
 = 0.1755; p < 0.0001) 
      
Bo Taiwo, et al 2009 Chicago Prospective cohort  
 
121 Time to achieve VL < 50 copies: 0.99 years 
Median age 42 years 
Risk of death:  
CD4 ≤ 200: HR 22.8 (ref. CD4 > 350)  
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Desilva M, et al 2009 Nigeria Retrospective 
cohort 
1552 Risk of death:  
Male: HR 1.77 
CD4 < 50 : HR 3.28 
TB-HIV: HR 3.53 
Unemployment: HR 1.79  
 
Grigoryan, 
 et all 
 
2009 USA Retrospective 
cohort 
 
27572 
 
Three years survival : 
Male: IDU (87.3%): MSM (91.6%)  
Female: IDU (89.5%): heterosexual 
(93.3%) 
 
Jaen,  
et al 
2008 Spain Retrospective and 
Prospective Cohort   
3427 Median age 35.5 years 
Risk of death: 
CD4 < 200: HR 3.79  
VL ≥ 100000 : HR 1.84  
HAART 2001-2004: HR 0.52 
 
Candiani, et al 2007 Brazil Prospective cohort 
 
371 Rate of OI: 18.32 per 100person years 
Risk of OI: 
No HAART: HR 5.4 (ref. HAART) 
CD4 < 15%: HR 0.3 (ref. > 15%) 
VL > 100000: HR 4.7 (ref. VL < 100000) 
 
Geretti, et al 2006 UK Prospective cohort  
 
1386 74.5% patients achieving a VL < 50 copies  
Time to achieve VL < 50 by regimen: 
-2NRTIs+1NNRTI : 0.3 (0.2-0.5) years 
-2 NRTIs+1PI/r :0.4 (0.2-0.5) years 
-2NRTIs+1PI : 0.6 (0.3-1.0) years 
-Others : 0.3 (0.2-0.5) years 
 
Hall, 
 et al  
 
2006 USA Prospective Cohort   
 
262,744 Risk to death:   
White: HR 1.15 (ref. Non Hispanic)  
American Indian: HR= 1.33  
Hispanic: HR= 1.16  
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Reference age 13-19 years 
Age 50-59 yr, HR = 3.66  
Age ≥ 60, HR = 5.91 
 
Perez-Hoyos, 
 et al 
2006 Spain Retrospective 
cohort 
 
2838 Risk of death: 
IDU: HR 2.17  
Bonnet et all. 
 
2005 France Prospective cohort  
 
709  
 
Risk of progression:  
Older age: HR of 1.2 by 10 years   
CD4 < 50: HR of 13.0 (ref. CD4 > 350) 
CD4 50- 199: HR 5.1   
 
Wong , et al 2004 Hongkong Retrospective 
cohort  
 
581 Survival time 
Pre-HAART era: 29.8 months 
HAART era: more than70 months  
Risk of death after CD4 <200 cell/µL: 
Age 50-59 yr: HR 2.31 
 
Anastos , et al.  
 
2004 USA Prospective cohort  
  
 
1132 Risk of death:  
Women with CD4 <200 all cause: HR 2.66  
AIDS Death: HR 47.61  
Cole, et al 2003 USA Prospective cohort  1498 Risk of death 
No HAART, HR= 0.81   
 
Egger,  
et al 
2002 Europe Prospective Cohort 
study 
 
12574 Risk of death 
Age ≥ 50 years: HR 3.09  
IDU: HR 2.44(ref. MSM) 
Heterosexual: HR 0.84 
CDC stage C: HR 2.07(ref. stage A/B) 
 
Jacobson ,  
et al 
 
2002 USA Retrospective 
cohort  
 
679 Risk of death: 
CD4 < 200: HR 2.29  
Age > 45 years: HR 1.81  
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Schwarcz, SK,  
et al  
 
2000 California Prospective and 
Retrospective 
Cohort 
5686  
 
Survival time:   
15 months (ART without PI) 
31 months (ART with PI) 
Risk of death:  
Age ≥ 40 years: HR 1.43  
Homosexual IDU: HR 1.33   
History of OI: HR 1.97  
 
Li Y, et al 2000 Australia Retrospective 
cohort 
 
4814  
 
Survival Time: 
In 1991: 16 months 
in 1991- 1996: 17.7 months 
in 1996: 27.7 months 
Risk of progression:  
Age > 45 years: HR 1.54  
 
Rapiti E, et al 2000 Italy Retrospective 
cohort  
 
1474 Risk of death: 
SES level III: HR 2.81 
SES level IV: HR 2.55    
Females in the level IV: HR 4.85  
IDU in level III: HR 4.54  
IDU in level IV: HR 4.68  
 
Pezzotti P, et al 
 
 
1999 Italy Prospective Cohort 771 Risk of death 
Monotherapy: HR 1.54  
Double therapy: HR 0.61  
Triple therapy: HR 0.36 
 
Darby, et al 
 
1996 UK Retrospective 
Cohort  
 
1216 10 year survival: 
Age < 15 years = 86% 
Age 15-34 years = 72% 
Age 35-54 years = 45% 
≥ 55 years = 12% 
 
